WO2023246656A1 - Sos1蛋白降解靶向嵌合体及其组合物、制剂和用途 - Google Patents
Sos1蛋白降解靶向嵌合体及其组合物、制剂和用途 Download PDFInfo
- Publication number
- WO2023246656A1 WO2023246656A1 PCT/CN2023/100787 CN2023100787W WO2023246656A1 WO 2023246656 A1 WO2023246656 A1 WO 2023246656A1 CN 2023100787 W CN2023100787 W CN 2023100787W WO 2023246656 A1 WO2023246656 A1 WO 2023246656A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- compound
- cancer
- alkyl
- cycloalkyl
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 86
- 239000000203 mixture Substances 0.000 title abstract description 24
- 229940124823 proteolysis targeting chimeric molecule Drugs 0.000 title abstract 2
- 101100421901 Caenorhabditis elegans sos-1 gene Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 531
- 102000057028 SOS1 Human genes 0.000 claims abstract description 54
- 108700022176 SOS1 Proteins 0.000 claims abstract description 30
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 20
- 230000002265 prevention Effects 0.000 claims abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 108
- 229910052739 hydrogen Inorganic materials 0.000 claims description 104
- 239000001257 hydrogen Substances 0.000 claims description 103
- 125000000217 alkyl group Chemical group 0.000 claims description 97
- 150000002431 hydrogen Chemical class 0.000 claims description 82
- 125000000623 heterocyclic group Chemical group 0.000 claims description 68
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 57
- 150000003839 salts Chemical class 0.000 claims description 56
- 229910052736 halogen Inorganic materials 0.000 claims description 52
- 150000002367 halogens Chemical class 0.000 claims description 52
- 229940002612 prodrug Drugs 0.000 claims description 51
- 239000000651 prodrug Substances 0.000 claims description 51
- 239000012453 solvate Substances 0.000 claims description 51
- 229910052757 nitrogen Inorganic materials 0.000 claims description 39
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 38
- 125000003118 aryl group Chemical group 0.000 claims description 36
- 230000000155 isotopic effect Effects 0.000 claims description 36
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 35
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 32
- 125000003545 alkoxy group Chemical group 0.000 claims description 31
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 29
- 125000004432 carbon atom Chemical group C* 0.000 claims description 28
- 125000002924 primary amino group Chemical class [H]N([H])* 0.000 claims description 28
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 27
- -1 amino, cyano, carbamoyl Chemical group 0.000 claims description 26
- 125000004093 cyano group Chemical class *C#N 0.000 claims description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims description 25
- 239000003814 drug Substances 0.000 claims description 23
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 21
- 229910052799 carbon Inorganic materials 0.000 claims description 20
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 19
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 18
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 18
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 16
- 125000004419 alkynylene group Chemical group 0.000 claims description 16
- 239000000460 chlorine Substances 0.000 claims description 16
- 201000011510 cancer Diseases 0.000 claims description 15
- 125000005549 heteroarylene group Chemical group 0.000 claims description 15
- 125000006586 (C3-C10) cycloalkylene group Chemical group 0.000 claims description 14
- 125000006585 (C6-C10) arylene group Chemical group 0.000 claims description 14
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 14
- 125000000449 nitro group Chemical class [O-][N+](*)=O 0.000 claims description 14
- 229910052801 chlorine Inorganic materials 0.000 claims description 13
- 125000004043 oxo group Chemical group O=* 0.000 claims description 13
- 125000004450 alkenylene group Chemical group 0.000 claims description 12
- 125000003342 alkenyl group Chemical group 0.000 claims description 11
- 125000002619 bicyclic group Chemical group 0.000 claims description 11
- 229910052794 bromium Inorganic materials 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 10
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 8
- 229910052731 fluorine Inorganic materials 0.000 claims description 8
- 150000004677 hydrates Chemical class 0.000 claims description 8
- 230000001404 mediated effect Effects 0.000 claims description 8
- 238000006467 substitution reaction Methods 0.000 claims description 8
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 7
- 239000012830 cancer therapeutic Substances 0.000 claims description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
- 125000001424 substituent group Chemical group 0.000 claims description 7
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 6
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 6
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 229910052740 iodine Inorganic materials 0.000 claims description 6
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 6
- 201000002528 pancreatic cancer Diseases 0.000 claims description 6
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 6
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- 201000002510 thyroid cancer Diseases 0.000 claims description 6
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 5
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 5
- 206010005003 Bladder cancer Diseases 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 5
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 5
- 206010014733 Endometrial cancer Diseases 0.000 claims description 5
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 5
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 5
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 5
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 5
- 208000034578 Multiple myelomas Diseases 0.000 claims description 5
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 5
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 5
- 206010033128 Ovarian cancer Diseases 0.000 claims description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 5
- 206010060862 Prostate cancer Diseases 0.000 claims description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 5
- 206010038389 Renal cancer Diseases 0.000 claims description 5
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 5
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 5
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 5
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 5
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 5
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 5
- 201000010881 cervical cancer Diseases 0.000 claims description 5
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 5
- 125000004122 cyclic group Chemical group 0.000 claims description 5
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 5
- 201000004101 esophageal cancer Diseases 0.000 claims description 5
- 239000012634 fragment Substances 0.000 claims description 5
- 206010017758 gastric cancer Diseases 0.000 claims description 5
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 5
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 5
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 5
- 201000010982 kidney cancer Diseases 0.000 claims description 5
- 201000000062 kidney sarcoma Diseases 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 201000001441 melanoma Diseases 0.000 claims description 5
- 201000011549 stomach cancer Diseases 0.000 claims description 5
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 5
- 206010046766 uterine cancer Diseases 0.000 claims description 5
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 4
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 4
- MDQRDWAGHRLBPA-UHFFFAOYSA-N fluoroamine Chemical compound FN MDQRDWAGHRLBPA-UHFFFAOYSA-N 0.000 claims description 4
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims description 4
- 208000005017 glioblastoma Diseases 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 3
- 125000006704 (C5-C6) cycloalkyl group Chemical group 0.000 claims description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 2
- 230000003449 preventive effect Effects 0.000 claims description 2
- NYBWUHOMYZZKOR-UHFFFAOYSA-N tes-adt Chemical class C1=C2C(C#C[Si](CC)(CC)CC)=C(C=C3C(SC=C3)=C3)C3=C(C#C[Si](CC)(CC)CC)C2=CC2=C1SC=C2 NYBWUHOMYZZKOR-UHFFFAOYSA-N 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 3
- 208000006593 Urologic Neoplasms Diseases 0.000 claims 3
- 201000000849 skin cancer Diseases 0.000 claims 3
- 230000000694 effects Effects 0.000 abstract description 16
- 230000017854 proteolysis Effects 0.000 abstract description 11
- 230000002401 inhibitory effect Effects 0.000 abstract description 6
- 241000124008 Mammalia Species 0.000 abstract description 3
- 101100404726 Arabidopsis thaliana NHX7 gene Proteins 0.000 abstract 3
- 101100197320 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) RPL35A gene Proteins 0.000 abstract 3
- 101150100839 Sos1 gene Proteins 0.000 abstract 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 311
- 238000006243 chemical reaction Methods 0.000 description 289
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 187
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 156
- 238000003756 stirring Methods 0.000 description 122
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 113
- 239000000243 solution Substances 0.000 description 100
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 96
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 94
- 238000004440 column chromatography Methods 0.000 description 90
- 239000012043 crude product Substances 0.000 description 83
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 78
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 64
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 58
- 239000003480 eluent Substances 0.000 description 58
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 56
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 50
- 238000000746 purification Methods 0.000 description 43
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 40
- 239000012141 concentrate Substances 0.000 description 39
- 235000008504 concentrate Nutrition 0.000 description 39
- 239000012074 organic phase Substances 0.000 description 36
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 32
- 239000012071 phase Substances 0.000 description 30
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 29
- 239000003208 petroleum Substances 0.000 description 29
- 230000002829 reductive effect Effects 0.000 description 29
- 239000000706 filtrate Substances 0.000 description 26
- 108090000623 proteins and genes Proteins 0.000 description 26
- 102000004169 proteins and genes Human genes 0.000 description 26
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 24
- 101710146001 Son of sevenless homolog 1 Proteins 0.000 description 24
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 24
- HQVFCQRVQFYGRJ-UHFFFAOYSA-N formic acid;hydrate Chemical compound O.OC=O HQVFCQRVQFYGRJ-UHFFFAOYSA-N 0.000 description 23
- 235000018102 proteins Nutrition 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 22
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 21
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- 239000012298 atmosphere Substances 0.000 description 19
- 229940079593 drug Drugs 0.000 description 17
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 15
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 15
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 15
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 239000007821 HATU Substances 0.000 description 13
- 125000006413 ring segment Chemical group 0.000 description 13
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 12
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 12
- 239000012065 filter cake Substances 0.000 description 12
- 102000016914 ras Proteins Human genes 0.000 description 12
- 239000012224 working solution Substances 0.000 description 12
- 239000000523 sample Substances 0.000 description 11
- 239000007787 solid Substances 0.000 description 11
- 102000007469 Actins Human genes 0.000 description 10
- 108010085238 Actins Proteins 0.000 description 10
- 125000004429 atom Chemical group 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 238000000605 extraction Methods 0.000 description 10
- 125000005842 heteroatom Chemical group 0.000 description 10
- 229910052760 oxygen Inorganic materials 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 229910052717 sulfur Inorganic materials 0.000 description 10
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 9
- 238000004113 cell culture Methods 0.000 description 9
- 238000001816 cooling Methods 0.000 description 9
- 238000006731 degradation reaction Methods 0.000 description 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 239000011550 stock solution Substances 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 8
- 230000015556 catabolic process Effects 0.000 description 8
- 229920006395 saturated elastomer Polymers 0.000 description 8
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 7
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 7
- 230000000903 blocking effect Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 238000004809 thin layer chromatography Methods 0.000 description 7
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 7
- 229910021642 ultra pure water Inorganic materials 0.000 description 7
- 239000012498 ultrapure water Substances 0.000 description 7
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 6
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 6
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 6
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 230000000670 limiting effect Effects 0.000 description 6
- 210000001853 liver microsome Anatomy 0.000 description 6
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 6
- 230000008685 targeting Effects 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 5
- 229960000583 acetic acid Drugs 0.000 description 5
- 125000000304 alkynyl group Chemical group 0.000 description 5
- 229910002092 carbon dioxide Inorganic materials 0.000 description 5
- 229940127573 compound 38 Drugs 0.000 description 5
- 125000001072 heteroaryl group Chemical group 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 5
- 238000012764 semi-quantitative analysis Methods 0.000 description 5
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 5
- 229910052938 sodium sulfate Inorganic materials 0.000 description 5
- 235000011152 sodium sulphate Nutrition 0.000 description 5
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- 239000004215 Carbon black (E152) Substances 0.000 description 4
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 239000006180 TBST buffer Substances 0.000 description 4
- 235000011054 acetic acid Nutrition 0.000 description 4
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000007405 data analysis Methods 0.000 description 4
- 229930195733 hydrocarbon Natural products 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 4
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 4
- 239000011976 maleic acid Substances 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 235000006408 oxalic acid Nutrition 0.000 description 4
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 125000003367 polycyclic group Chemical group 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 238000010791 quenching Methods 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 4
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 4
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 3
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 3
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 3
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 3
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 3
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 3
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 3
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 3
- QXOGPTXQGKQSJT-UHFFFAOYSA-N 1-amino-4-[4-(3,4-dimethylphenyl)sulfanylanilino]-9,10-dioxoanthracene-2-sulfonic acid Chemical compound Cc1ccc(Sc2ccc(Nc3cc(c(N)c4C(=O)c5ccccc5C(=O)c34)S(O)(=O)=O)cc2)cc1C QXOGPTXQGKQSJT-UHFFFAOYSA-N 0.000 description 3
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 3
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 3
- NPRYCHLHHVWLQZ-TURQNECASA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynylpurin-8-one Chemical compound NC1=NC=C2N(C(N(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C NPRYCHLHHVWLQZ-TURQNECASA-N 0.000 description 3
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 3
- WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 description 3
- HCCNBKFJYUWLEX-UHFFFAOYSA-N 7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)-3-(pyrazin-2-ylmethylamino)pyrido[3,4-b]pyrazin-2-one Chemical compound O=C1N(CCOCCC)C2=CC(C=3C=NC(OC)=CC=3)=NC=C2N=C1NCC1=CN=CC=N1 HCCNBKFJYUWLEX-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 229940126657 Compound 17 Drugs 0.000 description 3
- 229940127007 Compound 39 Drugs 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 3
- 239000008351 acetate buffer Substances 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 229940125904 compound 1 Drugs 0.000 description 3
- 229940126208 compound 22 Drugs 0.000 description 3
- 229940125851 compound 27 Drugs 0.000 description 3
- 229940125877 compound 31 Drugs 0.000 description 3
- 229940125878 compound 36 Drugs 0.000 description 3
- 229940126540 compound 41 Drugs 0.000 description 3
- 229940127271 compound 49 Drugs 0.000 description 3
- 229940126545 compound 53 Drugs 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 229960004679 doxorubicin Drugs 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000001530 fumaric acid Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 125000001188 haloalkyl group Chemical group 0.000 description 3
- 238000006317 isomerization reaction Methods 0.000 description 3
- RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 3
- 238000001819 mass spectrum Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 108010014186 ras Proteins Proteins 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- RMWVUWLBLWBQDS-UHFFFAOYSA-N tert-butyl 3-bromopropanoate Chemical compound CC(C)(C)OC(=O)CCBr RMWVUWLBLWBQDS-UHFFFAOYSA-N 0.000 description 3
- JYUQEWCJWDGCRX-UHFFFAOYSA-N tert-butyl 4-formylpiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(C=O)CC1 JYUQEWCJWDGCRX-UHFFFAOYSA-N 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 2
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- KKHFRAFPESRGGD-UHFFFAOYSA-N 1,3-dimethyl-7-[3-(n-methylanilino)propyl]purine-2,6-dione Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCCN(C)C1=CC=CC=C1 KKHFRAFPESRGGD-UHFFFAOYSA-N 0.000 description 2
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 2
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 2
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 description 2
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 2
- QEBYEVQKHRUYPE-UHFFFAOYSA-N 2-(2-chlorophenyl)-5-[(1-methylpyrazol-3-yl)methyl]-4-[[methyl(pyridin-3-ylmethyl)amino]methyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C1=CN(C)N=C1CN1C(=O)C=C2NN(C=3C(=CC=CC=3)Cl)C(=O)C2=C1CN(C)CC1=CC=CN=C1 QEBYEVQKHRUYPE-UHFFFAOYSA-N 0.000 description 2
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 2
- SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- DQAZPZIYEOGZAF-UHFFFAOYSA-N 4-ethyl-n-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]piperazine-1-carboxamide Chemical compound C1CN(CC)CCN1C(=O)NC(C(=CC1=NC=N2)OC)=CC1=C2NC1=CC=CC(C#C)=C1 DQAZPZIYEOGZAF-UHFFFAOYSA-N 0.000 description 2
- RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 description 2
- GDUANFXPOZTYKS-UHFFFAOYSA-N 6-bromo-8-[(2,6-difluoro-4-methoxybenzoyl)amino]-4-oxochromene-2-carboxylic acid Chemical compound FC1=CC(OC)=CC(F)=C1C(=O)NC1=CC(Br)=CC2=C1OC(C(O)=O)=CC2=O GDUANFXPOZTYKS-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- IYHHRZBKXXKDDY-UHFFFAOYSA-N BI-605906 Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(C(F)(F)CC)=CC=1N1CCC(S(C)(=O)=O)CC1 IYHHRZBKXXKDDY-UHFFFAOYSA-N 0.000 description 2
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical group C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 2
- 102100030708 GTPase KRas Human genes 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- ATHHXGZTWNVVOU-UHFFFAOYSA-N N-methylformamide Chemical compound CNC=O ATHHXGZTWNVVOU-UHFFFAOYSA-N 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 108091007960 PI3Ks Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 229940126271 SOS1 inhibitor Drugs 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 2
- 102000044159 Ubiquitin Human genes 0.000 description 2
- 108090000848 Ubiquitin Proteins 0.000 description 2
- ABRVLXLNVJHDRQ-UHFFFAOYSA-N [2-pyridin-3-yl-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound FC(C1=CC(=CC(=N1)C=1C=NC=CC=1)CN)(F)F ABRVLXLNVJHDRQ-UHFFFAOYSA-N 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 229960004538 alprazolam Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 125000000732 arylene group Chemical group 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- XJHCXCQVJFPJIK-UHFFFAOYSA-M caesium fluoride Chemical compound [F-].[Cs+] XJHCXCQVJFPJIK-UHFFFAOYSA-M 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 2
- 229960000991 ketoprofen Drugs 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 229960001632 labetalol Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- WBGPNPZUWVTYAA-UHFFFAOYSA-N methane;dihydrochloride Chemical compound C.Cl.Cl WBGPNPZUWVTYAA-UHFFFAOYSA-N 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- 210000001589 microsome Anatomy 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000012146 running buffer Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000001119 stannous chloride Substances 0.000 description 2
- 235000011150 stannous chloride Nutrition 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000001384 succinic acid Substances 0.000 description 2
- 229940014800 succinic anhydride Drugs 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- CESUXLKAADQNTB-UHFFFAOYSA-N tert-butanesulfinamide Chemical compound CC(C)(C)S(N)=O CESUXLKAADQNTB-UHFFFAOYSA-N 0.000 description 2
- BNWCETAHAJSBFG-UHFFFAOYSA-N tert-butyl 2-bromoacetate Chemical compound CC(C)(C)OC(=O)CBr BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 description 2
- NSCCYXHEZRMPPH-UHFFFAOYSA-N tert-butyl 3-(2-aminoethoxy)propanoate Chemical compound CC(C)(C)OC(=O)CCOCCN NSCCYXHEZRMPPH-UHFFFAOYSA-N 0.000 description 2
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- JMXKSZRRTHPKDL-UHFFFAOYSA-N titanium ethoxide Chemical compound [Ti+4].CC[O-].CC[O-].CC[O-].CC[O-] JMXKSZRRTHPKDL-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 206010044412 transitional cell carcinoma Diseases 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- GCTFTMWXZFLTRR-GFCCVEGCSA-N (2r)-2-amino-n-[3-(difluoromethoxy)-4-(1,3-oxazol-5-yl)phenyl]-4-methylpentanamide Chemical compound FC(F)OC1=CC(NC(=O)[C@H](N)CC(C)C)=CC=C1C1=CN=CO1 GCTFTMWXZFLTRR-GFCCVEGCSA-N 0.000 description 1
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
- OOKAZRDERJMRCJ-KOUAFAAESA-N (3r)-7-[(1s,2s,4ar,6s,8s)-2,6-dimethyl-8-[(2s)-2-methylbutanoyl]oxy-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]-3-hydroxy-5-oxoheptanoic acid Chemical compound C1=C[C@H](C)[C@H](CCC(=O)C[C@@H](O)CC(O)=O)C2[C@@H](OC(=O)[C@@H](C)CC)C[C@@H](C)C[C@@H]21 OOKAZRDERJMRCJ-KOUAFAAESA-N 0.000 description 1
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 1
- STPKWKPURVSAJF-LJEWAXOPSA-N (4r,5r)-5-[4-[[4-(1-aza-4-azoniabicyclo[2.2.2]octan-4-ylmethyl)phenyl]methoxy]phenyl]-3,3-dibutyl-7-(dimethylamino)-1,1-dioxo-4,5-dihydro-2h-1$l^{6}-benzothiepin-4-ol Chemical compound O[C@H]1C(CCCC)(CCCC)CS(=O)(=O)C2=CC=C(N(C)C)C=C2[C@H]1C(C=C1)=CC=C1OCC(C=C1)=CC=C1C[N+]1(CC2)CCN2CC1 STPKWKPURVSAJF-LJEWAXOPSA-N 0.000 description 1
- VUEGYUOUAAVYAS-JGGQBBKZSA-N (6ar,9s,10ar)-9-(dimethylsulfamoylamino)-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline Chemical compound C1=CC([C@H]2C[C@@H](CN(C)[C@@H]2C2)NS(=O)(=O)N(C)C)=C3C2=CNC3=C1 VUEGYUOUAAVYAS-JGGQBBKZSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 1
- DEVSOMFAQLZNKR-RJRFIUFISA-N (z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-n'-pyrazin-2-ylprop-2-enehydrazide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C2=NN(\C=C/C(=O)NNC=3N=CC=NC=3)C=N2)=C1 DEVSOMFAQLZNKR-RJRFIUFISA-N 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- ILWJAOPQHOZXAN-UHFFFAOYSA-N 1,3-dithianyl Chemical group [CH]1SCCCS1 ILWJAOPQHOZXAN-UHFFFAOYSA-N 0.000 description 1
- 125000005940 1,4-dioxanyl group Chemical group 0.000 description 1
- HKDFRDIIELOLTJ-UHFFFAOYSA-N 1,4-dithianyl Chemical group [CH]1CSCCS1 HKDFRDIIELOLTJ-UHFFFAOYSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- QKWWDTYDYOFRJL-UHFFFAOYSA-N 2,2-dimethoxyethanamine Chemical compound COC(CN)OC QKWWDTYDYOFRJL-UHFFFAOYSA-N 0.000 description 1
- JAPYIBBSTJFDAK-UHFFFAOYSA-N 2,4,6-tri(propan-2-yl)benzenesulfonyl chloride Chemical compound CC(C)C1=CC(C(C)C)=C(S(Cl)(=O)=O)C(C(C)C)=C1 JAPYIBBSTJFDAK-UHFFFAOYSA-N 0.000 description 1
- WGFNXGPBPIJYLI-UHFFFAOYSA-N 2,6-difluoro-3-[(3-fluorophenyl)sulfonylamino]-n-(3-methoxy-1h-pyrazolo[3,4-b]pyridin-5-yl)benzamide Chemical compound C1=C2C(OC)=NNC2=NC=C1NC(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=CC(F)=C1 WGFNXGPBPIJYLI-UHFFFAOYSA-N 0.000 description 1
- FQMZXMVHHKXGTM-UHFFFAOYSA-N 2-(1-adamantyl)-n-[2-[2-(2-hydroxyethylamino)ethylamino]quinolin-5-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=CC2=NC(NCCNCCO)=CC=C21 FQMZXMVHHKXGTM-UHFFFAOYSA-N 0.000 description 1
- VCUXVXLUOHDHKK-UHFFFAOYSA-N 2-(2-aminopyrimidin-4-yl)-4-(2-chloro-4-methoxyphenyl)-1,3-thiazole-5-carboxamide Chemical compound ClC1=CC(OC)=CC=C1C1=C(C(N)=O)SC(C=2N=C(N)N=CC=2)=N1 VCUXVXLUOHDHKK-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- QZVRTORVCKGPPY-UHFFFAOYSA-N 2-(3,6-dihydro-2h-thiopyran-4-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound O1C(C)(C)C(C)(C)OB1C1=CCSCC1 QZVRTORVCKGPPY-UHFFFAOYSA-N 0.000 description 1
- FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 description 1
- PAYROHWFGZADBR-UHFFFAOYSA-N 2-[[4-amino-5-(5-iodo-4-methoxy-2-propan-2-ylphenoxy)pyrimidin-2-yl]amino]propane-1,3-diol Chemical compound C1=C(I)C(OC)=CC(C(C)C)=C1OC1=CN=C(NC(CO)CO)N=C1N PAYROHWFGZADBR-UHFFFAOYSA-N 0.000 description 1
- VVCMGAUPZIKYTH-VGHSCWAPSA-N 2-acetyloxybenzoic acid;[(2s,3r)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate;1,3,7-trimethylpurine-2,6-dione Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C.C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 VVCMGAUPZIKYTH-VGHSCWAPSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- DFRAKBCRUYUFNT-UHFFFAOYSA-N 3,8-dicyclohexyl-2,4,7,9-tetrahydro-[1,3]oxazino[5,6-h][1,3]benzoxazine Chemical compound C1CCCCC1N1CC(C=CC2=C3OCN(C2)C2CCCCC2)=C3OC1 DFRAKBCRUYUFNT-UHFFFAOYSA-N 0.000 description 1
- YTEBMMMMLOOMBA-MRVPVSSYSA-N 3-[(1R)-1-aminoethyl]-2-methylbenzonitrile Chemical compound C[C@@H](N)c1cccc(C#N)c1C YTEBMMMMLOOMBA-MRVPVSSYSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- WFOVEDJTASPCIR-UHFFFAOYSA-N 3-[(4-methyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)methylamino]-n-[[2-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound N=1N=C(C=2C=CN=CC=2)N(C)C=1CNC(C=1)=CC=CC=1C(=O)NCC1=CC=CC=C1C(F)(F)F WFOVEDJTASPCIR-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- MPMKMQHJHDHPBE-RUZDIDTESA-N 4-[[(2r)-1-(1-benzothiophene-3-carbonyl)-2-methylazetidine-2-carbonyl]-[(3-chlorophenyl)methyl]amino]butanoic acid Chemical compound O=C([C@@]1(N(CC1)C(=O)C=1C2=CC=CC=C2SC=1)C)N(CCCC(O)=O)CC1=CC=CC(Cl)=C1 MPMKMQHJHDHPBE-RUZDIDTESA-N 0.000 description 1
- GSDQYSSLIKJJOG-UHFFFAOYSA-N 4-chloro-2-(3-chloroanilino)benzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC1=CC=CC(Cl)=C1 GSDQYSSLIKJJOG-UHFFFAOYSA-N 0.000 description 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 description 1
- VKLKXFOZNHEBSW-UHFFFAOYSA-N 5-[[3-[(4-morpholin-4-ylbenzoyl)amino]phenyl]methoxy]pyridine-3-carboxamide Chemical compound O1CCN(CC1)C1=CC=C(C(=O)NC=2C=C(COC=3C=NC=C(C(=O)N)C=3)C=CC=2)C=C1 VKLKXFOZNHEBSW-UHFFFAOYSA-N 0.000 description 1
- OKBMHIVCLCZGLA-UHFFFAOYSA-N 5-butyl-6-ethoxydec-5-ene;tin Chemical compound [Sn].CCCCC(CCCC)=C(CCCC)OCC OKBMHIVCLCZGLA-UHFFFAOYSA-N 0.000 description 1
- XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 1
- 125000005330 8 membered heterocyclic group Chemical group 0.000 description 1
- XASOHFCUIQARJT-UHFFFAOYSA-N 8-methoxy-6-[7-(2-morpholin-4-ylethoxy)imidazo[1,2-a]pyridin-3-yl]-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinolin-1-one Chemical compound C(N1C(=O)C2=C(OC)C=C(C=3N4C(=NC=3)C=C(C=C4)OCCN3CCOCC3)C=C2CC1)C(F)(F)F XASOHFCUIQARJT-UHFFFAOYSA-N 0.000 description 1
- IRBAWVGZNJIROV-SFHVURJKSA-N 9-(2-cyclopropylethynyl)-2-[[(2s)-1,4-dioxan-2-yl]methoxy]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(C#CC4CC4)C=C3CCN2C(=O)N=C1OC[C@@H]1COCCO1 IRBAWVGZNJIROV-SFHVURJKSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical class CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 102000008096 B7-H1 Antigen Human genes 0.000 description 1
- 108010074708 B7-H1 Antigen Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- JQUCWIWWWKZNCS-LESHARBVSA-N C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F Chemical compound C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F JQUCWIWWWKZNCS-LESHARBVSA-N 0.000 description 1
- SCLLZBIBSFTLIN-IFMUVJFISA-N C1=C(C=C(C2=C1C=CC(F)=C2C#C)C1=NC=C2C(N3CC4NC(CC4)C3)=NC(=NC2=C1F)OC[C@@]12C[C@H](CN2CCC1)F)O Chemical compound C1=C(C=C(C2=C1C=CC(F)=C2C#C)C1=NC=C2C(N3CC4NC(CC4)C3)=NC(=NC2=C1F)OC[C@@]12C[C@H](CN2CCC1)F)O SCLLZBIBSFTLIN-IFMUVJFISA-N 0.000 description 1
- UHNRLQRZRNKOKU-UHFFFAOYSA-N CCN(CC1=NC2=C(N1)C1=CC=C(C=C1N=C2N)C1=NNC=C1)C(C)=O Chemical compound CCN(CC1=NC2=C(N1)C1=CC=C(C=C1N=C2N)C1=NNC=C1)C(C)=O UHNRLQRZRNKOKU-UHFFFAOYSA-N 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- PKMUHQIDVVOXHQ-HXUWFJFHSA-N C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O Chemical compound C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O PKMUHQIDVVOXHQ-HXUWFJFHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- 101710167800 Capsid assembly scaffolding protein Proteins 0.000 description 1
- 229940126639 Compound 33 Drugs 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 108010074922 Cytochrome P-450 CYP1A2 Proteins 0.000 description 1
- 208000006104 Cytochrome P-450 CYP1A2 Inhibitors Diseases 0.000 description 1
- 102000009666 Cytochrome P-450 CYP2B6 Human genes 0.000 description 1
- 108010020070 Cytochrome P-450 CYP2B6 Proteins 0.000 description 1
- 208000006075 Cytochrome P-450 CYP2B6 Inhibitors Diseases 0.000 description 1
- 208000009011 Cytochrome P-450 CYP3A Inhibitors Diseases 0.000 description 1
- 102100026533 Cytochrome P450 1A2 Human genes 0.000 description 1
- 102100039205 Cytochrome P450 3A4 Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 239000004470 DL Methionine Substances 0.000 description 1
- 229940127399 DNA Polymerase Inhibitors Drugs 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 1
- KGQZGCIVHYLPBH-UHFFFAOYSA-N Furafylline Chemical group O=C1N(C)C(=O)C=2NC(C)=NC=2N1CC1=CC=CO1 KGQZGCIVHYLPBH-UHFFFAOYSA-N 0.000 description 1
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 102000018898 GTPase-Activating Proteins Human genes 0.000 description 1
- 108091006094 GTPase-accelerating proteins Proteins 0.000 description 1
- 108091006109 GTPases Proteins 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 206010069755 K-ras gene mutation Diseases 0.000 description 1
- 101150105104 Kras gene Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- 229940126203 MRTX1133 Drugs 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- AVYVHIKSFXVDBG-UHFFFAOYSA-N N-benzyl-N-hydroxy-2,2-dimethylbutanamide Chemical compound C(C1=CC=CC=C1)N(C(C(CC)(C)C)=O)O AVYVHIKSFXVDBG-UHFFFAOYSA-N 0.000 description 1
- POFVJRKJJBFPII-UHFFFAOYSA-N N-cyclopentyl-5-[2-[[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]amino]-5-fluoropyrimidin-4-yl]-4-methyl-1,3-thiazol-2-amine Chemical compound C1(CCCC1)NC=1SC(=C(N=1)C)C1=NC(=NC=C1F)NC1=NC=C(C=C1)CN1CCN(CC1)CC POFVJRKJJBFPII-UHFFFAOYSA-N 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- QOVYHDHLFPKQQG-NDEPHWFRSA-N N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O Chemical compound N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O QOVYHDHLFPKQQG-NDEPHWFRSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229940122907 Phosphatase inhibitor Drugs 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 101710204410 Scaffold protein Proteins 0.000 description 1
- 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 description 1
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- 102000007501 Thymosin Human genes 0.000 description 1
- 108010046075 Thymosin Proteins 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 1
- ZEEBGORNQSEQBE-UHFFFAOYSA-N [2-(3-phenylphenoxy)-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound C1(=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)C1=CC=CC=C1 ZEEBGORNQSEQBE-UHFFFAOYSA-N 0.000 description 1
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
- WREOTYWODABZMH-DTZQCDIJSA-N [[(2r,3s,4r,5r)-3,4-dihydroxy-5-[2-oxo-4-(2-phenylethoxyamino)pyrimidin-1-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N(C=C\1)C(=O)NC/1=N\OCCC1=CC=CC=C1 WREOTYWODABZMH-DTZQCDIJSA-N 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- QBYJBZPUGVGKQQ-SJJAEHHWSA-N aldrin Chemical compound C1[C@H]2C=C[C@@H]1[C@H]1[C@@](C3(Cl)Cl)(Cl)C(Cl)=C(Cl)[C@@]3(Cl)[C@H]12 QBYJBZPUGVGKQQ-SJJAEHHWSA-N 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229960003437 aminoglutethimide Drugs 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Natural products C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003432 anti-folate effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940127074 antifolate Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940078010 arimidex Drugs 0.000 description 1
- YCOXTKKNXUZSKD-UHFFFAOYSA-N as-o-xylenol Natural products CC1=CC=C(O)C=C1C YCOXTKKNXUZSKD-UHFFFAOYSA-N 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- YCNIBOIOWCTRCL-UHFFFAOYSA-N azane;2,2,2-trifluoroacetic acid Chemical compound [NH4+].[O-]C(=O)C(F)(F)F YCNIBOIOWCTRCL-UHFFFAOYSA-N 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 238000011095 buffer preparation Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- HGXJOXHYPGNVNK-UHFFFAOYSA-N butane;ethenoxyethane;tin Chemical compound CCCC[Sn](CCCC)(CCCC)C(=C)OCC HGXJOXHYPGNVNK-UHFFFAOYSA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229960005084 calcitriol Drugs 0.000 description 1
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 1
- 235000020964 calcitriol Nutrition 0.000 description 1
- 239000011612 calcitriol Substances 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000008004 cell lysis buffer Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125807 compound 37 Drugs 0.000 description 1
- 229940125936 compound 42 Drugs 0.000 description 1
- 229940125844 compound 46 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 229940127113 compound 57 Drugs 0.000 description 1
- 229940125900 compound 59 Drugs 0.000 description 1
- 229940126179 compound 72 Drugs 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- 125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- GPAYUJZHTULNBE-UHFFFAOYSA-N diphenylphosphine Chemical compound C=1C=CC=CC=1PC1=CC=CC=C1 GPAYUJZHTULNBE-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- BJXYHBKEQFQVES-NWDGAFQWSA-N enpatoran Chemical compound N[C@H]1CN(C[C@H](C1)C(F)(F)F)C1=C2C=CC=NC2=C(C=C1)C#N BJXYHBKEQFQVES-NWDGAFQWSA-N 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
- 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 description 1
- GWNFQAKCJYEJEW-UHFFFAOYSA-N ethyl 3-[8-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]octanoylamino]benzoate Chemical compound CCOC(=O)C1=CC(NC(=O)CCCCCCCSC2=NN=C(CC3=NN(C)C(=O)C4=CC=CC=C34)N2C)=CC=C1 GWNFQAKCJYEJEW-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- 229940013688 formic acid Drugs 0.000 description 1
- 229960002258 fulvestrant Drugs 0.000 description 1
- 229950004998 furafylline Drugs 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 229960004275 glycolic acid Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical group O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 1
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical group C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- OCVXZQOKBHXGRU-UHFFFAOYSA-N iodine(1+) Chemical compound [I+] OCVXZQOKBHXGRU-UHFFFAOYSA-N 0.000 description 1
- SNHMUERNLJLMHN-UHFFFAOYSA-N iodobenzene Chemical compound IC1=CC=CC=C1 SNHMUERNLJLMHN-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N methionine Chemical compound CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- HSPQMLCPRUPXSD-UHFFFAOYSA-N methyl 5-bromo-2-methoxypyridine-4-carboxylate Chemical compound COC(=O)C1=CC(OC)=NC=C1Br HSPQMLCPRUPXSD-UHFFFAOYSA-N 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- OVSARSKQWCLSJT-UHFFFAOYSA-N n,n-di(propan-2-yl)aniline Chemical compound CC(C)N(C(C)C)C1=CC=CC=C1 OVSARSKQWCLSJT-UHFFFAOYSA-N 0.000 description 1
- YGBMCLDVRUGXOV-UHFFFAOYSA-N n-[6-[6-chloro-5-[(4-fluorophenyl)sulfonylamino]pyridin-3-yl]-1,3-benzothiazol-2-yl]acetamide Chemical compound C1=C2SC(NC(=O)C)=NC2=CC=C1C(C=1)=CN=C(Cl)C=1NS(=O)(=O)C1=CC=C(F)C=C1 YGBMCLDVRUGXOV-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004957 naphthylene group Chemical group 0.000 description 1
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000005959 oncogenic signaling Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 1
- 229960005079 pemetrexed Drugs 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 125000004437 phosphorous atom Chemical group 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000006410 propenylene group Chemical group 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 229940095574 propionic acid Drugs 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- MWWATHDPGQKSAR-UHFFFAOYSA-N propyne Chemical group CC#C MWWATHDPGQKSAR-UHFFFAOYSA-N 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000005551 pyridylene group Chemical group 0.000 description 1
- NPWMTBZSRRLQNJ-UHFFFAOYSA-N pyroglutamine Chemical compound NC1CCC(=O)NC1=O NPWMTBZSRRLQNJ-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 239000011257 shell material Substances 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- KOTXAHKUCAQPQA-AAUVPWARSA-N taxine Chemical compound C1([C@@H]([C@@H](O)C(=O)O[C@@H]2C=3/C[C@@](C([C@H](O)C4=C(C)[C@@H](OC(C)=O)CC(C4(C)C)[C@@H](OC(C)=O)\C=3)=O)(C)[C@@H](O)C2)N(C)C)=CC=CC=C1 KOTXAHKUCAQPQA-AAUVPWARSA-N 0.000 description 1
- 229930189271 taxine Natural products 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- HWLNKJXLGQVMJH-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[3.5]nonane-2-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC21CCNCC2 HWLNKJXLGQVMJH-UHFFFAOYSA-N 0.000 description 1
- SJMDMGHPMLKLHQ-UHFFFAOYSA-N tert-butyl 2-aminoacetate Chemical compound CC(C)(C)OC(=O)CN SJMDMGHPMLKLHQ-UHFFFAOYSA-N 0.000 description 1
- PSRHRFNKESVOEL-UHFFFAOYSA-N tert-butyl 4-(2-oxoethyl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(CC=O)CC1 PSRHRFNKESVOEL-UHFFFAOYSA-N 0.000 description 1
- VVDCRJGWILREQH-UHFFFAOYSA-N tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC(B2OC(C)(C)C(C)(C)O2)=C1 VVDCRJGWILREQH-UHFFFAOYSA-N 0.000 description 1
- IRUJRVAXEALDLJ-UHFFFAOYSA-N tert-butyl 4-[2-(methylamino)ethyl]piperazine-1-carboxylate Chemical compound CNCCN1CCN(C(=O)OC(C)(C)C)CC1 IRUJRVAXEALDLJ-UHFFFAOYSA-N 0.000 description 1
- PSELCIMQRLODQE-UHFFFAOYSA-N tert-butyl 6-bromohexanoate Chemical compound CC(C)(C)OC(=O)CCCCCBr PSELCIMQRLODQE-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- VULKFBHOEKTQSF-UHFFFAOYSA-N tert-butyl n-[2-(2-aminoethoxy)ethyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCOCCN VULKFBHOEKTQSF-UHFFFAOYSA-N 0.000 description 1
- LPQZERIRKRYGGM-UHFFFAOYSA-N tert-butyl pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC1 LPQZERIRKRYGGM-UHFFFAOYSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000005556 thienylene group Chemical group 0.000 description 1
- VOVUARRWDCVURC-UHFFFAOYSA-N thiirane Chemical group C1CS1 VOVUARRWDCVURC-UHFFFAOYSA-N 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 1
- 235000019798 tripotassium phosphate Nutrition 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention requires an invention patent application submitted in China on June 23, 2022, titled “SOS1 protein degradation targeting chimera and its compositions, preparations and uses” and application number 202210725527.5 and filed in China on July 22, 2022.
- the invention belongs to the technical field of medicinal chemistry and relates to a series of chimeric compounds for targeted degradation of SOS1 protein, pharmaceutical compositions and pharmaceutical preparations containing them, and their medical uses.
- Protein degradation targeting chimera originated from scientists' discovery of the protein degradation process regulated by ubiquitin (Ub). Eukaryotic cells are constantly trying to maintain appropriate protein levels, producing and degrading thousands of proteins every moment. The key factor in maintaining protein balance is a low molecular weight protein called ubiquitin. When it is linked to proteins, it causes these proteins to be transported to the proteasome for degradation.
- Ub ubiquitin
- PROTAC is "event-driven” and can not only directly affect the function of the protein, but also mediate the degradation of the disease-causing target protein. As long as it can mediate the formation of the ternary complex and ubiquitinate the target protein, PROTAC can theoretically be recycled, so the catalytic amount can be effective. Moreover, for proteins without active sites (such as scaffold proteins, etc.), as long as PROTAC can produce a binding effect, the protein can be induced to be degraded, so the scope of application of the target can be greatly expanded.
- KRAS gene mutations are common in pancreatic cancer, lung adenocarcinoma, colorectal cancer, gallbladder cancer, cholangiocarcinoma and thyroid cancer. It is a GTP-binding protein.
- RAS mainly has two forms in the body: an inactive state bound to GDP and an activated state bound to GTP. Its activity is regulated by two proteins. Guanylate exchange factors (GEF) such as SOS1 promote the release of GDP from the RAS protein, allowing GTP binding to activate RAS; GTPase activating protein activates the GTPase activity of the RAS protein and binds to the RAS protein. GTP is hydrolyzed into GDP, inactivating RAS.
- GEF Guanylate exchange factors
- RAS family proteins When in the GTP-bound state, RAS family proteins are active and engage effector proteins (including RAF and PI3K) to promote RAF/MEK/ERK, PI3K/AKT/mTOR and other pathways. These pathways influence diverse cellular processes such as proliferation, survival, metabolism, etc.
- effector proteins including RAF and PI3K
- SOS1 (son of sevenless homolog 1) has two binding sites for RAS family proteins: one is a catalytic site that binds GDP-bound RAS family proteins to promote guanine nucleotide exchange, and the other is a GTP-bound RAS family proteins thereby cause the catalytic GEF function of SOS1 to further increase the allosite site (Biochem. Pharmacol., 2011, 82(9):1049-1056).
- SOS1 plays an important role in mutant KRAS activation and oncogenic signaling in cancer (Nat. Commun., 2012, 3:1168). In tumor cells carrying KRAS mutations, reducing SOS1 content can reduce the proliferation rate of tumor cells, but no effect is observed in KRAS wild-type cell lines.
- RAS is the oncogene with the highest mutation rate, accounting for 25% of human cancers.
- RAS family protein-SOS1 protein interactions have gained increasing recognition.
- SOS1 inhibitor BI1701963 has entered Phase I clinical research, and no SOS1 inhibitor has yet been developed and marketed.
- PROTAC based on SOS1 protein also No relevant literature reports have been found.
- the present invention aims to provide a small molecule compound, which, in addition to directly inhibiting SOS1 activity, more importantly, can also ubiquitin-label SOS1, thereby inducing SOS1 protein degradation.
- the present invention provides a compound having the structure of formula (I') or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, tautomer, cis-trans isomer thereof , isotope markers or prodrugs:
- A is selected from C 6-10 aryl, 5 to 10 membered heteroaryl and 3 to 6 membered heterocyclyl;
- W 1 is N, NR 2 , C or CR 2 ;
- W 2 is N, NR 4 , C or CR 4 ;
- W 3 is N, CR 5 or C(R 5 ) 2 ;
- W 4 is N, CR 6 or C(R 6 ) 2 ;
- W 5 is N or C
- n 1 or 2;
- n 1, 2 or 3;
- Each R 1 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 6-10 aryl, 5 to 10 membered heteroaryl , C 3-6 cycloalkyl, 3 to 6-membered heterocyclyl, hydroxyl-substituted C 1-6 alkyl, hydroxyl-substituted C 1-6 haloalkyl, amino, halogen, cyano and nitro;
- Each R 3 is independently selected from hydrogen, C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, and halogen;
- R 2 is selected from hydrogen, C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, halogen, cyano, -NR 2a R 2b and -OR 2a , where R 2a and R 2b is independently selected from hydrogen, C 1-6 alkyl, C 1-6 haloalkyl and C 3-6 cycloalkyl;
- R 4 is selected from hydrogen, C 1-6 alkyl, C 3-6 cycloalkyl, 3 to 6 membered heterocyclyl, C 1-6 alkoxy, amino and halogen;
- W 1 is C
- W 2 is NR 4
- W 1 and W 2 are connected through a single bond
- W 1 is connected to R 4 to form a 5- to 10-membered heteroaryl group
- W 1 is NR 2
- W 2 is C
- W 1 and W 2 are connected through a single bond
- W 2 is connected to R 2 to form a 5- to 10-membered heteroaryl group
- each R 5 and R 6 is independently selected from hydrogen, oxo, hydroxyl, C 1-6 alkoxy, nitro, halogen, and amino; alternatively, at least one R 5 and at least one R 6
- R 7 is selected from hydrogen, C 1-6 alkyl, C 2-6 alkenyl and C 3-6 cycloalkyl;
- each R 9 is independently selected from F, Cl, Br, I, OH, NH 2 , CH 3 , CH 2 F, CHF 2 and CF 3 ;
- RE is a group represented by formula (X 1 ), formula (X 2 ) or formula (X 3 ):
- q is any integer from 0 to 3;
- r is any integer from 0 to 4.
- each Ry is independently selected from hydrogen, halogen, hydroxyl, amino, cyano, C 1-6 alkyl, C 3-6 cycloalkyl, 3 to 6 membered heterocyclyl, C 1-6 alkoxy group, C 1-6 alkylthio group and C 1-6 alkylamino group.
- W 5 and RE are separated by at least 6-25 covalent bonds, preferably at least 8-22 covalent bonds, and more preferably at least 20-22 covalent bonds. price key.
- the present invention provides a compound having the structure of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, tautomer, cis-trans isomer, and isotope thereof.
- Markers or prodrugs are described in detail below.
- A is selected from C 6-10 aryl, 5 to 10 membered heteroaryl and 3 to 6 membered heterocyclyl;
- W 1 is N or CR 2 ;
- W 2 is N or CR 4 ;
- W 3 is N, CR 5 or C(R 5 ) 2 ;
- W 4 is N, CR 6 or C(R 6 ) 2 ;
- W 5 is N or C
- n 1 or 2;
- n 1, 2 or 3;
- Each R 1 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 6-10 aryl, 5 to 10 membered heteroaryl , C 3-6 cycloalkyl, 3 to 6-membered heterocyclyl, hydroxyl-substituted C 1-6 alkyl, hydroxyl-substituted C 1-6 haloalkyl, amino, halogen, cyano and nitro;
- Each R 3 is independently selected from hydrogen, C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, and halogen;
- R 2 is selected from hydrogen, C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, halogen, cyano, -NR 2a R 2b and -OR 2a , where R 2a and R 2b is independently selected from hydrogen, C 1-6 alkyl, C 1-6 haloalkyl and C 3-6 cycloalkyl;
- R 4 is selected from hydrogen, C 1-6 alkyl, C 3-6 cycloalkyl, 3 to 6 membered heterocyclyl, C 1-6 alkoxy, amino and halogen;
- each R 5 and R 6 is independently selected from hydrogen, oxo, hydroxyl, C 1-6 alkoxy, nitro, halogen, and amino; alternatively, at least one R 5 and at least one R 6
- R 7 is selected from hydrogen, C 1-6 alkyl, C 2-6 alkenyl and C 3-6 cycloalkyl;
- each R 9 is independently selected from F, Cl, Br, I, OH, NH 2 , CH 3 , CH 2 F, CHF 2 and CF 3 ;
- RE is a group represented by formula (X 1 ), formula (X 2 ) or formula (X 3 ):
- q is any integer from 0 to 3;
- r is any integer from 0 to 4.
- each Ry is independently selected from hydrogen, halogen, hydroxyl, amino, cyano, C 1-6 alkyl, C 3-6 cycloalkyl, 3 to 6 membered heterocyclyl, C 1-6 alkoxy group, C 1-6 alkylthio group and C 1-6 alkylamino group.
- W 5 and RE are separated by at least 6-25 covalent bonds, preferably at least 8-22 covalent bonds, and more preferably at least 20-22 covalent bonds. key.
- the present invention provides a pharmaceutical composition, which contains the above-mentioned compound having the structure of formula (I') or formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, or stereoisomer thereof. , tautomers, cis-trans isomers, isotopic labels or prodrugs, and at least one pharmaceutically acceptable carrier.
- the pharmaceutically acceptable carrier includes (but is not limited to) diluents (or fillers), binders, disintegrants, lubricants, wetting agents, and thickeners.
- diluents or fillers
- binders or fillers
- disintegrants e.g., kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, etc.
- lubricants e.g., lubricants, wetting agents, and thickeners.
- the present invention provides a pharmaceutical preparation, which is composed of the above-mentioned compound having the structure of formula (I') or formula (I) or its pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, Made from tautomers, cis-trans isomers, isotopic labels or prodrugs, or from the above pharmaceutical compositions.
- the present invention provides the above-mentioned compound having the structure of formula (I') or formula (I) or its pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, tautomer, cis
- the disease mediated at least in part by SOS1 protein is cancer, especially selected from the group consisting of pancreatic cancer, lung cancer, colorectal cancer, cholangiocarcinoma, multiple myeloma, melanoma, uterine cancer, Endometrial cancer, thyroid cancer, acute myeloid leukemia, bladder cancer, urothelial cancer, gastric cancer, cervical cancer, head and neck squamous cell carcinoma, diffuse large B-cell lymphoma, esophageal cancer, chronic lymphocytic leukemia, Cancers such as hepatocellular carcinoma, breast cancer, ovarian cancer, prostate cancer, glioblastoma, renal cancer, and sarcoma.
- cancers such as hepatocellular carcinoma, breast cancer, ovarian cancer, prostate cancer, glioblastoma, renal cancer, and sarcoma.
- the present invention provides a pharmaceutical combination form, which contains the above-mentioned compound having the structure of formula (I') or formula (I) or its pharmaceutically acceptable salt, hydrate, solvate, stereoisomer , tautomers, cis-trans isomers, isotopic labels or prodrugs, or the above-mentioned pharmaceutical compositions, or the above-mentioned pharmaceutical preparations, and at least one additional cancer therapeutic agent.
- the compounds of the present invention can also ubiquitylate SOS1 to further Inducing SOS1 protein degradation has good effects on preventing and/or treating tumor diseases in mammals (including humans).
- the compounds of the present invention also have good pharmacokinetic properties, such as lower plasma clearance, longer half-life and better exposure.
- Figure 1 shows the WB results of examining the remaining amount of SOS1 protein over time after H358 cells were treated with Compound 38 (concentration 1 ⁇ M).
- Figure 2 shows the semi-quantitative analysis results of the remaining amount of SOS1 protein over time after H358 cells were treated with Compound 38 (concentration 1 ⁇ M).
- pharmaceutically acceptable salt refers to a salt of a compound of formula I that is substantially non-toxic to organisms.
- Pharmaceutically acceptable salts generally include (but are not limited to) salts formed by reacting the compounds of the present invention with pharmaceutically acceptable inorganic or organic acids. Such salts are also called acid addition salts.
- Common inorganic acids include (but are not limited to) hydrochloric acid, hydrobromic acid, hydriodic acid, nitric acid, sulfuric acid (can form sulfate or acid sulfate), phosphoric acid (can form phosphate or acid phosphate), etc.
- the organic acids include (but are not limited to) trifluoroacetic acid, citric acid (can form citric acid monosalt, disalt or trisalt), maleic acid (can form maleic acid monosalt or disalt), fumaric acid (can form maleic acid monosalt or disalt), fumaric acid (can form maleic acid monosalt or disalt), Can form fumaric acid monosalt or disalt), succinic acid (can form succinic acid monosalt or disalt), tartaric acid (can form tartaric acid monosalt or disalt), oxalic acid (can form oxalic acid monosalt or disalt) disalt), malonic acid (can form malonic acid monosalt or disalt), malic acid (can form malic acid monosalt or disalt), oxalic acid (can form oxalic acid monosalt or disalt), lactic acid, pyruvic acid , salicylic acid, formic acid, acetic acid, propionic acid, benzoic acid, lactic
- hydrate refers to a substance formed by the combination of a compound of the present invention or a pharmaceutically acceptable salt thereof and water through non-covalent intermolecular forces. Common hydrates include (but are not limited to) hemihydrate, monohydrate, dihydrate, trihydrate, etc.
- solvate refers to a substance formed by the combination of a compound of the invention or a pharmaceutically acceptable salt thereof and at least one solvent molecule through non-covalent intermolecular forces.
- solvate includes "hydrate”. Common solvates include (but are not limited to) hydrates, ethanolates, acetones, etc. It should be understood that the present invention encompasses all solvate forms possessing SOS1 inhibitory activity.
- isomers refers to compounds that have the same number of atoms and types of atoms, and therefore the same molecular weight, but different spatial arrangements or configurations of the atoms.
- stereoisomer refers to having a vertical asymmetric plane due to having at least one chiral factor (including chiral center, chiral axis, chiral plane, etc.), A stable isomer capable of rotating plane-polarized light. Since there are asymmetric centers and other chemical structures that may lead to stereoisomerism in the compounds of the present invention, the present invention also includes these stereoisomers and their mixtures. Since the compounds of the present invention and their salts include asymmetric carbon atoms, they can exist as single stereoisomers, racemates, enantiomeric and diastereomeric mixtures. Generally, these compounds can be prepared in the form of racemic mixtures.
- such compounds can be prepared or isolated to obtain pure stereoisomers, that is, single enantiomers or diastereomers, or single stereoisomer enrichment (purity ⁇ 98%, ⁇ 95%, ⁇ 93%, ⁇ 90%, ⁇ 88%, ⁇ 85% or ⁇ 80%) mixtures.
- a single stereoisomer of a compound is formed by containing the desired chiral center Prepared synthetically from optically active starting materials, or prepared by preparing a mixture of enantiomeric products and then separating or resolving them, for example, converting into a mixture of diastereoisomers and then separating or recombining them.
- tautomers refers to structural isomers with different energies that can be interconverted through a low energy barrier. If tautomerism is possible (eg in solution), a chemical equilibrium of tautomers can be achieved.
- proton tautomers include (but are not limited to) interconversions through proton migration, such as keto-enol isomerization, imine-enamine isomerization chemical, amide-iminoalcohol isomerization, etc. Unless otherwise indicated, all tautomeric forms of the compounds of the invention are within the scope of the invention.
- cis-trans isomers refers to the stereoisomers formed by the atoms (or groups) located on both sides of the double bond or ring system due to their different positions relative to the reference plane; in the cis-isomer the atoms (or groups) are located on the same side of the double bond or ring system. In the trans isomer, the atoms (or groups) are located on opposite sides of the double bond or ring system. Unless otherwise indicated, all cis and trans isomeric forms of the compounds of the invention are within the scope of the invention.
- isotopic label refers to a compound formed by replacing specific atoms in a structure with atoms of its isotope.
- the compounds of the present invention include various isotopes of H, C, N, O, F, P, S, and Cl, such as 2 H (D), 3 H (T), 13 C, 14 C, 15 N, 17 O, 18 O, 18 F, 31 P, 32 P, 35 S, 36 S and 37 Cl.
- prodrug refers to a derivative compound capable of providing, directly or indirectly, a compound of the invention when administered to a patient.
- Particularly preferred derivative compounds or prodrugs are compounds that increase the bioavailability of the compounds of the invention when administered to a patient (e.g., are more readily absorbed into the bloodstream), or enhance delivery of the parent compound to the site of action (e.g., the lymphatic system) compound of.
- all prodrug forms of the compounds of the invention are within the scope of the invention, and various prodrug forms are well known in the art.
- aryl refers to an aromatic monocyclic or fused polycyclic monovalent group whose ring atoms are all C atoms, for example, it may have 6 to 20, 6 to 14 or 6 to 12 carbon atoms.
- Non-limiting examples of aryl groups include, but are not limited to, phenyl, naphthyl, anthracenyl, tetralin, and the like.
- C 6-10 aryl refers to an aryl group having 6-10 carbon atoms.
- Non-limiting examples of C 6-10 aryl include (but are not limited to) phenyl, naphthyl and 1,2,3 ,4-tetralin, etc.
- arylene refers to a divalent group formed by further losing one hydrogen atom from an aryl group.
- C 6-10 arylene refers to an arylene group having 6 to 10 carbon atoms.
- Non-limiting examples of C 6-10 arylene groups include, but are not limited to, phenylene, naphthylene and Anthracene et al.
- heteroaryl refers to an aromatic monocyclic or fused polycyclic monovalent group, at least one (for example, 1, 2, 3 or 4) of the ring atoms is selected from N, O and S Heteroatom, the remaining ring atoms are C, for example, it can be a 5- to 10-membered ring, especially a 5- to 8-membered ring.
- Non-limiting examples of heteroaryl groups include, but are not limited to wait.
- the term "5- to 10-membered heteroaryl” refers to a heteroaryl group having 5 to 10 ring atoms, which may contain 1 to 4 heteroatoms selected from N, O, and S.
- the 5- to 10-membered heteroaryl group Non-limiting examples include, but are not limited to, furyl, pyrrolyl, thienyl, oxazolyl, imidazolyl, thiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, pyridyl, indolyl, and quinolyl Phylline etc.
- heteroaryl refers to a bivalent group formed by further losing one hydrogen atom from a heteroaryl group.
- the term “5- to 10-membered heteroarylene” refers to a heteroarylene group having 5 to 10 ring atoms, which may contain 1 to 4 heteroatoms selected from N, O, and S.
- the 5- to 10-membered heteroarylene group Non-limiting examples of aryl groups include, but are not limited to, furylene, pyrrolylene, thienylene, pyridylene, and the like.
- heterocyclyl refers to a fully saturated or partially unsaturated (but not completely unsaturated, such as having 1 or 2 double bonds) monocyclic, bridged or spirocyclic monovalent group, at least one of which (For example, 1, 2, 3 or 4) ring atoms are heteroatoms selected from N, O and S, and the remaining ring atoms are C, which can be, for example, a 3 to 14-membered ring, or even a 3- to 6-membered ring.
- 3- to 14-membered heterocyclyl refers to a heterocyclyl having 3 to 14 ring atoms, which may contain 1 to 4 heteroatoms selected from N, O and S;
- the term “3- to 6-membered heterocyclyl” “Basic” refers to a heterocyclic group with 3 to 6 ring atoms, which may contain 1 or 2 heteroatoms selected from N, O and S;
- the term “5 to 8-membered heterocyclic group” refers to a group with 5 to 8 ring atoms.
- Non-limiting examples of saturated 3-membered heterocyclyl groups include (but are not limited to) oxirane groups, ethylene sulfide groups, cyclozethanyl groups, etc.; non-limiting examples of saturated 4-membered heterocyclyl groups include (but not limited to) azetidinyl, oxbutidinyl, thibutidinyl, etc.; non-limiting examples of saturated 5-membered heterocyclic groups include (but are not limited to) tetrahydrofuryl, tetrahydrothienyl, pyrrolidinyl, isoxazolidinyl , oxazolidinyl, isothiazolidinyl, thiazolidinyl, imidazolidinyl, pyrazolidinyl, etc.; non-limiting examples of saturated 6-membered heterocyclic groups include (but are not limited to) piperidinyl, tetrahydropyridyl Pyryl, tetrahydro
- Non-limiting examples of partially unsaturated heterocyclyl include (but are not limited to) wait.
- heterocyclylene refers to a bivalent group formed by further losing one hydrogen atom of a heterocyclyl group.
- the term “3- to 10-membered heterocyclylene” refers to a heterocyclylene with 3 to 10 ring atoms, which may contain 1 to 4 heteroatoms selected from N, O, and S; the term “3- to 6-membered "Heterocyclylene” has 3 to 6 ring atoms, which may contain 1 or 2 heteroatoms selected from N, O and S.
- Non-limiting examples of 3 to 10 membered heterocyclylene include (But not limited to) aziridylene, azetidinylene, pyrrolidinylene, piperidinylene, piperazinylene, etc., as well as ring-forming heteroatoms (such as sulfur atoms, phosphorus atoms, etc.) after further oxidation The resulting heterocyclylene, e.g. wait.
- alkyl refers to a straight or branched chain monovalent hydrocarbon radical containing no unsaturation.
- C 1-6 alkyl refers to an alkyl group having 1 to 6 carbon atoms.
- Non-limiting examples of C 1-6 alkyl include (but are not limited to) methyl (-CH 3 ), ethyl ( -CH 2 CH 3 ), n-propyl (-CH 2 CH 2 CH 3 ), isopropyl (-CH(CH 3 ) 2 ), n-butyl (-CH 2 CH 2 CH 2 CH 3 ), sec-butyl Base (-CH(CH 3 )CH 2 CH 3 ), isobutyl (-CH 2 CH(CH 3 ) 2 ), tert-butyl (-C(CH 3 ) 3 ), n-pentyl (-CH 2 CH 2 CH 2 CH 3 ), neopentyl (-CH 2 C(CH 3 ) 3 ), etc.
- alkylene refers to a linear or branched divalent hydrocarbon radical formed by further losing one hydrogen atom from an alkyl group, and does not contain unsaturation.
- C 1-6 alkylene refers to an alkylene group having 1 to 6 carbon atoms, and non-limiting examples of C 1-6 alkylene include (but are not limited to) methylene (-CH 2 - ), ethylene (for example -CH 2 -CH 2 -), propylene (for example -CH 2 -CH 2 -CH 2 -), butylene (for example -CH 2 -CH 2 -CH 2 -CH 2 - )wait.
- alkenyl refers to a linear or branched monovalent hydrocarbon group having one or more carbon-carbon double bonds, which may have, for example, 2 to 20 carbon atoms.
- C 2-6 alkenyl refers to an alkenyl group having 2 to 6 carbon atoms; the term “C 2-4 alkenyl” refers to an alkenyl group having 2 to 4 carbon atoms.
- Non-limiting examples of C 2-6 alkenyl include, but are not limited to, vinyl, propenyl, allyl, butenyl, 2-methyl-2-buten-1-yl, pentenyl, hexyl Alkenyl etc.
- alkenylene refers to a linear or branched divalent hydrocarbon radical formed by further losing one hydrogen atom from the alkenyl group.
- C 2-3 alkenylene refers to an alkenylene group having 2 to 3 carbon atoms.
- alkynyl refers to a linear or branched monovalent hydrocarbon group having one or more carbon-carbon triple bonds, which may have, for example, 2 to 20 carbon atoms.
- C 2-6 alkynyl refers to an alkynyl group having 2 to 6 carbon atoms; the term “C 2-4 alkynyl” refers to an alkynyl group having 2 to 4 carbon atoms.
- Non-limiting examples of C 2-6 alkynyl groups include, but are not limited to, ethynyl, propargyl, 1-propynyl, 1-butynyl, pentynyl, hexynyl, and the like.
- alkynylene refers to a linear or branched divalent hydrocarbon radical formed by further losing one hydrogen atom from an alkynyl group.
- C 2-3 alkynylene refers to an alkynylene group having 2 to 3 carbon atoms.
- Non-limiting examples of C 2-3 alkynylene include (but are not limited to) ethynylene, propynylene , propargylene, etc.
- haloalkyl refers to a linear or branched monovalent group formed by replacing at least one hydrogen atom in an alkyl group with a halogen atom and containing no unsaturation.
- C 1-6 haloalkyl refers to a haloalkyl group having 1 to 6 carbon atoms;
- C 1-4 haloalkyl refers to a haloalkyl group having 1 to 4 carbon atoms.
- Non-limiting examples of C 1-6 haloalkyl include, but are not limited to, -CH 2 F, -CHF 2 , -CF 3 , -CH 2 CH 2 F, -CH 2 CHF 2 , -CH 2 CF 3 , - CH 2 CH 2 CH 2 F, -CH 2 CH 2 CHF 2 , -CH 2 CH 2 CF 3 , etc.
- cycloalkyl refers to a fully saturated monocyclic or polycyclic (such as spiro, fused or bridged) monovalent cyclic hydrocarbon group, such as to have 3 to 20, 3 to 12, 3 to 6, or 5 to 6 carbon atoms.
- C 3-14 cycloalkyl refers to a cycloalkyl group having 3 to 14 carbon atoms;
- C 3-6 cycloalkyl refers to a cycloalkyl group having 3 to 6 carbon atoms;
- C 5-8 cycloalkyl refers to a cycloalkyl group having 5 to 8 carbon atoms.
- Non-limiting examples of monocyclic C 3-14 cycloalkyl include (but are not limited to) cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, etc.; polycyclic C 3 -14 Cycloalkyl groups include (but are not limited to) decalinyl, adamantyl, etc.
- halogen refers to fluorine (F), chlorine (Cl), bromine (Br) and iodine (I) located in main group VII of the periodic table of elements.
- alkoxy refers to an "-O-alkyl” group in which the alkyl portion is as defined above.
- amino refers to the "-NH 2 " group.
- amino can also represent a monovalent hydrogen atom formed by further replacing at least one hydrogen atom in the structure with an alkyl group (such as C 1-6 alkyl).
- alkyl group such as C 1-6 alkyl.
- alkylamino or dialkylamino.
- nitro refers to the " -NO2 " group.
- single bond refers to the chemical bond between atoms used to connect or interact with each other, such as ionic bonds, covalent bonds, coordination bonds, etc.; in the molecular structure of organic compounds, single bonds are usually covalent bonds.
- R 4d is "optionally" substituted by halogen, which means that R 4d may be unsubstituted, or may be mono-substituted, poly-substituted or completely substituted by halogen atoms. It will be understood by those skilled in the art that any substitution or substitution pattern that is sterically impossible and/or cannot be synthesized will not be introduced for any group containing one or more substituents.
- the present invention provides a series of SOS1 protein degradation targeting chimeras or pharmaceutically acceptable forms thereof, for example, they can be salts, hydrates, solvates, stereoisomers, tautomers, cis-trans of such compounds. Isomers, isotopic labels or prodrugs.
- A is selected from C 6-10 aryl, 5 to 10 membered heteroaryl and 3 to 6 membered heterocyclyl;
- W 1 is N, NR 2 , C or CR 2 ;
- W 2 is N, NR 4 , C or CR 4 ;
- W 3 is N, CR 5 or C(R 5 ) 2 ;
- W 4 is N, CR 6 or C(R 6 ) 2 ;
- W 5 is N or C
- n 1 or 2;
- n 1, 2 or 3;
- Each R 1 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 6-10 aryl, 5 to 10 membered heteroaryl , C 3-6 cycloalkyl, 3 to 6-membered heterocyclyl, hydroxyl-substituted C 1-6 alkyl, hydroxyl-substituted C 1-6 haloalkyl, amino, halogen, cyano and nitro;
- Each R 3 is independently selected from hydrogen, C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, and halogen;
- R 2 is selected from hydrogen, C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, halogen, cyano, -NR 2a R 2b and -OR 2a , where R 2a and R 2b is independently selected from hydrogen, C 1-6 alkyl, C 1-6 haloalkyl and C 3-6 cycloalkyl;
- R 4 is selected from hydrogen, C 1-6 alkyl, C 3-6 cycloalkyl, 3 to 6 membered heterocyclyl, C 1-6 alkoxy, amino and halogen;
- W 1 when W 1 is C, W 2 is NR 4 , and W 1 and W 2 are connected by a single bond; or when W 1 is NR 2 , W 2 is C, and W 1 and W 2 are connected by a single bond, W 1 Connected to R 4 or W 2 and R 2 to form a 5- to 10-membered heteroaryl group;
- W 1 is CR 2
- W 2 is NR 4
- W 1 and W 2 are connected through a double bond
- R 2 and R 4 are connected to form a 5- to 10-membered heteroaryl group
- each R 5 and R 6 is independently selected from hydrogen, oxo, hydroxyl, C 1-6 alkoxy, nitro, halogen, and amino; alternatively, at least one R 5 and at least one R 6
- R 7 is selected from hydrogen, C 1-6 alkyl, C 2-6 alkenyl and C 3-6 cycloalkyl;
- each R 9 is independently selected from F, Cl, Br, I, OH, NH 2 , CH 3 , CH 2 F, CHF 2 and CF 3 ;
- RE is a group represented by formula (X 1 ), formula (X 2 ) or formula (X 3 ):
- q is any integer from 0 to 3;
- r is any integer from 0 to 4.
- each Ry is independently selected from hydrogen, halogen, hydroxyl, amino, cyano, C 1-6 alkyl, C 3-6 cycloalkyl, 3 to 6 membered heterocyclyl, C 1-6 alkoxy group, C 1-6 alkylthio group and C 1-6 alkylamino group.
- At least 6-25 covalent bonds can be separated between W 5 and RE in the structure of formula (I').
- At least 8-22 covalent bonds can be separated between W 5 and RE in the structure of formula (I').
- W 5 and RE in the structure of formula (I') may be separated by at least 20-22 covalent bonds.
- A is selected from C 6-10 aryl, 5 to 10 membered heteroaryl and 3 to 6 membered heterocyclyl;
- W 1 is N or CR 2 ;
- W 2 is N or CR 4 ;
- W 3 is N, CR 5 or C(R 5 ) 2 ;
- W 4 is N, CR 6 or C(R 6 ) 2 ;
- W 5 is N or C
- n 1 or 2;
- n 1, 2 or 3;
- Each R 1 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 6-10 aryl, 5 to 10 membered heteroaryl , C 3-6 cycloalkyl, 3 to 6-membered heterocyclyl, hydroxyl-substituted C 1-6 alkyl, hydroxyl-substituted C 1-6 haloalkyl, amino, halogen, cyano and nitro;
- R 2 is selected from hydrogen, C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, halogen, cyano, -NR 2a R 2b and -OR 2a , where R 2a and R 2b is independently selected from hydrogen, C 1-6 alkyl, C 1-6 haloalkyl and C 3-6 cycloalkyl;
- Each R 3 is independently selected from hydrogen, C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, and halogen;
- R 4 is selected from hydrogen, C 1-6 alkyl, C 3-6 cycloalkyl, 3 to 6 membered heterocyclyl, C 1-6 alkoxy, amino and halogen;
- each R 5 and R 6 is independently selected from hydrogen, oxo, hydroxyl, C 1-6 alkoxy, nitro, halogen, and amino; alternatively, at least one R 5 and at least one R 6
- R 7 is selected from hydrogen, C 1-6 alkyl, C 2-6 alkenyl and C 3-6 cycloalkyl;
- each R 9 is independently selected from F, Cl, Br, I, OH, NH 2 , CH 3 , CH 2 F, CHF 2 and CF 3 ;
- RE is a group represented by formula (X 1 ), formula (X 2 ) or formula (X 3 ):
- q is any integer from 0 to 3;
- r is any integer from 0 to 4.
- each Ry is independently selected from hydrogen, halogen, hydroxyl, amino, cyano, C 1-6 alkyl, C 3-6 cycloalkyl, 3 to 6 membered heterocyclyl, C 1-6 alkoxy group, C 1-6 alkylthio group and C 1-6 alkylamino group.
- W 5 and RE in the structure of formula (I) may be separated by at least 6-25 covalent bonds.
- At least 8-22 covalent bonds can be separated between W 5 and RE in the structure of formula (I).
- W 5 and RE in the structure of formula (I) may be separated by at least 20-22 covalent bonds.
- the distance between W 5 and RE in the present invention is calculated by the following method: considering one of W 5 and RE as the starting point and the other as the end point, the covalent distance covered by the main chain when crossing the shortest path will be calculated. The keys are counted, and the total number is the distance between them.
- formula (I') or a compound of formula (I) can be any one of a compound of formula (IA) to a compound of formula (IF):
- A, n, R 1 -R 7 , L and RE are as defined in formula (I).
- formula (I') or a compound of formula (I) can be any one of a compound of formula (I-1) to a compound of formula (I-10):
- D is N or CR 5 ;
- A, n, R 1 , R 3 , R 5 , R 6 , R 7 , L and RE are as defined in formula (I).
- the main chain of the -L- fragment in the structures of formulas (I-1) to (I-10) may contain at least 8 to 22 covalent bonds.
- the main chain of the -L- fragment in the structures of formulas (I-1) to (I-10) may contain at least 20-22 covalent bonds.
- the compound of Formula (IA) may be a compound represented by Formula (IA'):
- G is C 5-8 cycloalkyl or 5 to 8-membered heterocyclyl, preferably C 5-6 cycloalkyl, more preferably C 5 cycloalkyl;
- A, n, R 1 -R 3 , R 7 , L and RE are as defined in formula (I).
- A, n, R 1 -R 3 , R 7 , L and RE are as defined in formula (I).
- A, n, R 1 , R 3 , R 4 , R 7 , L and RE are as defined in formula (I).
- Formula (I') or Formula (I) (or Formula (IA), Formula (IA'), Formula (IB), Formula (IB'), Formula (IC), Formula (IC' ), formula (ID), formula (IE), formula (IF), formula (I-1), formula (I-2), formula (I-3), formula (I-4), formula (I-5 ),
- a in any one of formula (I-6), formula (I-7), formula (I-8), formula (I-9), formula (I-10)) is selected from C 6-10 Aryl and 5 to 10 membered heteroaryl, preferably C 6-10 aryl, more preferably phenyl.
- Formula (I') or Formula (I) (or Formula (IA), Formula (IA'), Formula (IB), Formula (IB'), Formula (IC), Formula (IC' ), formula (ID), formula (IE), formula (IF), formula (I-1), formula (I-2), formula (I-3), formula (I-4), formula (I-5 ), n in any one of formula (I-6), formula (I-7), formula (I-8), formula (I-9), formula (I-10)) is 1 or 2, preferably 2.
- segment A is replaced by one R 1 , and this R 1 is substituted at any substitutable position of segment A.
- the A fragment is substituted by two R 1s , and the two R 1s are independently substituted at any two substitutable positions of the A fragment.
- Formula (I') or Formula (I) (or Formula (IA), Formula (IA'), Formula (IB), Formula (IB'), Formula (IC), Formula (IC' ), formula (ID), formula (IE), formula (IF), formula (I-1), formula (I-2), formula (I-3), formula (I-4), formula (I-5 ), each R 1 in formula (I-6), formula (I-7), formula (I-8), formula (I-9), formula (I-10)) is independently selected From C 1-6 alkyl, C 1-6 haloalkyl, amino, halogen and cyano, preferably methyl, ethyl, propyl, isopropyl, butyl, isobutyl, -CH 2 F, -CHF 2 , -CF 3 , -CH 2 CH 2 F , -CH 2 CHF 2 , -CH 2 CF 3 , -CH 2 CH 2 CH 2 F , -CH 2 CH 2 CHF 2 , -CH 2 CH 2 CF 3
- Formula (I') or Formula (I) (or Formula (IA), Formula (IA'), Formula (IB), Formula (IB'), Formula (ID), Formula (IF) R 2 in any one of) is selected from hydrogen, C 1-6 alkyl and C 1-6 haloalkyl, preferably hydrogen, methyl, fluoromethyl, difluoromethyl and trifluoromethyl, preferably methyl .
- Formula (I') or Formula (I) (or Formula (IA), Formula (IA'), Formula (IB), Formula (IB'), Formula (IC), Formula (IC' ), formula (ID), formula (IE), formula (IF), formula (I-1), formula (I-2), formula (I-3), formula (I-4), formula (I-5 ), each R 3 in formula (I-6), formula (I-7), formula (I-8), formula (I-9), formula (I-10)) is selected independently From hydrogen, C 1-6 alkyl and C 1-6 haloalkyl, hydrogen, methyl, fluoromethyl, difluoromethyl and trifluoromethyl are preferred, and hydrogen is more preferred.
- R 4 in formula (I') or formula (I) (or any one of formula (IC), formula (IC'), formula (IE)) is selected from hydrogen, C 1- 6 alkyl and C 1-6 alkoxy, preferably hydrogen, methyl, ethyl, methoxy and ethoxy, more preferably methyl.
- Formula (I') or Formula (I) is independently selected from hydrogen, hydroxyl and C 1-6 alkoxy, preferably hydrogen , hydroxyl, methoxy and ethoxy, preferably hydrogen, hydroxyl and methoxy.
- Formula (I') or Formula (I) (or Formula (IA), Formula (IA'), Formula (IB), Formula (IB'), Formula (IC), Formula (IC' ), formula (ID), formula (IE), formula (IF), formula (I-1), formula (I-2), formula (I-3), formula (I-4), formula (I-5 ), R 7 in any one of formula (I-6), formula (I-7), formula (I-8), formula (I-9), formula (I-10)) is selected from hydrogen, C 1-6 alkyl and C 3-6 cycloalkyl, preferably hydrogen, methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, more preferably methyl.
- Formula (I') or Formula (I) (or Formula (IA), Formula (IA'), Formula (IB), Formula (IB'), Formula (IC), Formula (IC' ), formula (ID), formula (IE), formula (IF), formula (I-1), formula (I-2), formula (I-3), formula (I-4), formula (I-5 ), any one of formula (I-6), formula (I-7), formula (I-8), formula (I-9), formula (I-10)), L in formula (L 1 ) to one of the groups represented by formula (L 40 ), preferably one of the groups represented by formula (L 1 ) to formula (L 27 ), or preferably one of the groups represented by formula (L 8 ) or formula (L 22 ) , one of the groups represented by formula (L 28 ), formula (L 29 ) and formula (L 31 ), and the left end of the group is connected to a fused bicyclic group, and the right end is connected to RE :
- p1, p6 and p7 are independently any integer from 1 to 6;
- p2, p9 and p11 are independently any integer from 1 to 4;
- p3, p5, p10, p12 and p13 are independently any integer from 1 to 4, preferably any integer from 1 to 2;
- p4 and p8 are independently any integer from 1 to 8;
- p14 is any integer from 0-2.
- Formula (I') or Formula (I) (or Formula (IA), Formula (IA'), Formula (IB), Formula (IB'), Formula (IC), Formula (IC' ), formula (ID), formula (IE), formula (IF), formula (I-1), formula (I-2), formula (I-3), formula (I-4), formula (I-5 ), any one of formula (I-6), formula (I-7), formula (I-8), formula (I-9), formula (I-10)), L in formula (L 8 ), and the left end of the group is connected to a fused bicyclic group, and the right end is connected to RE :
- p9 is any integer from 1 to 4, preferably any integer from 2 to 4;
- p10 is any integer from 1 to 2, preferably 2.
- Formula (I') or Formula (I) (or Formula (IA), Formula (IA'), Formula (IB), Formula (IB'), Formula (IC), Formula (IC' ), formula (ID), formula (IE), formula (IF), formula (I-1), formula (I-2), formula (I-3), formula (I-4), formula (I-5 ), any one of formula (I-6), formula (I-7), formula (I-8), formula (I-9), formula (I-10)), L in formula (L 22 ), and the left end of the group is connected to a fused bicyclic group, and the right end is connected to RE :
- p2 is any integer from 1 to 4, preferably any integer from 1 to 2, more preferably 1;
- p3 is any integer from 1 to 2, preferably 1;
- p10 is any integer from 1 to 2, preferably 2.
- Formula (I') or Formula (I) (or Formula (IA), Formula (IA'), Formula (IB), Formula (IB'), Formula (IC), Formula (IC' ), formula (ID), formula (IE), formula (IF), formula (I-1), formula (I-2), formula (I-3), formula (I-4), formula (I-5 ), any one of formula (I-6), formula (I-7), formula (I-8), formula (I-9), formula (I-10)), L in formula (L 28 ), and the left end of the group is connected to a fused bicyclic group, and the right end is connected to RE :
- p9 is any integer from 1 to 4, preferably any integer from 1 to 2, more preferably 1;
- p10 is any integer from 1 to 2, preferably 1;
- p14 is any integer from 0 to 2, preferably any integer from 1 to 2.
- Formula (I') or Formula (I) (or Formula (IA), Formula (IA'), Formula (IB), Formula (IB'), Formula (IC), Formula (IC' ), formula (ID), formula (IE), formula (IF), formula (I-1), formula (I-2), formula (I-3), formula (I-4), formula (I-5 ), any one of formula (I-6), formula (I-7), formula (I-8), formula (I-9), formula (I-10)), L in formula (L 29 ), and the left end of the group is connected to a fused bicyclic group, and the right end is connected to RE :
- p9 is any integer from 1 to 4, preferably any integer from 1 to 2, more preferably 1;
- p10 is any integer from 1 to 2, preferably 2;
- p14 is any integer from 0 to 2, preferably any integer from 1 to 2, and more preferably 1.
- Formula (I') or Formula (I) (or Formula (IA), Formula (IA'), Formula (IB), Formula (IB'), Formula (IC), Formula (IC' ), formula (ID), formula (IE), formula (IF), formula (I-1), formula (I-2), formula (I-3), formula (I-4), formula (I-5 ), any one of formula (I-6), formula (I-7), formula (I-8), formula (I-9), formula (I-10)), L in formula (L 31 ), and the left end of the group is connected to a fused bicyclic group, and the right end is connected to RE :
- p9 is any integer from 1 to 4, preferably any integer from 1 to 2, more preferably 1;
- p10 is any integer from 1 to 2, preferably 2;
- p14 is any integer from 0 to 2, preferably any integer from 1 to 2, and more preferably 1.
- Formula (I') or Formula (I) (or Formula (IA), Formula (IA'), Formula (IB), Formula (IB'), Formula (IC), Formula (IC' ), formula (ID), formula (IE), formula (IF), formula (I-1), formula (I-2), formula (I-3), formula (I-4), formula (I-5 ), R E in any one of formula (I-6), formula (I-7), formula (I-8), formula (I-9), and formula (I-10)) is as in formula (X 1-1 ) to one of the groups represented by formula (X 1-6 ):
- Formula (I') or Formula (I) (or Formula (IA), Formula (IA'), Formula (IB), Formula (IB'), Formula (IC), Formula (IC' ), formula (ID), formula (IE), formula (IF), formula (I-1), formula (I-2), formula (I-3), formula (I-4), formula (I-5 ), R E in any one of formula (I-6), formula (I-7), formula (I-8), formula (I-9), and formula (I-10)) is as in formula (X Groups shown in 2-1 ):
- Formula (I') or Formula (I) (or Formula (IA), Formula (IA'), Formula (IB), Formula (IB'), Formula (IC), Formula (IC' ), formula (ID), formula (IE), formula (IF), formula (I-1), formula (I-2), formula (I-3), formula (I-4), formula (I-5 ), R E in any one of formula (I-6), formula (I-7), formula (I-8), formula (I-9), and formula (I-10)) is as in formula (X 3-1 ) or a group represented by formula (X 3-2 ):
- the SOS1 protein degradation targeting chimera of the present invention includes (but is not limited to) the following compounds:
- composition refers to a composition that can be used as a medicament and contains a pharmaceutically active ingredient (API) and optionally one or more pharmaceutically acceptable carriers.
- API pharmaceutically active ingredient
- pharmaceutically acceptable carrier refers to pharmaceutical excipients that are compatible with the active pharmaceutical ingredients and are not harmful to the subject, including (but not limited to) diluents (or fillers), binders, disintegrating agents, Agent, lubricant, wetting agent, thickener, glidant, flavoring agent, olfactory agent, preservative, antioxidant, pH adjuster, solvent, co-solvent, surfactant, opacifying agent ), etc., one or more.
- the present invention provides a pharmaceutical composition, which contains the above-mentioned general formula compound or its pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, tautomer, cis-trans isomer, and isotopic labeling substances or prodrugs.
- the above pharmaceutical composition further comprises at least one pharmaceutically acceptable carrier.
- pharmaceutical preparation refers to a finished pharmaceutical product prepared in a certain form for use by patients.
- the invention provides a pharmaceutical preparation, which is composed of the above-mentioned general formula compound or its pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, tautomer, cis-trans isomer, and isotope label. or prodrugs or pharmaceutical compositions mentioned above.
- the above pharmaceutical preparation is a solid preparation for oral administration, including (but not limited to) pharmaceutically acceptable capsules, tablets, pills, powders, granules, etc.
- the solid preparation may be coated or microencapsulated using a coating or shell material (such as enteric coating or other materials known in the art).
- the solid preparation may contain opacifying agents and permit release of the active ingredient in a portion of the digestive tract in a delayed manner. Examples of embedding components that can be used are polymeric substances and waxy substances.
- the active ingredient may be in microencapsulated form with one or more of the above-mentioned carriers.
- the above-mentioned pharmaceutical preparation is a liquid dosage form for oral administration, including (but not limited to) pharmaceutically acceptable emulsions, solutions, suspensions, syrups, tinctures, etc.
- the above-mentioned pharmaceutical preparation is a dosage form for parenteral injection, including (but not limited to) pharmaceutical preparations.
- the above-mentioned pharmaceutical preparation is a dosage form for local administration, including (but not limited to) ointments, powders, suppositories, drops, sprays, inhalants, etc.
- the present invention provides the above-mentioned general formula compound or its pharmaceutically acceptable salts and hydrates , solvates, stereoisomers, tautomers, cis-trans isomers, isotopic labels or prodrugs or the above-mentioned pharmaceutical compositions or the above-mentioned pharmaceutical preparations prepared for the prevention and/or treatment of SOS1 protein at least in part Use of drugs in mediated diseases.
- the present invention provides the above-mentioned general formula compound or its pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, tautomer, cis-trans isomer, isotope label or prodrug or the above-mentioned pharmaceutical combination. or the use of the above-mentioned pharmaceutical preparations in the preparation of medicaments for the prevention and/or treatment of cancer.
- cancer refers to a cellular disorder characterized by uncontrolled or dysregulated cell proliferation, reduced cell differentiation, inappropriate ability to invade surrounding tissue, and/or the ability to establish new growth in ectopic locations.
- Non-limiting examples of cancer include, but are not limited to, pancreatic cancer, lung cancer, colorectal cancer, cholangiocarcinoma, multiple myeloma, melanoma, uterine cancer, endometrial cancer, thyroid cancer, acute myeloid leukemia, bladder cancer Cancer, urothelial cancer, gastric cancer, cervical cancer, head and neck squamous cell carcinoma, diffuse large B-cell lymphoma, esophageal cancer, chronic lymphocytic leukemia, hepatocellular carcinoma, breast cancer, ovarian cancer, prostate cancer, gum Blastoma, renal cancer, and sarcoma.
- the present invention also provides the above-mentioned general formula compound or its pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, tautomer, cis-trans isomer, isotope label or prodrug or the above-mentioned medicine.
- the present invention also provides a method for preventing and/or treating diseases (especially cancer) at least partially mediated by SOS1 protein, which includes adding a preventive and/or therapeutically effective amount of a compound of the above general formula or a pharmaceutical thereof Acceptable salts, hydrates, solvates, stereoisomers, tautomers, cis-trans isomers, isotopic labels or prodrugs or the above-mentioned pharmaceutical compositions or the above-mentioned pharmaceutical preparations are administered to a patient in need thereof individual.
- the invention provides a pharmaceutical combination form, which contains the above-mentioned general formula compound or its pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, tautomer, cis-trans isomer, and isotopic labeling drug or prodrug or a pharmaceutical composition as described above or a pharmaceutical preparation as described above, and at least one additional cancer therapeutic agent.
- cancer therapeutic agent refers to a pharmaceutical composition or pharmaceutical preparation that is effective in controlling and/or combating cancer.
- Common cancer therapeutic agents include (but are not limited to) antipurine drugs (such as pentostatin, etc.), antipyrimidine drugs (such as 5-fluorouracil), antifolate drugs (such as methotrexate), DNA polymerase inhibitors (such as Cytarabine), alkylating agents (such as cyclophosphamide), platinum complexes (such as cisplatin, carboplatin), DNA-damaging antibiotics (such as mitomycin), topoisomerase inhibitors (such as dendritic alkaloids), DNA-interfering drugs that interfere with nucleic acid synthesis (such as epirubicin), drugs that block the supply of raw materials (such as asparaginase), drugs that interfere with tubulin formation (such as paclitaxel), drugs that interfere with ribosome function (such as tricuspid Taxine), cytokines (such as IL-1),
- the above-mentioned pharmaceutical composition or the above-mentioned pharmaceutical preparation can be administered alone or in combination with other cancer therapeutic agents (or anti-tumor drugs). This combination therapy can be achieved by administering different cancer therapeutics simultaneously, sequentially, or separately.
- compound 1-2a (30.00g, 111.55mmol, 1.0eq), dioxane (300mL), tributyl(1-ethoxyvinyl)tin (48.34g, 133.86mmol, 1.2eq), triethylamine (33.86g, 334.66mmol, 3eq) and [1,1'-bis(diphenylphosphine)ferrocene]palladium dichloride (4.06g, 5.58mmol, 0.05eq ), after the addition is completed, the temperature is raised to 90°C, and the reaction is stirred overnight. The reaction system was cooled to room temperature and then filtered.
- compound 1-2b (25.00g, 107.28mmol, 1.0eq), tetrahydrofuran (300mL), tert-butylsulfinamide (19.48g, 160.92mmol, 1.5eq) and tetrahydrofuran titanate were added in sequence to the reaction flask. After adding ethyl ester (48.94g, 214.56mmol, 2.0eq), the temperature was raised to 80°C, and the reaction was stirred overnight. After the reaction system was cooled to room temperature, water (300 mL) was added, and ethyl acetate (300 mL) was added for extraction twice.
- compound 1-3d (25.0g, 66.63mmol, 1.0eq), 2,4,6-triisopropylbenzenesulfonyl chloride (20.18g, 66.63mmol, 1.0eq), triethylamine (22.0 g, 199.90mmol, 3.0eq), 4-dimethylaminopyridine (0.81g, 6.66mmol, 0.1eq), dichloromethane (300mL), after completion, stir the reaction overnight, concentrate the system under reduced pressure, and add water (200mL) , then add ethyl acetate (300mL) to extract 3 times, add anhydrous sodium sulfate, dry, filter and concentrate to obtain the crude product.
- Compound 31 was synthesized according to a substantially similar operation to Example 30.
- Example 86 and Example 88 Preparation of Compounds 86 and 88
- compound 39-2a (20.00g, 106.36mmol, 1.0eq) and tetrahydrofuran (150mL) were added in sequence to the reaction bottle.
- tert-butylsulfinamide (19.31g, 159.54mmol, 1.5eq)
- tetraethyl titanate 74.65g, 327.26mmol, 2.0eq
- raise the temperature to 80°C stir for 4 hours, and cool the reaction system to After room temperature, water (150 mL) was added, and then ethyl acetate (150 mL) was added for extraction twice.
- Phosphorus 11.68g, 76.20mmol, 3.0eq
- raise the temperature to 80°C stir the reaction for 3 hours, spin the system to dryness, add ethyl acetate (100ml), and adjust the pH of the system to 8 with saturated sodium carbonate aqueous solution under ice bath conditions -9, separate the liquids, wash the organic phase once with water (50ml) and once with saturated sodium chloride aqueous solution (50ml), dry the organic phase with anhydrous sodium sulfate, and spin to dryness to obtain compound 39-3d (6.53g); MS: m/z 258.0[M+1] + ;
- compound 39-3e (7g, 17.07mmol, 1.0eq), N-tert-butoxycarbonylpiperazine (21.02g, 85.36mmol, 5.0eq), copper iodide (325.13mg) were added to the reaction bottle in sequence.
- 1.71mmol, 0.1eq potassium phosphate (10.87g, 51.21mmol, 3.0eq)
- isopropyl alcohol (70ml) and ethylene glycol (70ml) after adding, raise the temperature to 80°C, stir the reaction overnight, and cool the reaction system After reaching room temperature, water (150 mL) was added, and then ethyl acetate (150 mL) was added for extraction twice.
- compound 40-1b 140.0 mg, 0.31 mmol, 1.0 eq
- dipolyrhodium acetate 5.55 mg, 0.01 mmol, 0.04 eq
- iodobenzene diethyl ester 152.23 mg, 0.47 mmol, 1.5eq
- ammonium trifluoroacetate 71.12mg, 0.62mmol, 2.0eq
- magnesium oxide 51.07mg, 1.24mmol, 4.0eq
- dichloromethane 4mL
- the reaction system was lowered to room temperature, water (50 mL) was added, extracted twice with ethyl acetate (50 mL), and saturated with chlorine. Wash twice with sodium solution (50 mL), dry, filter with anhydrous sodium sulfate, and concentrate to obtain a crude product.
- compound 36-1c (300.0 mg, 0.88 mmol, 1.5 eq), dimethylformamide (10 mL), glutaric acid (173.7 mg, 1.32 mmol, 1.5 eq), and diisopropylethylamine were added in sequence.
- reaction solution Filter, spin the filtrate to dryness, and perform reverse-phase column chromatography purification (Shim-pack GIS-C18 20*250nm, 5 ⁇ m; 0.01% formic acid-water/acetonitrile) to obtain compound 49 (18.4 mg);
- Compound 53 was synthesized following substantially similar procedures to Example 52.
- compound 83-1d (83 mg, 0.18 mmol, 1.0 eq) and N-Boc-1,2,5,6-tetrahydropyridine-4-boronic acid pinacol ester (67 mg, 0.22mmol, 1.2eq), tetrakis(triphenylphosphine)palladium (31.2mg, 0.027mmol, 0.15eq), sodium carbonate (47.7mg, 0.45mmol, 2.5eq), dioxane (4mL) and water (1mL ) is added, raise the temperature to 90°C and stir for 6 hours.
- adipic acid (30mg, 1.0eq.) into the reaction bottle, use thionyl chloride (2mL) as the solvent, then add a drop of DMF to catalyze it, react at 80°C for 1.5h, spin the reaction system to dryness, and then add DCM (3mL) As a solvent, add TEA (113 mg, 6 eq.) and compound 60-2 (81 mg, 1.0 eq.) in sequence, and react at room temperature for 1 hour. After the reaction is completed, pour the reaction system into 10 mL water, extract EA (10 mL ⁇ 2), and freeze the water phase. After drying, the crude product compound 106a (130 mg) was obtained. No purification was needed, and the next step was carried out directly.
- Example 107-114 Synthetic route of compounds 107-114
- Examples 116-123 and 126-128 Synthetic routes for compounds 116-123 and 126-128
- This experiment uses the Western Blot method to evaluate the changes in SOS1 protein levels in H358 cells treated with the test compound.
- H358 cells (ATCC CRL-5807)
- the compounds to be tested were dissolved in DMSO to prepare a stock solution with a concentration of 10mM.
- Freshly prepared stock solutions can be stored at 2-8°C for up to 1 month. For long-term storage, they need to be placed in a -20°C refrigerator.
- H358 cells were cultured using RPMI-1640+10% FBS+1% P/S medium at 37°C, 5% CO2 , and experiments were conducted in the exponential growth phase.
- H358 cells Inoculate H358 cells into a 96-well cell culture plate, with 3 ⁇ 10 cells per well and 100 ⁇ L culture medium.
- SOS1 protein primary antibody working solution add 20 ⁇ l of SOS1 Antibody antibody to 20 mL of blocking solution;
- ⁇ -Actin primary antibody working solution Add 2 ⁇ l of beta-actin (13E5) Rabbit mAb antibody to 20 mL of blocking solution.
- SOS1 protein secondary antibody working solution Anti-rabbit IgG, HRP-linked antibody diluted 1/5000 in blocking solution;
- ⁇ -Actin secondary antibody working solution Anti-rabbit IgG, HRP-linked antibody is diluted 1/10000 in blocking solution.
- (SOS1) represents the content of SOS1 at a certain time point
- (actin) represents the content of actin at a certain time point
- t represents the time point detected after adding the compound
- t0 is the time point before adding the compound.
- the compound of the present invention exhibits excellent induction degradation activity against SOS1, has good anti-tumor activity, and has good effects in treating tumor diseases in mammals (including humans).
- compound 38 had a significant degradation effect on SOS1 protein at 6 hours after treating H358 cells at a concentration of 1 ⁇ M for 6, 15, 24, and 48 hours, and had a significant degradation effect on SOS1 protein at 15, 24, and 48 hours.
- the test method is similar to Test Example 1.
- the final concentration of the compound to be tested is selected as 10 ⁇ m, 3.33 ⁇ m, 1.11 ⁇ m, 0.37 ⁇ m, 0.123 ⁇ m, 0.041 ⁇ m and 0.013 ⁇ m, and the data is analyzed according to the following method.
- Semi-quantitative analysis uses ImageJ software, calculates the gray value of each band according to the following formula, and performs semi-quantitative analysis:
- (SOS1) represents the content of SOS1 at a certain time point
- (actin) represents the content of actin at a certain time point
- t represents the time point of detection after adding the compound (this test time point is 24h)
- t0 is the added compound previous time point.
- the final concentrations of the compounds to be tested were selected from 10 ⁇ m, 3.33 ⁇ m, 1.11 ⁇ m, 0.37 ⁇ m, 0.123 ⁇ m, 0.041 ⁇ m, 0.0137 ⁇ m, 0.0045 ⁇ m, 0.0015 ⁇ m and 0.00051 ⁇ m.
- the gradient diluted compounds were incubated with the cells overnight for 3 hours, the cells were fixed and permeably blocked, and incubated in primary antibodies overnight. Secondary antibodies labeled with infrared fluorescent dyes were then used, and the fluorescence signal was detected using the Odyssey two-color infrared fluorescence imaging system.
- NCI-H358/MKN1 cells were seeded in a 384-well cell culture plate and cultured overnight in a 37°C, 5% carbon dioxide cell culture incubator.
- Relative inhibition rate (%) (fluorescence signal ratio of the compound - average value of positive control) / (average value of negative control - average value of positive control) * 100%;
- the negative control is DMSO
- the positive control is 10 ⁇ M compound MRTX1133.
- the results show that the compound of the present invention can inhibit the phosphorylation of ERK, a downstream protein of SOS1, and has excellent anti-tumor activity.
- Mouse liver microsomes product number M1000, purchased from Xenotech;
- NADPH item number BD11658, purchased from Bide.
- Microsomes (20 mg/mL) were stored in a -80°C refrigerator, thawed in a 37°C water bath before use, and then placed on ice until use.
- reaction samples Take out 50 ⁇ L reaction samples at 0, 5, 15, 30 and 60 min respectively, and use 4 times the solution containing internal standard (3% formic acid, 100 nM alprazolam, 200 nM labetalol, 2 ⁇ M ketoprofen, 200 nM caffeine). Quench with cold acetonitrile. The samples were centrifuged at 3220 g for 45 min. After centrifugation is completed, take 100 ⁇ L of the supernatant and mix it with 100 ⁇ L of ultrapure water for LC-MS/MS analysis and detection.
- internal standard 3% formic acid, 100 nM alprazolam, 200 nM labetalol, 2 ⁇ M ketoprofen, 200 nM caffeine. Quench with cold acetonitrile. The samples were centrifuged at 3220 g for 45 min. After centrifugation is completed, take 100 ⁇ L of the supernatant and mix it with 100 ⁇ L of ultrapure water for LC-MS/MS analysis and detection.
- the incubation volume is 400uL and the protein amount is 0.2mg.
- NADPH item number BD11658, purchased from Bide.
- the reaction was terminated with 400 ⁇ L of cold methanol (internal standard, 500 nM Labetalol, 100 nM Alprazolam and 2 ⁇ M Ketoprofen). Samples were centrifuged at 3220 g for 60 min to precipitate proteins. Take 100 ⁇ L of the supernatant and dilute it with 100 ⁇ L of ultrapure water (according to the peak shape and signal intensity of LC-MS/MS), and analyze it with LC-MS/MS.
- cold methanol internal standard, 500 nM Labetalol, 100 nM Alprazolam and 2 ⁇ M Ketoprofen.
- pH6.8 phosphate buffer measure 0.2mol/L potassium dihydrogen phosphate solution (250mL) and 0.2mol/L sodium hydroxide solution (118mL), add water to dilute to 1000mL, and degas by ultrasonic.
- pH4.5 acetate buffer Weigh sodium acetate (18g), add an appropriate amount of water, slowly add glacial acetic acid (9.8mL), stir evenly, add water to dilute to 1000mL, and degas by ultrasonic.
- CD-1 mice SPF grade, male, were purchased from Spefford (Beijing) Biotechnology Co., Ltd.
- the candidate compound was prepared into a clear solution and given to mice as a single intravenous injection.
- the intravenous injection vehicle was pH 4.5 acetate buffer.
- Each compound was intravenously administered to 6 mice, and the dosage was 10 mg/kg (the concentration of the drug solution was 1 mg/mL, and the dosage volume was 10 ⁇ L/g).
- Samples were taken at 0.0833h, 0.25h, 0.5h, 1h, 2h, 4h, 8h and 24h after intragastric administration. Whole blood samples were placed on ice immediately after collection. Within 0.5h after collection, samples were collected at 4°C and 2000g. Centrifuge for 5 minutes, separate the plasma, collect the upper sample into a sample tube, freeze it in a -10 ⁇ -30°C refrigerator within 0.5h, and transfer it to a -60 ⁇ -90°C refrigerator within 24h.
- the LC-MS/MS method was used to detect the concentration of each prototype drug in plasma samples at each time point, and WinNonlin software was used to calculate the peak concentration (C max ), half-life (t 1/2 ), and area under the drug-time curve (AUC 0-t ), tissue distribution volume (Vd), plasma clearance (CL) and other PK parameters.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明属于药物化学技术领域,涉及SOS1蛋白降解靶向嵌合体及其组合物、制剂和用途。具体而言,该嵌合体化合物的通式结构如式(I')所示。除了可以直接抑制SOS1活性以外,更重要的是,本发明的嵌合体化合物还可以对SOS1进行泛素化标记,进而诱导SOS1蛋白降解,对于预防和/或治疗哺乳动物(包括人类)的肿瘤性疾病具有良好的效果。
Description
相关申请的引用
本发明要求2022年6月23日在中国提交的,名称为“SOS1蛋白降解靶向嵌合体及其组合物、制剂和用途”、申请号为202210725527.5的发明专利申请和2022年7月22日在中国提交的,名称为“SOS1蛋白降解靶向嵌合体及其组合物、制剂和用途”、申请号为202210868337.9的发明专利申请的优先权,通过引用的方式将该专利申请的全部内容并入本文。
本发明属于药物化学技术领域,涉及一系列用于SOS1蛋白靶向降解的嵌合体化合物,包含其的药物组合物和药物制剂,及其医药用途。
蛋白降解靶向嵌合体(proteolysis targeting chimera,PROTAC)技术源于科学家发现了泛素(Ubiquitin,Ub)调节的蛋白降解过程。真核生物细胞一直在努力维持适当的蛋白水平,每一时刻它们都在生成和降解成千上万种蛋白。维持蛋白平衡的关键因子是一种被称为泛素的低分子量蛋白。当它被链接到蛋白上后,会导致这些蛋白被运送到蛋白酶体中进行降解。
传统的小分子抑制剂通过“占位驱动(occupancy-driven)”的作用模式来抑制靶蛋白的功能,进而发挥治疗疾病的作用,但这种作用模式需要较高浓度的抑制剂才能占据靶点的活性位点。而PROTAC是“事件驱动(event-driven)”的,不但可以直接影响蛋白的功能,而且可以介导致病靶蛋白被降解。只要能够介导三元复合物的形成并使靶蛋白泛素化,PROTAC理论上是可以循环使用的,因此催化量即可发挥作用。而且,对于没有活性位点的蛋白(如支架蛋白等)而言,只要PROTAC能够产生结合作用,就可以诱导该蛋白被降解,因此可以大大拓展靶点的施用范围。
KRAS基因突变在胰腺癌、肺腺癌、结直肠癌、胆囊癌、胆管癌和甲状腺癌中常见,是一种GTP结合蛋白。RAS在机体内主要有两种形态:与GDP结合的失活状态和与GTP结合的激活状态。其活性受两个蛋白调控,鸟苷酸交换因子(GEF)如SOS1促使GDP从RAS蛋白上释放,使GTP结合激活RAS;GTP酶激活蛋白激活RAS蛋白的GTP酶活性,将结合在RAS蛋白上的GTP水解成GDP,使RAS失活。当处于GTP结合状态时,RAS家族蛋白具有活性且接合效应蛋白(包括RAF以及PI3K)以促进RAF/MEK/ERK、PI3K/AKT/mTOR等路径。这些路径影响多种细胞过程,例如增殖、存活、代谢等。
SOS1(son of sevenless homolog 1)具有两个用于RAS家族蛋白的结合位点:一个为结合GDP结合的RAS家族蛋白以促进鸟嘌呤核苷酸交换的催化位点,另一个为结合GTP结合的RAS家族蛋白从而引起SOS1的催化性GEF功能进一步增加的别位位点(Biochem.Pharmacol.,2011,82(9):1049-1056)。SOS1在癌症中的突变KRAS活化及致癌信号传导中有重要参与(Nat.Commun.,2012,3:1168)。在携带KRAS突变的肿瘤细胞中,降低SOS1含量,可以降低肿瘤细胞的增殖速率,而在KRAS野生型细胞系中观察不到效应。
RAS作为第一个被确认的癌基因,是突变率最高的致癌基因,在人类癌症中占25%。近几十年来,RAS家族蛋白-SOS1蛋白相互作用已获得越来越多的认识。目前,仅勃林格殷格翰的SOS1抑制剂BI1701963进入临床I期研究,还没有开发上市的SOS1抑制剂。此外,基于SOS1蛋白的PROTAC亦
未见相关文献报道。
发明内容
发明要解决的问题
本发明旨在提供一种小分子化合物,其除了可以直接抑制SOS1活性以外,更重要的是,还可以对SOS1进行泛素化标记,进而诱导SOS1蛋白降解。
用于解决问题的方案
第一方面,本发明提供了一种具有式(I’)结构的化合物或其药学上可接受的盐、水合物、溶剂化物、立体异构体、互变异构体、顺反异构体、同位素标记物或前药:
其中:
表示单键或双键;
A选自C6-10芳基、5至10元杂芳基和3至6元杂环基;
W1为N、NR2、C或CR2;
W2为N、NR4、C或CR4;
W3为N、CR5或C(R5)2;
W4为N、CR6或C(R6)2;
W5为N或C;
m为1或2;
n为1、2或3;
每一个R1独立地选自C1-6烷基、C2-6烯基、C2-6炔基、C1-6卤代烷基、C6-10芳基、5至10元杂芳基、C3-6环烷基、3至6元杂环基、羟基取代的C1-6烷基、羟基取代的C1-6卤代烷基、氨基、卤素、氰基和硝基;
每一个R3独立地选自氢、C1-6烷基、C1-6卤代烷基、C3-6环烷基和卤素;
若存在,R2选自氢、C1-6烷基、C1-6卤代烷基、C3-6环烷基、卤素、氰基、-NR2aR2b和-OR2a,其中R2a和R2b独立地选自氢、C1-6烷基、C1-6卤代烷基和C3-6环烷基;
若存在,R4选自氢、C1-6烷基、C3-6环烷基、3至6元杂环基、C1-6烷氧基、氨基和卤素;
或者,当W1为C,W2为NR4,W1与W2通过单键连接时,W1与R4连接,形成5至10元杂芳基;
或者,当W1为NR2,W2为C,W1与W2通过单键连接时,W2与R2连接,形成5至10元杂芳基;
或者,当W1为CR2,W2为CR4,W1与W2通过双键连接时,R2与R4连接,形成5至10元杂
芳基;
若存在,每一个R5和R6独立地选自氢、氧代基、羟基、C1-6烷氧基、硝基、卤素和氨基;或者,至少一个R5和至少一个R6与其所连接的碳原子一起形成至少一个C5-8环烷基或5至8元杂环基,所述C5-8环烷基和5至8元杂环基独立地任选被1、2、3、4、5或6个选自如下取代基的基团取代:氢、卤素、氧代基、-C(=O)R5a、-C(=O)NR5bR5c、-NR5bR5c、-OR5d、C1-6烷基、C3-14环烷基、3至14元杂环基、C6-10芳基和5至10元杂芳基,其中R5a、R5b、R5c和R5d独立地选自氢、C1-6烷基、C3-14环烷基、3至14元杂环基、C6-10芳基和5至10元杂芳基;
R7选自氢、C1-6烷基、C2-6烯基和C3-6环烷基;
L为-(Z)t-,其中t为1-20中的任一整数;每一个Z独立地选自单键、-O-、-S-、-NH-、-C(=O)-、-C(=S)-、-S(=O)-、-S(=O)2-、C1-6亚烷基、C2-3亚烯基、C2-3亚炔基、C3-10亚环烷基、3至10元亚杂环基、C6-10亚芳基和5至10元亚杂芳基,所述C1-6亚烷基、C2-3亚烯基、C2-3亚炔基、C3-10亚环烷基、3至10元亚杂环基、C6-10亚芳基和5至10元亚杂芳基独立地任选被1、2或3个R8取代;
若存在,每一个R8独立地选自氢、卤素、羟基、氨基、氰基、氨基甲酰基、亚磷酸基、C1-6烷基、C3-6环烷基、3至6元杂环基、C1-6烷基-C(=O)-、C1-6烷基-C(=O)NH-、C1-6烷氧基、C1-6烷硫基和C1-6烷氨基,所述C1-6烷基、C3-6环烷基、3至6元杂环基、C1-6烷基-C(=O)-、C1-6烷基-C(=O)NH-、C1-6烷氧基、C1-6烷硫基和C1-6烷氨基独立地任选被1、2或3个R9取代;
若存在,每一个R9独立地选自F、Cl、Br、I、OH、NH2、CH3、CH2F、CHF2和CF3;
RE为如式(X1)、式(X2)或式(X3)所示的基团:
其中:
Y1、Y2、Y3和Y4独立地为-C(=O)-或-CH2-,且Y1和Y2中的至少一个为-C(=O)-,Y3和Y4中的至少一个为-C(=O)-;
q为0-3中的任一整数;
r为0-4中的任一整数;
若存在,每一个Ry独立地选自氢、卤素、羟基、氨基、氰基、C1-6烷基、C3-6环烷基、3至6元杂环基、C1-6烷氧基、C1-6烷硫基和C1-6烷氨基。
优选地,在具有式(I’)结构的化合物中,W5与RE之间间隔至少6-25个共价键,优选至少8-22个共价键,更优选至少20-22个共价键。
优选地,本发明提供了一种具有式(I)结构的化合物或其药学上可接受的盐、水合物、溶剂化物、立体异构体、互变异构体、顺反异构体、同位素标记物或前药:
其中:
表示单键或双键;
A选自C6-10芳基、5至10元杂芳基和3至6元杂环基;
W1为N或CR2;
W2为N或CR4;
W3为N、CR5或C(R5)2;
W4为N、CR6或C(R6)2;
W5为N或C;
m为1或2;
n为1、2或3;
每一个R1独立地选自C1-6烷基、C2-6烯基、C2-6炔基、C1-6卤代烷基、C6-10芳基、5至10元杂芳基、C3-6环烷基、3至6元杂环基、羟基取代的C1-6烷基、羟基取代的C1-6卤代烷基、氨基、卤素、氰基和硝基;
每一个R3独立地选自氢、C1-6烷基、C1-6卤代烷基、C3-6环烷基和卤素;
若存在,R2选自氢、C1-6烷基、C1-6卤代烷基、C3-6环烷基、卤素、氰基、-NR2aR2b和-OR2a,其中R2a和R2b独立地选自氢、C1-6烷基、C1-6卤代烷基和C3-6环烷基;
若存在,R4选自氢、C1-6烷基、C3-6环烷基、3至6元杂环基、C1-6烷氧基、氨基和卤素;
若存在,每一个R5和R6独立地选自氢、氧代基、羟基、C1-6烷氧基、硝基、卤素和氨基;或者,至少一个R5和至少一个R6与其所连接的碳原子一起形成至少一个C5-8环烷基或5至8元杂环基,所述C5-8环烷基和5至8元杂环基独立地任选被1、2、3、4、5或6个选自如下取代基的基团取代:氢、卤素、氧代基、-C(=O)R5a、-C(=O)NR5bR5c、-NR5bR5c、-OR5d、C1-6烷基、C3-14环烷基、3至14元杂环基、C6-10芳基和5至10元杂芳基,其中R5a、R5b、R5c和R5d独立地选自氢、C1-6烷基、C3-14环烷基、3至14元杂环基、C6-10芳基和5至10元杂芳基;
R7选自氢、C1-6烷基、C2-6烯基和C3-6环烷基;
L为-(Z)t-,其中t为1-20中的任一整数;每一个Z独立地选自单键、-O-、-S-、-NH-、-C(=O)-、-C(=S)-、-S(=O)-、-S(=O)2-、C1-6亚烷基、C2-3亚烯基、C2-3亚炔基、C3-10亚环烷基、3至10元亚杂环基、C6-10亚芳基和5至10元亚杂芳基,所述C1-6亚烷基、C2-3亚烯基、C2-3亚炔基、C3-10亚环烷基、3至10元亚杂环基、C6-10亚芳基和5至10元亚杂芳基独立地任选被1、2或3个R8取代;
若存在,每一个R8独立地选自氢、卤素、羟基、氨基、氰基、氨基甲酰基、亚磷酸基、C1-6烷基、C3-6环烷基、3至6元杂环基、C1-6烷基-C(=O)-、C1-6烷基-C(=O)NH-、C1-6烷氧基、C1-6烷硫基和C1-6烷氨基,所述C1-6烷基、C3-6环烷基、3至6元杂环基、C1-6烷基-C(=O)-、C1-6烷基-C(=O)NH-、C1-6烷氧基、C1-6烷硫基和C1-6烷氨基独立地任选被1、2或3个R9取代;
若存在,每一个R9独立地选自F、Cl、Br、I、OH、NH2、CH3、CH2F、CHF2和CF3;
RE为如式(X1)、式(X2)或式(X3)所示的基团:
其中:
Y1、Y2、Y3和Y4独立地为-C(=O)-或-CH2-,且Y1和Y2中的至少一个为-C(=O)-,Y3和Y4中的至少一个为-C(=O)-;
q为0-3中的任一整数;
r为0-4中的任一整数;
若存在,每一个Ry独立地选自氢、卤素、羟基、氨基、氰基、C1-6烷基、C3-6环烷基、3至6元杂环基、C1-6烷氧基、C1-6烷硫基和C1-6烷氨基。
优选地,在具有式(I)结构的化合物中,W5与RE之间间隔至少6-25个共价键,优选至少8-22个共价键,更优选至少20-22个共价键。
第二方面,本发明提供了一种药物组合物,其包含上述具有式(I’)或式(I)结构的化合物或其药学上可接受的盐、水合物、溶剂化物、立体异构体、互变异构体、顺反异构体、同位素标记物或前药,以及至少一种药学上可接受的载体。
优选地,在上述药物组合物中,所述药学上可接受的载体包括(但不限于)稀释剂(或称填充剂)、粘合剂、崩解剂、润滑剂、润湿剂、增稠剂、助流剂、矫味剂、矫嗅剂、防腐剂、抗氧化剂、pH调节剂、溶剂、助溶剂、表面活性剂、蔽光剂(不透明剂)等。
第三方面,本发明提供了一种药物制剂,其由上述具有式(I’)或式(I)结构的化合物或其药学上可接受的盐、水合物、溶剂化物、立体异构体、互变异构体、顺反异构体、同位素标记物或前药制成,或者由上述药物组合物制成。
第四方面,本发明提供了上述具有式(I’)或式(I)结构的化合物或其药学上可接受的盐、水合物、溶剂化物、立体异构体、互变异构体、顺反异构体、同位素标记物或前药,或者上述药物组合物,或者上述药物制剂,在制备用于预防和/或治疗至少部分由SOS1蛋白介导的疾病的药物中的用途。
优选地,在上述用途中,所述至少部分由SOS1蛋白介导的疾病为癌症,特别是选自胰腺癌、肺癌、结直肠癌、胆管癌、多发性骨髓瘤、黑素瘤、子宫癌、子宫内膜癌、甲状腺癌、急性髓性白血病、膀胱癌、尿路上皮癌、胃癌、宫颈癌、头颈部鳞状细胞癌、弥漫性大B细胞淋巴瘤、食道癌、慢性淋巴细胞白血病、肝细胞癌、乳腺癌、卵巢癌、前列腺癌、胶质母细胞瘤、肾癌和肉瘤的癌症。
第五方面,本发明提供了一种药物联合形式,其包含上述具有式(I’)或式(I)结构的化合物或其药学上可接受的盐、水合物、溶剂化物、立体异构体、互变异构体、顺反异构体、同位素标记物或前药,或者上述药物组合物,或者上述药物制剂,以及至少一种额外的癌症治疗剂。
发明的效果
除了针对SOS1具有优异的抑制活性以外,本发明的化合物还可以对SOS1进行泛素化标记,进
而诱导SOS1蛋白降解,对于预防和/或治疗哺乳动物(包括人类)的肿瘤性疾病具有良好的效果。另外,本发明的化合物还具有良好的药代动力学性质,例如较低的血浆清除率,较长的半衰期以及较好的暴露量。
图1为使用化合物38(浓度1μm)处理H358细胞后SOS1蛋白剩余量随时间考察的WB结果。
图2为使用化合物38(浓度1μm)处理H358细胞后SOS1蛋白剩余量随时间考察的半定量分析结果。
在进一步描述本发明之前,应当理解,本发明不限于本文中所述的特定实施方案;还应该理解,本文中所使用的术语仅用于描述而非限制特定实施方案。
[术语定义]
除非另有说明,下列术语的含义如下。
术语“药学上可接受的盐”是指对生物体基本上无毒性的具有式I结构的化合物的盐。药学上可接受的盐通常包括(但不限于)本发明的化合物与药学上可接受的无机酸或有机酸反应而形成的盐,此类盐又被称为酸加成盐。常见的无机酸包括(但不限于)盐酸、氢溴酸、氢碘酸、硝酸、硫酸(可形成硫酸盐或酸式硫酸盐)、磷酸(可形成磷酸盐或酸式磷酸盐)等,常见的有机酸包括(但不限于)三氟乙酸、柠檬酸(可形成柠檬酸单盐、二盐或三盐)、马来酸(可形成马来酸单盐或二盐)、富马酸(可形成富马酸单盐或二盐)、琥珀酸(可形成琥珀酸单盐或二盐)、酒石酸(可形成酒石酸单盐或二盐)、乙二酸(可形成乙二酸单盐或二盐)、丙二酸(可形成丙二酸单盐或二盐)、苹果酸(可形成苹果酸单盐或二盐)、草酸(可形成草酸单盐或二盐)、乳酸、丙酮酸、水杨酸、甲酸、乙酸、丙酸、苯甲酸、羟乙酸、甲磺酸、苯磺酸、对甲苯磺酸等。
术语“水合物”是指由本发明的化合物或其药学上可接受的盐与水通过非共价分子间作用力结合而形成的物质。常见的水合物包括(但不限于)半水合物、一水合物、二水合物、三水合物等。
术语“溶剂化物”是指由本发明的化合物或其药学上可接受的盐与至少一种溶剂分子通过非共价分子间作用力结合而形成的物质。术语“溶剂化物”包括“水合物”。常见的溶剂化物包括(但不限于)水合物、乙醇合物、丙酮合物等。应该理解的是,本发明涵盖拥有SOS1抑制活性的所有溶剂化物形式。
术语“异构体”是指具有相同原子数和原子类型因而具有相同分子量,但原子的空间排列或构型不同的化合物。
术语“立体异构体”(或称“旋光异构体”)是指由于具有至少一个手性因素(包括手性中心、手性轴、手性面等)而导致具有垂直的不对称平面,从而能够使平面偏振光旋转的稳定异构体。由于本发明化合物中存在可能导致立体异构的不对称中心以及其他化学结构,因此本发明也包括这些立体异构体及其混合物。由于本发明的化合物及其盐包括不对称碳原子,因而能够以单一立体异构体形式、外消旋物、对映异构体和非对映异构体的混合物形式存在。通常,这些化合物能够以外消旋混合物的形式制备。然而,如果需要的话,可以将这类化合物制备或分离后得到纯的立体异构体,即单一对映异构体或非对映异构体,或者单一立体异构体富集化(纯度≥98%、≥95%、≥93%、≥90%、≥88%、≥85%或≥80%)的混合物。如下文中所述,化合物的单一立体异构体是由含有所需手性中心
的旋光起始原料合成制备得到的,或者是通过制备得到对映异构体产物的混合物之后再分离或拆分制备得到的,例如转化为非对映异构体的混合物之后再进行分离或重结晶、色谱处理、使用手性拆分试剂,或者在手性色谱柱上将对映异构体进行直接分离。具有特定立体化学的起始化合物既可以商购得到,也可以按照下文中描述的方法制备再通过本领域熟知的方法拆分得到。术语“对映异构体”是指彼此具有不能重叠的镜像的一对立体异构体。术语“非对映异构体”或“非对映体”是指彼此不构成镜像的旋光异构体。术语“外消旋混合物”或“外消旋物”是指含有等份的单一对映异构体的混合物(即两种R和S对映体的等摩尔量混合物)。术语“非外消旋混合物”是指含有不等份的单一对映异构体的混合物。除非另外指出,本发明的化合物的所有立体异构体形式都在本发明的范围之内。
术语“互变异构体”(或称“互变异构形式”)是指具有不同能量的可通过低能垒互相转化的结构异构体。若互变异构是可能的(如在溶液中),则可以达到互变异构体的化学平衡。例如,质子互变异构体(或称质子转移互变异构体)包括(但不限于)通过质子迁移来进行的互相转化,如酮-烯醇异构化、亚胺-烯胺异构化、酰胺-亚胺醇异构化等。除非另外指出,本发明的化合物的所有互变异构体形式都在本发明的范围之内。
术语“顺反异构体”是指位于双键或环系两侧的原子(或基团)因相对于参考平面的位置不同而形成的立体异构体;在顺式异构体中原子(或基团)位于双键或环系的同侧,在反式异构体中原子(或基团)位于双键或环系的异侧。除非另外指出,本发明的化合物的所有顺反异构体形式都在本发明的范围之内。
术语“同位素标记物”是指将结构中的特定原子替换为其同位素原子而形成的化合物。除非另外指出,本发明的化合物中包括H、C、N、O、F、P、S、Cl的各种同位素,如2H(D)、3H(T)、13C、14C、15N、17O、18O、18F、31P、32P、35S、36S和37Cl。
术语“前药”是指在适用于患者后能够直接或间接地提供本发明的化合物的衍生化合物。特别优选的衍生化合物或前药是在施用于患者时可以提高本发明的化合物的生物利用度的化合物(例如,更易吸收入血),或者促进母体化合物向作用位点(例如,淋巴系统)递送的化合物。除非另外指出,本发明的化合物的所有前药形式都在本发明的范围之内,且各种前药形式是本领域熟知的。
术语“芳基”是指具有芳香性的单环或稠合多环的一价基团,其环原子均为C原子,例如可以具有6至20、6至14或6至12个碳原子。芳基的非限制性实例包括(但不限于)苯基、萘基、蒽基和1,2,3,4-四氢化萘等。术语“C6-10芳基”是指具有6-10个碳原子的芳基,C6-10芳基的非限制性实例包括(但不限于)苯基、萘基和1,2,3,4-四氢化萘等。
术语“亚芳基”是指芳基进一步失去一个氢原子所形成的二价基团。术语“C6-10亚芳基”是指具有6-10个碳原子的亚芳基,C6-10亚芳基的非限制性实例包括(但不限于)亚苯基、亚萘基和亚蒽基等。
术语“杂芳基”是指具有芳香性的单环或稠合多环的一价基团,其至少一个(例如1、2、3或4个)环原子为选自N、O和S的杂原子,其余环原子为C,例如可以为5至10元环,尤其是5至8元环。杂芳基的非限制性实例包括(但不限于)
等。术语“5至10元杂芳基”是指具有5至10个环原子的杂芳基,其中可以含有1至4个选自N、O和S的杂原子,5至10元杂芳基的非限制性实例包括(但不限于)呋喃基、吡咯基、噻吩基、噁唑基、咪唑基、噻唑基、异噁唑基、吡唑基、异噻唑基、吡啶基、吲哚基和喹啉基等。
术语“亚杂芳基”是指杂芳基进一步失去一个氢原子所形成的二价基团。术语“5至10元亚杂芳基”是指具有5至10个环原子的亚杂芳基,其中可以含有1至4个选自N、O和S的杂原子,5至10元亚杂芳基的非限制性实例包括(但不限于)亚呋喃基、亚吡咯基、亚噻吩基和亚吡啶基等。
术语“杂环基”是指完全饱和的或部分不饱和的(但非完全不饱和的,例如具有1或2个双键)单环、桥环或螺环的一价基团,其至少一个(例如1、2、3或4个)环原子为选自N、O和S的杂原子,其余环原子为C,例如可以为3至14元环,甚至是3至6元环。术语“3至14元杂环基”是指具有3至14个环原子的杂环基,其中可以含有1至4个选自N、O和S的杂原子;术语“3至6元杂环基”是指具有3至6个环原子的杂环基,其中可以含有1或2个选自N、O和S的杂原子;术语“5至8元杂环基”是指具有5至8个环原子的杂环基,其中可以含有1至3个选自N、O和S的杂原子。
饱和的3元杂环基的非限制性实例包括(但不限于)环氧乙烷基、环硫乙烷基、环氮乙烷基等;饱和的4元杂环基的非限制性实例包括(但不限于)吖丁啶基、噁丁啶基、噻丁啶基等;饱和的5元杂环基的非限制性实例包括(但不限于)四氢呋喃基、四氢噻吩基、吡咯烷基、异噁唑烷基、噁唑烷基、异噻唑烷基、噻唑烷基、咪唑烷基、吡唑烷基等;饱和的6元杂环基的非限制性实例包括(但不限于)哌啶基、四氢吡喃基、四氢噻喃基、吗啉基、哌嗪基、1,4-噻噁烷基、1,4-二氧六环基、硫代吗啉基、1,3-二噻烷基、1,4-二噻烷基等;饱和的7元杂环基的非限制性实例包括(但不限于)氮杂环庚烷基、氧杂环庚烷基、硫杂环庚烷基等;饱和的8元杂环基的非限制性实例包括(但不限于)氮杂环辛烷基、氧杂环辛烷基、硫杂环辛烷基等。
部分不饱和的杂环基的非限制性实例包括(但不限于)
等。
术语“亚杂环基”是指杂环基进一步失去一个氢原子所形成的二价基团。术语“3至10元亚杂环基”是指具有3至10个环原子的亚杂环基,其中可以含有1至4个选自N、O和S的杂原子;术语“3至6元亚杂环基”具有3至6个环原子的亚杂环基,其中可以含有1或2个选自N、O和S的杂原子,3至10元亚杂环基的非限制性实例包括(但不限于)亚环氮乙烷基、亚吖丁啶基、亚吡咯烷基、亚哌啶基和亚哌嗪基等,以及成环杂原子(如硫原子、磷原子等)被进一步氧化后得到的亚杂环基,例如
等。
术语“烷基”是指直链或支链的一价烃基,不含有不饱和度。术语“C1-6烷基”是指具有1至6个碳原子的烷基,C1-6烷基的非限制性实例包括(但不限于)甲基(-CH3)、乙基(-CH2CH3)、正丙基(-CH2CH2CH3)、异丙基(-CH(CH3)2)、正丁基(-CH2CH2CH2CH3)、仲丁基(-CH(CH3)CH2CH3)、异丁基(-CH2CH(CH3)2)、叔丁基(-C(CH3)3)、正戊基(-CH2CH2CH2CH2CH3)、新戊基(-CH2C(CH3)3)等。
术语“亚烷基”是指烷基进一步失去一个氢原子所形成的直链或支链的二价烃基,不含有不饱和度。术语“C1-6亚烷基”是指具有1至6个碳原子的亚烷基,C1-6亚烷基的非限制性实例包括(但不限于)亚甲基(-CH2-)、亚乙基(例如-CH2-CH2-)、亚丙基(例如-CH2-CH2-CH2-)、亚丁基(例如-CH2-CH2-CH2-CH2-)等。
术语“烯基”是指具有一个或多个碳碳双键的直链或支链的一价烃基,例如可以具有2至20个碳原子。术语“C2-6烯基”是指具有2至6个碳原子的烯基;术语“C2-4烯基”是指具有2至4个碳原子的烯基。C2-6烯基的非限制性实例包括(但不限于)乙烯基、丙烯基、烯丙基、丁烯基、2-甲基-2-丁烯-1-基、戊烯基、己烯基等。
术语“亚烯基”是指烯基进一步失去一个氢原子所形成的直链或支链的二价烃基。术语“C2-3亚烯基”是指具有2至3个碳原子的亚烯基,C2-3亚烯基的非限制性实例包括(但不限于)亚乙烯基(例如-CH=CH-)、亚丙烯基(例如-CH2-CH=CH-)、亚烯丙基(例如-CH=CH-CH2-)等。
术语“炔基”是指具有一个或多个碳碳叁键的直链或支链的一价烃基,例如可以具有2至20个碳原子。术语“C2-6炔基”是指具有2至6个碳原子的炔基;术语“C2-4炔基”是指具有2至4个碳原子的炔基。C2-6炔基的非限制性实例包括(但不限于)乙炔基、炔丙基、1-丙炔基、1-丁炔基、戊炔基、己炔基等。
术语“亚炔基”是指炔基进一步失去一个氢原子所形成的直链或支链的二价烃基。术语“C2-3亚炔基”是指具有2至3个碳原子的亚炔基,C2-3亚炔基的非限制性实例包括(但不限于)亚乙炔基、亚丙炔基、亚炔丙基等。
术语“卤代烷基”是指直链或支链的一价基团,其由烷基中的至少一个氢原子被卤素原子取代后形成,不含有不饱和度。术语“C1-6卤代烷基”是指具有1至6个碳原子的卤代烷基;术语“C1-4卤代烷基”是指具有1至4个碳原子的卤代烷基。C1-6卤代烷基的非限制性实例包括(但不限于)-CH2F、-CHF2、-CF3、-CH2CH2F、-CH2CHF2、-CH2CF3、-CH2CH2CH2F、-CH2CH2CHF2、-CH2CH2CF3等。
术语“环烷基”是指完全饱和的单环或多环(例如螺环、稠环或桥环)的一价环状烃基,例如可
以具有3至20、3至12、3至6或5至6个碳原子。术语“C3-14环烷基”是指具有3至14个碳原子的环烷基;术语“C3-6环烷基”是指具有3至6个碳原子的环烷基;术语“C5-8环烷基”是指具有5至8个碳原子的环烷基。单环的C3-14环烷基的非限制性实例包括(但不限于)环丙基、环丁基、环戊基、环己基、环庚基、环辛基等;多环的C3-14环烷基包括(但不限于)十氢萘基、金刚烷基等。
术语“卤素”是指位于元素周期表第VII主族的氟(F)、氯(Cl)、溴(Br)和碘(I)。
术语“氧代基”是指“=O”基团。
术语“羟基”是指“-OH”基团。
术语“烷氧基”是指“-O-烷基”基团,其中的烷基部分如上所定义。
术语“氨基”是指“-NH2”基团,在某些情况下,氨基还可以表示结构中的至少一个氢原子进一步被烷基(例如C1-6烷基)取代所形成的一价基团,例如“烷氨基”或“二烷氨基”。
术语“硝基”是指“-NO2”基团。
术语“氰基”是指“-CN”基团。
术语“氨基甲酰基”是指“-C(=O)-NH2”基团。
术语“单键”是指原子之间用于相互连接或相互作用的化学键,例如离子键、共价键、配位键等;在有机化合物的分子结构中,单键通常为共价键。
术语“任选地”是指随后描述的事件或情况可以发生或不发生,该描述包括发生所述事件或情况和不发生所述事件或情况。例如,R4d“任选地”被卤素取代,是指R4d可以是未被取代的,也可以是被卤素原子单取代、多取代或完全取代的。本领域技术人员可理解,对于包含一个或多个取代基的任何基团,不会引入任何在空间上不可能存在和/或不能合成的取代或取代模式。
[SOS1蛋白降解靶向嵌合体]
本发明提供了一系列SOS1蛋白降解靶向嵌合体或其药学上可接受的形式,例如可以为该类化合物的盐、水合物、溶剂化物、立体异构体、互变异构体、顺反异构体、同位素标记物或前药。
在一项实施方案中,该类化合物的结构如式(I’)所示:
其中:
表示单键或双键;
A选自C6-10芳基、5至10元杂芳基和3至6元杂环基;
W1为N、NR2、C或CR2;
W2为N、NR4、C或CR4;
W3为N、CR5或C(R5)2;
W4为N、CR6或C(R6)2;
W5为N或C;
m为1或2;
n为1、2或3;
每一个R1独立地选自C1-6烷基、C2-6烯基、C2-6炔基、C1-6卤代烷基、C6-10芳基、5至10元杂芳基、C3-6环烷基、3至6元杂环基、羟基取代的C1-6烷基、羟基取代的C1-6卤代烷基、氨基、卤素、氰基和硝基;
每一个R3独立地选自氢、C1-6烷基、C1-6卤代烷基、C3-6环烷基和卤素;
若存在,R2选自氢、C1-6烷基、C1-6卤代烷基、C3-6环烷基、卤素、氰基、-NR2aR2b和-OR2a,其中R2a和R2b独立地选自氢、C1-6烷基、C1-6卤代烷基和C3-6环烷基;
若存在,R4选自氢、C1-6烷基、C3-6环烷基、3至6元杂环基、C1-6烷氧基、氨基和卤素;
或者,当W1为C,W2为NR4,W1与W2通过单键连接时或当W1为NR2,W2为C,W1与W2通过单键连接时,W1与R4或W2与R2连接,形成5至10元杂芳基;
或者,当W1为CR2,W2为NR4,W1与W2通过双键连接时,R2与R4连接,形成5至10元杂芳基;
若存在,每一个R5和R6独立地选自氢、氧代基、羟基、C1-6烷氧基、硝基、卤素和氨基;或者,至少一个R5和至少一个R6与其所连接的碳原子一起形成至少一个C5-8环烷基或5至8元杂环基,所述C5-8环烷基和5至8元杂环基独立地任选被1、2、3、4、5或6个选自如下取代基的基团取代:氢、卤素、氧代基、-C(=O)R5a、-C(=O)NR5bR5c、-NR5bR5c、-OR5d、C1-6烷基、C3-14环烷基、3至14元杂环基、C6-10芳基和5至10元杂芳基,其中R5a、R5b、R5c和R5d独立地选自氢、C1-6烷基、C3-14环烷基、3至14元杂环基、C6-10芳基和5至10元杂芳基;
R7选自氢、C1-6烷基、C2-6烯基和C3-6环烷基;
L为-(Z)t-,其中t为1-20中的任一整数;每一个Z独立地选自单键、-O-、-S-、-NH-、-C(=O)-、-C(=S)-、-S(=O)-、-S(=O)2-、C1-6亚烷基、C2-3亚烯基、C2-3亚炔基、C3-10亚环烷基、3至10元亚杂环基、C6-10亚芳基和5至10元亚杂芳基,所述C1-6亚烷基、C2-3亚烯基、C2-3亚炔基、C3-10亚环烷基、3至10元亚杂环基、C6-10亚芳基和5至10元亚杂芳基独立地任选被1、2或3个R8取代;
若存在,每一个R8独立地选自氢、卤素、羟基、氨基、氰基、氨基甲酰基、亚磷酸基、C1-6烷基、C3-6环烷基、3至6元杂环基、C1-6烷基-C(=O)-、C1-6烷基-C(=O)NH-、C1-6烷氧基、C1-6烷硫基和C1-6烷氨基,所述C1-6烷基、C3-6环烷基、3至6元杂环基、C1-6烷基-C(=O)-、C1-6烷基-C(=O)NH-、C1-6烷氧基、C1-6烷硫基和C1-6烷氨基独立地任选被1、2或3个R9取代;
若存在,每一个R9独立地选自F、Cl、Br、I、OH、NH2、CH3、CH2F、CHF2和CF3;
RE为如式(X1)、式(X2)或式(X3)所示的基团:
其中:
Y1、Y2、Y3和Y4独立地为-C(=O)-或-CH2-,且Y1和Y2中的至少一个为-C(=O)-,Y3和Y4中的至少一个为-C(=O)-;
q为0-3中的任一整数;
r为0-4中的任一整数;
若存在,每一个Ry独立地选自氢、卤素、羟基、氨基、氰基、C1-6烷基、C3-6环烷基、3至6元杂环基、C1-6烷氧基、C1-6烷硫基和C1-6烷氨基。
在一项优选的实施方案中,式(I’)结构中的W5与RE之间可以间隔至少6-25个共价键。
在一项更优选的实施方案中,式(I’)结构中的W5与RE之间可以间隔至少8-22个共价键。
在一项进一步优选的实施方案中,式(I’)结构中的W5与RE之间可以间隔至少20-22个共价键。
在一项实施方案中,该类化合物的结构如式(I)所示:
其中:
表示单键或双键;
A选自C6-10芳基、5至10元杂芳基和3至6元杂环基;
W1为N或CR2;
W2为N或CR4;
W3为N、CR5或C(R5)2;
W4为N、CR6或C(R6)2;
W5为N或C;
m为1或2;
n为1、2或3;
每一个R1独立地选自C1-6烷基、C2-6烯基、C2-6炔基、C1-6卤代烷基、C6-10芳基、5至10元杂芳基、C3-6环烷基、3至6元杂环基、羟基取代的C1-6烷基、羟基取代的C1-6卤代烷基、氨基、卤素、氰基和硝基;
若存在,R2选自氢、C1-6烷基、C1-6卤代烷基、C3-6环烷基、卤素、氰基、-NR2aR2b和-OR2a,其中R2a和R2b独立地选自氢、C1-6烷基、C1-6卤代烷基和C3-6环烷基;
每一个R3独立地选自氢、C1-6烷基、C1-6卤代烷基、C3-6环烷基和卤素;
若存在,R4选自氢、C1-6烷基、C3-6环烷基、3至6元杂环基、C1-6烷氧基、氨基和卤素;
若存在,每一个R5和R6独立地选自氢、氧代基、羟基、C1-6烷氧基、硝基、卤素和氨基;或者,至少一个R5和至少一个R6与其所连接的碳原子一起形成至少一个C5-8环烷基或5至8元杂环基,所述C5-8环烷基和5至8元杂环基独立地任选被1、2、3、4、5或6个选自如下取代基的基团取代:氢、卤素、氧代基、-C(=O)R5a、-C(=O)NR5bR5c、-NR5bR5c、-OR5d、C1-6烷基、C3-14环烷基、3至14元杂环基、C6-10芳基和5至10元杂芳基,其中R5a、R5b、R5c和R5d独立地选自氢、C1-6烷基、C3-14环烷基、3至14元杂环基、C6-10芳基和5至10元杂芳基;
R7选自氢、C1-6烷基、C2-6烯基和C3-6环烷基;
L为-(Z)t-,其中t为1-20中的任一整数;每一个Z独立地选自单键、-O-、-S-、-NH-、-C(=O)-、-C(=S)-、-S(=O)-、-S(=O)2-、C1-6亚烷基、C2-3亚烯基、C2-3亚炔基、C3-10亚环烷基、3至10元亚杂环基、C6-10亚芳基和5至10元亚杂芳基,所述C1-6亚烷基、C2-3亚烯基、C2-3亚炔基、C3-10亚环烷基、3至10元亚杂环基、C6-10亚芳基和5至10元亚杂芳基独立地任选被1、2或3个R8取代;
若存在,每一个R8独立地选自氢、卤素、羟基、氨基、氰基、氨基甲酰基、亚磷酸基、C1-6烷基、C3-6环烷基、3至6元杂环基、C1-6烷基-C(=O)-、C1-6烷基-C(=O)NH-、C1-6烷氧基、C1-6烷硫基和C1-6烷氨基,所述C1-6烷基、C3-6环烷基、3至6元杂环基、C1-6烷基-C(=O)-、C1-6烷基-C(=O)NH-、C1-6烷氧基、C1-6烷硫基和C1-6烷氨基独立地任选被1、2或3个R9取代;
若存在,每一个R9独立地选自F、Cl、Br、I、OH、NH2、CH3、CH2F、CHF2和CF3;
RE为如式(X1)、式(X2)或式(X3)所示的基团:
其中:
Y1、Y2、Y3和Y4独立地为-C(=O)-或-CH2-,且Y1和Y2中的至少一个为-C(=O)-,Y3和Y4中的至少一个为-C(=O)-;
q为0-3中的任一整数;
r为0-4中的任一整数;
若存在,每一个Ry独立地选自氢、卤素、羟基、氨基、氰基、C1-6烷基、C3-6环烷基、3至6元杂环基、C1-6烷氧基、C1-6烷硫基和C1-6烷氨基。
在一项优选的实施方案中,式(I)结构中的W5与RE之间可以间隔至少6-25个共价键。
在一项更优选的实施方案中,式(I)结构中的W5与RE之间可以间隔至少8-22个共价键。
在一项进一步优选的实施方案中,式(I)结构中的W5与RE之间可以间隔至少20-22个共价键。
除非另有说明,本发明中W5与RE之间的距离均以下法计算:视W5和RE之一为起点,另一为终点,将跨越最短路径时主链所涵盖的共价键进行计数,其总数即为二者之间的距离。
在一项实施方案中,式(I’)或式(I)化合物可以为式(IA)化合物至式(IF)化合物中的任意一种:
其中:
A、n、R1-R7、L和RE如式(I)中所定义。
在另一项实施方案中,式(I’)或式(I)化合物可以为式(I-1)化合物至式(I-10)化合物中的任意一种:
其中:
D为N或CR5;
A、n、R1、R3、R5、R6、R7、L和RE如式(I)中所定义。
在一项优选的实施方案中,式(I-1)至式(I-10)结构中-L-片段的主链可以包含至少8-22个共价键。
在一项更优选的实施方案中,式(I-1)至式(I-10)结构中-L-片段的主链可以包含至少20-22个共价键。
在一项实施方案中,当式(IA)中的R5和R6与其所连接的碳原子一起形成环系时,式(IA)化合物可以为如式(IA’)所示的化合物:
其中:
G为C5-8环烷基或5至8元杂环基,优选C5-6环烷基,更优选C5环烷基;
A、n、R1-R3、R7、L和RE如式(I)中所定义。
在一项实施方案中,当式(IB)中的R6为羟基时,式(IB)化合物可以互变异构为如式(IB’)所示的化合物:
其中:
A、n、R1-R3、R7、L和RE如式(I)中所定义。
在一项实施方案中,当式(IC)中的R5为羟基时,式(IC)化合物可以互变异构为如式(IC’)所示的化合物:
其中:
A、n、R1、R3、R4、R7、L和RE如式(I)中所定义。
在一项实施方案中,式(I’)或式(I)(或式(IA)、式(IA’)、式(IB)、式(IB’)、式(IC)、式(IC’)、式(ID)、式(IE)、式(IF)、式(I-1)、式(I-2)、式(I-3)、式(I-4)、式(I-5)、式(I-6)、式(I-7)、式(I-8)、式(I-9)、式(I-10)中的任意一个)中的A选自C6-10芳基和5至10元杂芳基,优选C6-10芳基,更优选苯基。
在一项实施方案中,式(I’)或式(I)(或式(IA)、式(IA’)、式(IB)、式(IB’)、式(IC)、式(IC’)、式(ID)、式(IE)、式(IF)、式(I-1)、式(I-2)、式(I-3)、式(I-4)、式(I-5)、式(I-6)、式(I-7)、式(I-8)、式(I-9)、式(I-10)中的任意一个)中的n为1或2,优选2。
当n为1时,A片段被1个R1取代,且该R1在A片段的任意一个可取代位点上进行取代。
当n为2时,A片段被2个R1取代,且该2个R1独立地在A片段的任意两个可取代位点上进行取代。
在一项实施方案中,式(I’)或式(I)(或式(IA)、式(IA’)、式(IB)、式(IB’)、式(IC)、式(IC’)、式(ID)、式(IE)、式(IF)、式(I-1)、式(I-2)、式(I-3)、式(I-4)、式(I-5)、式(I-6)、式(I-7)、式(I-8)、式(I-9)、式(I-10)中的任意一个)中的每一个R1独立地选自C1-6烷基、C1-6卤代烷基、氨基、卤素和氰基,优选甲基、乙基、丙基、异丙基、丁基、异丁基、-CH2F、-CHF2、-CF3、-CH2CH2F、-CH2CHF2、-CH2CF3、-CH2CH2CH2F、-CH2CH2CHF2、-CH2CH2CF3、氨基、氟、氯、溴和氰基,更优选甲基、-CH2F、-CHF2、-CF3、氨基、氟、氯、溴和氰基。
在一项实施方案中,式(I’)或式(I)(或式(IA)、式(IA’)、式(IB)、式(IB’)、式(ID)、式(IF)中的任意一个)中的R2选自氢、C1-6烷基和C1-6卤代烷基,优选氢、甲基、氟甲基、二氟甲基和三氟甲基,优选甲基。
在一项实施方案中,式(I’)或式(I)(或式(IA)、式(IA’)、式(IB)、式(IB’)、式(IC)、式(IC’)、式(ID)、式(IE)、式(IF)、式(I-1)、式(I-2)、式(I-3)、式(I-4)、式(I-5)、式(I-6)、式(I-7)、式(I-8)、式(I-9)、式(I-10)中的任意一个)中的每一个R3独立地选自氢、C1-6烷基和C1-6卤代烷基,优选氢、甲基、氟甲基、二氟甲基和三氟甲基,更优选氢。
在一项实施方案中,式(I’)或式(I)(或式(IC)、式(IC’)、式(IE)中的任意一个)中的R4选自氢、C1-6烷基和C1-6烷氧基,优选氢、甲基、乙基、甲氧基和乙氧基,更优选甲基。
在一项实施方案中,式(I’)或式(I)(或式(IA)、式(IB)、式(IC)、式(ID)、式(IE)、式(IF)、式(I-1)、式(I-2)、式(I-3)、式(I-4)、式(I-5)、式(I-6)、式(I-7)、式(I-8)、式(I-9)、式(I-10)中的任意一个)中的每一个R5和R6独立地选自氢、羟基和C1-6烷氧基,优选氢、羟基、甲氧基和乙氧基,优选氢、羟基和甲氧基。
在一项实施方案中,式(I’)或式(I)(或式(IA)、式(IA’)、式(IB)、式(IB’)、式(IC)、式(IC’)、式(ID)、式(IE)、式(IF)、式(I-1)、式(I-2)、式(I-3)、式(I-4)、式(I-5)、式(I-6)、式(I-7)、式(I-8)、式(I-9)、式(I-10)中的任意一个)中的R7选自氢、C1-6烷基和C3-6环烷基,优选氢、甲基、乙基、丙基、异丙基、环丙基、环丁基、环戊基和环己基,更优选甲基。
在一项实施方案中,式(I’)或式(I)(或式(IA)、式(IA’)、式(IB)、式(IB’)、式(IC)、式(IC’)、式(ID)、式(IE)、式(IF)、式(I-1)、式(I-2)、式(I-3)、式(I-4)、式(I-5)、式(I-6)、式(I-7)、式(I-8)、式(I-9)、式(I-10)中的任意一个)中的L为-(Z)t-,其中t为4-18中的任一整数,优选4-13中的任一整数或5-18中的任一整数,例如4、5、6、7、8、9、10、11、12、13、14、15、16、17或18;每一个Z独立地选自单键、-O-、-NH-、-C(=O)-、C1-6亚烷基、C2-3亚烯基、C3-10亚环烷基和3至10元亚杂环基,优选单键、-O-、-NH-、-C(=O)-、-CH2-、-CH=CH-、C3-6亚环烷基和3至6元亚杂环基。
在一项实施方案中,式(I’)或式(I)(或式(IA)、式(IA’)、式(IB)、式(IB’)、式(IC)、式(IC’)、式(ID)、式(IE)、式(IF)、式(I-1)、式(I-2)、式(I-3)、式(I-4)、式(I-5)、式(I-6)、式(I-7)、式(I-8)、式(I-9)、式(I-10)中的任意一个)中的L为如式(L1)至式(L40)所示的基团之一,优选如式(L1)至式(L27)所示的基团之一,或者优选如式(L8)、式(L22)、式(L28)、式(L29)和式(L31)所示的基团之一,且基团左端连接稠合双环基团,右端连接RE:
其中:
p1、p6和p7独立地为1-6中的任一整数;
p2、p9和p11独立地为1-4中的任一整数;
p3、p5、p10、p12和p13独立地为1-4中的任一整数,优选1-2中的任一整数;
p4和p8独立地为1-8中的任一整数;
p14为0-2中的任一整数。
在一项实施方案中,式(I’)或式(I)(或式(IA)、式(IA’)、式(IB)、式(IB’)、式(IC)、式(IC’)、式(ID)、式(IE)、式(IF)、式(I-1)、式(I-2)、式(I-3)、式(I-4)、式(I-5)、式(I-6)、式(I-7)、式(I-8)、式(I-9)、式(I-10)中的任意一个)中的L为如式(L8)所示的基团之一,且基团左端连接稠合双环基团,右端连接RE:
其中:
p9为1-4中的任一整数,优选2-4中的任一整数;
p10为1-2中的任一整数,优选2。
在一项实施方案中,式(I’)或式(I)(或式(IA)、式(IA’)、式(IB)、式(IB’)、式(IC)、式(IC’)、式(ID)、式(IE)、式(IF)、式(I-1)、式(I-2)、式(I-3)、式(I-4)、式(I-5)、式(I-6)、式(I-7)、式(I-8)、式(I-9)、式(I-10)中的任意一个)中的L为如式(L22)所示的基团之一,且基团左端连接稠合双环基团,右端连接RE:
其中:
p2为1-4中的任一整数,优选1-2中的任一整数,更优选1;
p3为1-2中的任一整数,优选1;
p10为1-2中的任一整数,优选2。
在一项实施方案中,式(I’)或式(I)(或式(IA)、式(IA’)、式(IB)、式(IB’)、式(IC)、式(IC’)、式(ID)、式(IE)、式(IF)、式(I-1)、式(I-2)、式(I-3)、式(I-4)、式(I-5)、式(I-6)、式(I-7)、式(I-8)、式(I-9)、式(I-10)中的任意一个)中的L为如式(L28)所示的基团之一,且基团左端连接稠合双环基团,右端连接RE:
其中:
p9为1-4中的任一整数,优选1-2中的任一整数,更优选1;
p10为1-2中的任一整数,优选1;
p14为0-2中的任一整数,优选1-2中的任一整数。
在一项实施方案中,式(I’)或式(I)(或式(IA)、式(IA’)、式(IB)、式(IB’)、式(IC)、式(IC’)、式(ID)、式(IE)、式(IF)、式(I-1)、式(I-2)、式(I-3)、式(I-4)、式(I-5)、式(I-6)、式(I-7)、式(I-8)、式(I-9)、式(I-10)中的任意一个)中的L为如式(L29)所示的基团之一,且基团左端连接稠合双环基团,右端连接RE:
其中:
p9为1-4中的任一整数,优选1-2中的任一整数,更优选1;
p10为1-2中的任一整数,优选2;
p14为0-2中的任一整数,优选1-2中的任一整数,更优选1。
在一项实施方案中,式(I’)或式(I)(或式(IA)、式(IA’)、式(IB)、式(IB’)、式(IC)、式(IC’)、式(ID)、式(IE)、式(IF)、式(I-1)、式(I-2)、式(I-3)、式(I-4)、式(I-5)、式(I-6)、式(I-7)、式(I-8)、式(I-9)、式(I-10)中的任意一个)中的L为如式(L31)所示的基团之一,且基团左端连接稠合双环基团,右端连接RE:
其中:
p9为1-4中的任一整数,优选1-2中的任一整数,更优选1;
p10为1-2中的任一整数,优选2;
p14为0-2中的任一整数,优选1-2中的任一整数,更优选1。
在一项实施方案中,式(I’)或式(I)(或式(IA)、式(IA’)、式(IB)、式(IB’)、式(IC)、式(IC’)、式(ID)、式(IE)、式(IF)、式(I-1)、式(I-2)、式(I-3)、式(I-4)、式(I-5)、式(I-6)、式(I-7)、式(I-8)、式(I-9)、式(I-10)中的任意一个)中的RE为如式(X1-1)至式(X1-6)所示的基团之一:
在一项实施方案中,式(I’)或式(I)(或式(IA)、式(IA’)、式(IB)、式(IB’)、式(IC)、式(IC’)、式(ID)、式(IE)、式(IF)、式(I-1)、式(I-2)、式(I-3)、式(I-4)、式(I-5)、式(I-6)、式(I-7)、式(I-8)、式(I-9)、式(I-10)中的任意一个)中的RE为如式(X2-1)所示的基团:
在一项实施方案中,式(I’)或式(I)(或式(IA)、式(IA’)、式(IB)、式(IB’)、式(IC)、式(IC’)、式(ID)、式(IE)、式(IF)、式(I-1)、式(I-2)、式(I-3)、式(I-4)、式(I-5)、式(I-6)、式(I-7)、式(I-8)、式(I-9)、式(I-10)中的任意一个)中的RE为如式(X3-1)或式(X3-2)所示的基团:
具体地,本发明的SOS1蛋白降解靶向嵌合体包括(但不限于)下列化合物:
[药物组合物]
术语“药物组合物”是指可以用作药物的组合物,其包含药物活性成分(API)以及可选的一种或多种药学上可接受载体。
术语“药学上可接受的载体”是指与药物活性成分相容并且对受试者无害的药用辅料,包括(但不限于)稀释剂(或称填充剂)、粘合剂、崩解剂、润滑剂、润湿剂、增稠剂、助流剂、矫味剂、矫嗅剂、防腐剂、抗氧化剂、pH调节剂、溶剂、助溶剂、表面活性剂、蔽光剂(不透明剂)等中的一种或几种。
本发明提供了一种药物组合物,其包含上述通式化合物或其药学上可接受的盐、水合物、溶剂化物、立体异构体、互变异构体、顺反异构体、同位素标记物或前药。
在一项实施方案中,上述药物组合物还包含至少一种药学上可接受的载体。
[药物制剂]
术语“药物制剂”是指按照一定的形式制备而得的,可供患者使用的药物成品。
本发明提供了一种药物制剂,其由上述通式化合物或其药学上可接受的盐、水合物、溶剂化物、立体异构体、互变异构体、顺反异构体、同位素标记物或前药或者上述药物组合物制成。
在一项实施方案中,上述药物制剂为用于口服给药的固体制剂,包括(但不限于)药学上可接受的胶囊剂、片剂、丸剂、散剂、颗粒剂等。该固体制剂可以采用包衣或壳材料(如肠溶衣或本领域公知的其他材料)进行包衣或微囊化。该固体制剂可以包含不透明剂,并且其中的活性成分能够以延迟的方式在消化道的某一部分中释放。可采用的包埋组分的实例是聚合物质和蜡类物质。另外,活性成分也可与上述载体中的一种或多种形成微胶囊形式。
在本发明的另一项实施方案中,上述药物制剂为用于口服给药的液体剂型,包括(但不限于)药学上可接受的乳液、溶液、悬浮液、糖浆、酊剂等。
在本发明的再一项实施方案中,上述药物制剂为用于胃肠外注射的剂型,包括(但不限于)生
理上可接受的无菌的含水或无水溶液、分散液、悬浮液或乳液,以及用于重新溶解成无菌的可注射溶液和分散液的无菌粉末。
在本发明的又一项实施方案中,上述药物制剂为用于局部给药的剂型,包括(但不限于)软膏剂、散剂、栓剂、滴剂、喷射剂、吸入剂等。
[医药用途]
无论是上述通式化合物或其药学上可接受的盐、水合物、溶剂化物、立体异构体、互变异构体、顺反异构体、同位素标记物或前药,还是上述药物组合物,抑或是上述药物制剂,都能够对SOS1表现出抑制活性,并且能够诱导SOS1被泛素化标记,进而被降解,因此本发明提供了上述通式化合物或其药学上可接受的盐、水合物、溶剂化物、立体异构体、互变异构体、顺反异构体、同位素标记物或前药或者上述药物组合物或者上述药物制剂在制备用于预防和/或治疗至少部分由SOS1蛋白介导的疾病的药物中的用途。
本发明提供了上述通式化合物或其药学上可接受的盐、水合物、溶剂化物、立体异构体、互变异构体、顺反异构体、同位素标记物或前药或者上述药物组合物或者上述药物制剂在制备用于预防和/或治疗癌症的药物中的用途。
术语“癌症”是指以失控的或失调的细胞增殖、减少的细胞分化、不适宜的侵入周围组织的能力和/或在异位建立新生长的能力为特征的细胞障碍。癌症的非限制性实例包括(但不限于)胰腺癌、肺癌、结直肠癌、胆管癌、多发性骨髓瘤、黑素瘤、子宫癌、子宫内膜癌、甲状腺癌、急性髓性白血病、膀胱癌、尿路上皮癌、胃癌、宫颈癌、头颈部鳞状细胞癌、弥漫性大B细胞淋巴瘤、食道癌、慢性淋巴细胞白血病、肝细胞癌、乳腺癌、卵巢癌、前列腺癌、胶质母细胞瘤、肾癌和肉瘤。
本发明还提供了上述通式化合物或其药学上可接受的盐、水合物、溶剂化物、立体异构体、互变异构体、顺反异构体、同位素标记物或前药或者上述药物组合物或者上述药物制剂,其用于预防和/或治疗至少部分由SOS1蛋白介导的疾病(特别是癌症)。
本发明还提供了一种用于预防和/或治疗至少部分由SOS1蛋白介导的疾病(特别是癌症)的方法,其包括将预防和/或治疗有效量的上述通式化合物或其药学上可接受的盐、水合物、溶剂化物、立体异构体、互变异构体、顺反异构体、同位素标记物或前药或者上述药物组合物或者上述药物制剂施用于对其有需求的个体。
[联合用药]
本发明提供了一种药物联合形式,其包含上述通式化合物或其药学上可接受的盐、水合物、溶剂化物、立体异构体、互变异构体、顺反异构体、同位素标记物或前药或者上述药物组合物或者上述药物制剂,以及至少一种额外的癌症治疗剂。
术语“癌症治疗剂”是指能够有效控制和/或对抗癌症的药物组合物或药物制剂。常见的癌症治疗剂包括(但不限于)抗嘌呤药(例如喷司他丁等)、抗嘧啶药(例如5-氟尿嘧啶)、抗叶酸药(例如甲氨蝶呤)、DNA多聚酶抑制剂(如阿糖胞苷)、烷化剂(如环磷酰胺)、铂类配合物(例如顺铂、卡铂)、破坏DNA的抗生素(例如丝裂霉素)、拓扑异构酶抑制剂(例如喜树碱)、嵌入DNA干扰核酸合成药(例如表柔比星)、阻止原料供应药(例如门冬酰胺酶)、干扰微管蛋白形成药(例如紫杉醇)、干扰核糖体功能药(例如三尖杉酯碱)、细胞因子(例如IL-1)、胸腺肽、肿瘤细胞增殖病毒(如腺病毒ONYX-015)、长春碱类(例如长春瑞滨)、阿霉素类(例如阿霉素、表阿霉素、阿克拉霉素)、替尼类(例如伊马替尼、吉非替尼、厄洛替尼、达沙替尼、舒尼替尼)、单抗类(例如曲妥单抗、帕尼单抗、贝伐单抗)、硼替佐米、骨化三醇、卡培他滨、氨鲁米特、来曲唑、
瑞宁德、依维莫司、氟维司群、伊立替康、培美曲塞、西罗莫司、PD-1、PD-L1等。
在一项实施方案中,上述通式化合物或其药学上可接受的盐、水合物、溶剂化物、立体异构体、互变异构体、顺反异构体、同位素标记物或前药或者上述药物组合物或者上述药物制剂既可以单独施用,也可以与其他癌症治疗剂(或称抗肿瘤药物)组合施用。该联合治疗可以通过同时、顺序或分开施用不同的癌症治疗剂来实现。
以下将结合具体实施例来进一步描述本发明中的技术方案。除非另有说明,下列实施例中所使用的试剂、材料、仪器等均可通过常规商业手段获得,所使用的实验方法均为本领域常规方法。
实施例1:化合物1的制备
(1)中间体1-2合成路线
氮气保护下,向反应瓶中依次加入化合物1-2a(30.00g,111.55mmol,1.0eq),二氧六环(300mL),三丁基(1-乙氧基乙烯基)锡(48.34g,133.86mmol,1.2eq),三乙胺(33.86g,334.66mmol,3eq)和[1,1'-双(二苯基膦)二茂铁]二氯化钯(4.06g,5.58mmol,0.05eq),加毕,升温至90℃,搅拌反应过夜。反应体系冷却至室温后过滤,滤液用4M盐酸调节pH至3后,加入水(300mL),再加入乙酸乙酯(300mL)萃取2次,有机相用无水硫酸钠干燥,浓缩,柱层析纯化(洗脱剂:石油醚/乙酸乙酯=20/1),得到化合物1-2b(25.0g);
氮气保护下,向反应瓶中依次加入化合物1-2b(25.00g,107.28mmol,1.0eq),四氢呋喃(300mL),叔丁基亚磺酰胺(19.48g,160.92mmol,1.5eq)和钛酸四乙酯(48.94g,214.56mmol,2.0eq),加毕,升温至80℃,搅拌反应过夜。反应体系冷却至室温后加入水(300mL),再加入乙酸乙酯(300mL)萃取2次,有机相用无水硫酸钠干燥,浓缩,柱层析纯化(洗脱剂:石油醚/乙酸乙酯=10/1),得到化合物1-2c(18.4.0g);MS:m/z 337.0[M+1]+;
向反应瓶中依次加入化合物1-2c(18.4.00g,54.75mmol,1.0eq),四氢呋喃(300mL)和水(5mL),降温至-70~-60℃后,缓慢加入硼氢化钠(3.75g,98.55mmol,1.8eq),加毕,-60℃继续搅拌30分钟。向体系加入水(300mL)淬灭反应,再加入乙酸乙酯(300mL)萃取2次,有机相用无水硫酸钠干燥,浓缩,柱层析纯化(洗脱剂:石油醚/乙酸乙酯=2/1),得到化合物1-2d(11.85g);MS:m/z 339.0[M+1]+;
向反应瓶中依次加入化合物1-2d(11.85g,35.05mmol,1.0eq),二氧六环(50mL)和4M盐酸(20mL),加毕,室温搅拌反应2小时,使用1M氢氧化钠溶液将体系pH调节至8-9,再加入乙酸乙酯(100mL)2次,有机相用无水硫酸钠干燥,浓缩,所得固体使用石油醚打浆,得到中间体1-2(7.5g);MS:m/z235.0[M+1]+;
(2)中间体1-3合成路线
向反应瓶中依次加入化合物1-3a(50.0g,94.75mmol,1.0eq),乙腈(200mL),甲基磺酸(100mL),加毕,升温至150℃,搅拌反应48h。反应体系冷却至室温,体系减压浓缩,向体系中加入冰水(300mL),用氢氧化钠调节pH至7,过滤后得到滤饼,滤饼在烘箱中烘干,得到化合物1-3b(50.68g);MS:m/z221.0[M+1]+;
向反应瓶中依次加入化合物1-3b(50.68g,230.28mmol,1.0eq),甲基磺酸(300mL),DL-蛋氨酸(51.48g,345.42mmol,1.5eq),加毕,升温至90℃,搅拌过夜,反应体系冷却至室温,向体系中加入冰水(300mL),用氢氧化钠调节pH至7,过滤后得到滤饼,滤饼在烘箱中烘干,得到化合物1-3c(40.75g);MS:m/z 207.0[M+1]+;
向反应瓶中依次加入化合物1-3c(40.75g,197.75mmol,1.0eq),N,N-二甲基甲酰胺(400mL),碳酸铯(128.86g,395.62mmol,2.0eq),(R)-3-(对甲苯磺酰氧基)吡咯烷-1-甲酸叔丁酯(67.50g,197.75mmol,1.0eq),加毕,升温至100℃,搅拌反应过夜,反应体系冷却至室温后,加入水(300mL),再加入乙酸乙酯(300mL)萃取3次,将有机相减压浓缩至200mL后,用饱和食盐水洗涤,有大量固体析出,过滤后得到滤饼,滤饼在烘箱中烘干,得到化合物1-3d(25.0g);MS:m/z 376.2[M+1]+;
向反应瓶中依次加入化合物1-3d(25.0g,66.63mmol,1.0eq),2,4,6-三异丙基苯磺酰氯(20.18g,66.63mmol,1.0eq),三乙胺(22.0g,199.90mmol,3.0eq),4-二甲氨基吡啶(0.81g,6.66mmol,0.1eq),二氯甲烷(300mL),加毕,搅拌反应过夜,体系减压浓缩,加入水(200mL),再加入乙酸乙酯(300mL)萃取3次,加入无水硫酸钠干燥、过滤和浓缩后得到粗品,粗品经打浆(石油醚/乙酸乙酯=5/1)过滤后,得到固体,固体在烘箱中烘干,得到化合物1-3e(29.0g);MS:m/z 642.2[M+1]+;
氮气保护下,向反应瓶中依次加入化合物1-3e(14.0g,21.83mmol,1.0eq),三乙胺(11.05g,109.15mmol,5.0eq),化合物1-2(7.66g,32.75mmol,1.5eq),二甲基亚砜(100mL),加毕,升温至90℃,搅拌反应过夜,反应体系冷却至室温后加入水(100mL),再加入乙酸乙酯(100mL)萃取2次,有机相用饱和氯化钠溶液(200mL),洗涤2次后,加入无水硫酸钠干燥、过滤和浓缩得到粗品,粗品经柱层析纯化(洗脱剂:二氯甲烷/甲醇=20/1),得到化合物1-3f(11.86g);MS:m/z 592.4[M+1]+;
向反应瓶中依次加入化合物1-3f(11.86g,20.06mmol,1.0eq),二氧六环(50mL)和4M盐酸(20mL),加毕,室温搅拌反应3小时,使用1M氢氧化钠溶液将体系pH调节至8-9,再加入乙酸乙酯(100mL)2次,有机相用无水硫酸钠干燥,浓缩,所得固体使用石油醚打浆,得到中间体1-3(8.5g);MS:m/z492.2[M+1]+;
(3)中间体1-1合成路线
向反应瓶中依次加入化合物1-1a(200.00mg,0.72mmol,1.0eq),甘氨酸叔丁酯(145.65mg,0.87mmol,1.2eq),二异丙基乙胺(561.47mg,4.34mmol,6.0eq),N-甲基吡咯烷酮(5mL),加毕,升温至100℃,搅拌反应过夜,反应体系冷却至室温后加入水(50mL),再加入乙酸乙酯(50mL)萃取3次,有机相用饱和氯化钠溶液(100mL)洗涤2次后,加入无水硫酸钠干燥、过滤和浓缩得到粗品,粗品经柱层析纯化(洗脱剂:石油醚/乙酸乙酯=1/1),得到化合物1-1b(180.0mg);MS:m/z 388.0[M+1]+;
向反应瓶中依次加入化合物1-1b(180.0mg,0.46mmol,1.0eq)、1,4-二氧六环(5mL)、4N盐酸(2mL),加毕,室温搅拌反应过夜,体系减压浓缩,得到化合物1-1c(200mg),不经纯化,直接投入下一步反应;MS:m/z 332.0[M+1]+;
向反应瓶中依次加入化合物1-1c(101.1mg,0.31mmol,1.5eq),二甲基甲酰胺(5mL),HATU(116.12mg,0.31mmol,1.5eq),二异丙基乙胺(105mg,0.80mmol,4.0eq),搅拌5分钟后,加入化合物1-3(100mg,0.20mol,1.0eq),然后室温搅拌反应过夜。向体系加入水(30mL),再加入乙酸乙酯(30mL)萃取3次,饱和氯化钠溶液(50mL)洗涤2次后,加入无水硫酸钠干燥、过滤、浓缩,所得粗品经柱层析纯化(洗脱剂:二氯甲烷/甲醇=15/1),得到化合物1-1(130mg);MS:m/z 805.2[M+1]+;
(4)化合物1的制备
向反应瓶中依次加入化合物1-1(130mg,0.16mmol,1.0eq),四氢呋喃(10mL),20%钯碳(26mg),在氢气氛围下控温30℃反应过夜,反应液过滤,滤液旋干,进行反相柱层析纯化(Shim-pack GIS-C1820*250nm,5μm;0.01%甲酸-水/乙腈),得到化合物1(11.8mg);1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),8.40(d,J=42.3Hz,1H),8.00(d,J=8.0Hz,1H),7.78(d,J=8.4Hz,1H),7.51(s,1H),7.38(d,J=8.8Hz,1H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.76-5.72(m,1H),5.65(s,1H),5.12(dd,J=12.9,5.4Hz,1H),4.23(d,J=13.5Hz,2H),3.96(s,3H),3.76-3.69(m,2H),3.64-3.56(m,2H),3.49-3.45(m,2H),2.96-2.80(m,2H),2.61-2.58(m,3H),2.55(s,3H),2.39-2.33(m,2H),1.65(d,
J=7.0Hz,3H);MS:m/z 775.4[M+1]+。
实施例2-6:化合物2-6的制备
按照与实施例1基本相似的操作,合成化合物2至化合物6。
化合物2-6的核磁数据如下:
化合物2
1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),8.40(d,J=42.3Hz,1H),8.00(d,J=8.0Hz,1H),7.78(d,J=8.4Hz,1H),7.51(s,1H),7.38(d,J=8.8Hz,1H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.76-5.72(m,1H),5.65(s,1H),5.12(dd,J=12.9,5.4Hz,1H),4.23(d,J=13.5Hz,2H),3.96(s,3H),3.76-3.69(m,2H),3.64-3.56(m,2H),3.49-3.45(m,2H),2.96-2.80(m,2H),2.66-2.63(m,2H),2.61-2.58(m,3H),2.55(s,3H),2.39-2.33(m,2H),1.65(d,J=7.0Hz,3H).
化合物3
1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),8.40(d,J=42.3Hz,1H),8.00(d,J=8.0Hz,1H),7.78(d,J=8.4Hz,1H),7.51(s,1H),7.38(d,J=8.8Hz,1H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.76-5.72(m,1H),5.65(s,1H),5.12(dd,J=12.9,5.4Hz,1H),4.23(d,J=13.5Hz,
2H),3.96(s,3H),3.76-3.69(m,2H),3.64-3.56(m,2H),3.49-3.45(m,2H),2.96-2.80(m,2H),2.66-2.63(m,2H),2.61-2.58(m,3H),2.55(s,3H),2.39-2.33(m,2H),2.12-1.98(m,2H),1.65(d,J=7.0Hz,3H).
化合物4
1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),8.40(d,J=42.3Hz,1H),8.00(d,J=8.0Hz,1H),7.78(d,J=8.4Hz,1H),7.51(s,1H),7.38(d,J=8.8Hz,1H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.76-5.72(m,1H),5.65(s,1H),5.12(dd,J=12.9,5.4Hz,1H),4.23(d,J=13.5Hz,2H),3.96(s,3H),3.76-3.69(m,2H),3.64-3.56(m,2H),3.49-3.45(m,2H),2.96-2.80(m,2H),2.66-2.63(m,2H),2.61-2.58(m,3H),2.55(s,3H),2.39-2.33(m,2H),2.12-1.85(m,4H),1.65(d,J=7.0Hz,3H).
化合物5
1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),8.40(d,J=42.3Hz,1H),8.00(d,J=8.0Hz,1H),7.78(d,J=8.4Hz,1H),7.51(s,1H),7.38(d,J=8.8Hz,1H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.76-5.72(m,1H),5.65(s,1H),5.12(dd,J=12.9,5.4Hz,1H),4.23(d,J=13.5Hz,2H),3.96(s,3H),3.76-3.69(m,2H),3.64-3.56(m,2H),3.49-3.45(m,2H),2.96-2.80(m,2H),2.66-2.63(m,2H),2.61-2.58(m,3H),2.55(s,3H),2.39-2.33(m,2H),2.12-1.98(m,2H),1.67-1.63(m,5H),1.58-1.44(m,2H).
化合物6
1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),8.40(d,J=42.3Hz,1H),8.00(d,J=8.0Hz,1H),7.78(d,J=8.4Hz,1H),7.51(s,1H),7.38(d,J=8.8Hz,1H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.76-5.72(m,1H),5.65(s,1H),5.12(dd,J=12.9,5.4Hz,1H),4.23(d,J=13.5Hz,2H),3.96(s,3H),3.76-3.69(m,2H),3.64-3.56(m,2H),3.49-3.45(m,2H),2.96-2.80(m,2H),2.66-2.63(m,2H),2.61-2.58(m,3H),2.55(s,3H),2.39-2.33(m,2H),2.12-1.98(m,2H),1.67-1.63(m,5H),1.62-1.45(m,4H).
实施例7:化合物7的制备
(1)中间体7-1合成路线
向反应瓶中依次加入化合物1-1a(200.00mg,0.72mmol,1.0eq),3-(2-氨基乙氧基)丙酸叔丁酯(164.34mg,0.87mmol,1.2eq),二异丙基乙胺(561.47mg,4.34mmol,6.0eq),N-甲基吡咯烷酮(5mL),加毕,升温至100℃,搅拌反应过夜,反应体系降至室温,加入水(50mL),再加入乙酸乙酯(50mL)萃取3次,有机相用饱和氯化钠溶液(100mL),洗涤2次后,加入无水硫酸钠干燥、过滤和浓缩得到
粗品,粗品经柱层析纯化(洗脱剂:二氯甲烷/甲醇=20/1),得到化合物7-1a(280mg);MS:m/z 446.2[M+1]+;
向反应瓶中依次加入化合物7-1a(180mg,0.46mmol,1.0eq),1,4-二氧六环(5mL),4N盐酸(2mL),加毕,室温搅拌过夜,体系减压浓缩,得到化合物7-1b(283mg);MS:m/z 390.2[M+1]+;
向反应瓶中依次加入化合物7-1b(118.9mg,0.31mmol,1.5eq),二甲基甲酰胺(5mL),HATU(116.12mg,0.31mmol,1.5eq),二异丙基乙胺(105mg,0.80mmol,4.0eq),室温搅拌5分钟后,加入化合物1-3(100mg,0.20mol,1.0eq),加毕,室温搅拌过夜,加入水(50mL),再加入乙酸乙酯(50mL)萃取3次,有机相用饱和氯化钠溶液(100mL),洗涤2次后,加入无水硫酸钠干燥、过滤和浓缩得到粗品,粗品经柱层析纯化(洗脱剂:二氯甲烷/甲醇=20/1),得到化合物7-1(116mg);MS:m/z 863.4[M+1]+;
(2)化合物7的制备
向反应瓶中依次加入化合物7-1(116mg,0.16mmol,1.0eq),四氢呋喃(10ml),20%钯碳(23mg),在氢气氛围下控温30℃反应过夜,反应液过滤,滤液旋干,进行反相柱层析纯化(Shim-pack GIS-C1820*250nm,5μm;0.01%甲酸-水/乙腈),得到化合物7(6.7mg);1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),8.40(d,J=42.3Hz,1H),8.00(d,J=8.0Hz,1H),7.78(d,J=8.4Hz,1H),7.51(s,1H),7.38(d,J=8.8Hz,1H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.76-5.72(m,1H),5.65(s,1H),5.12(dd,J=12.9,5.4Hz,1H),4.23(d,J=13.5Hz,2H),3.96(s,3H),3.76-3.69(m,2H),3.65-3.50(m,8H),3.49-3.45(m,2H),2.96-2.80(m,2H),2.61-2.58(m,3H),2.55(s,3H),2.39-2.33(m,2H),1.65(d,J=7.0Hz,3H);MS:m/z 833.4[M+1]+。
实施例8-10:化合物8-10的制备
按照与实施例7基本相似的操作,合成化合物8-10。
化合物8-10的核磁数据如下:
化合物8
1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),8.40(d,J=42.3Hz,1H),8.00(d,J=8.0Hz,1H),7.78(d,J=8.4Hz,1H),7.51(s,1H),7.38(d,J=8.8Hz,1H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.76-5.72(m,1H),5.65(s,1H),5.12(dd,J=12.9,5.4Hz,1H),4.23(d,J=13.5Hz,2H),3.96(s,3H),3.76-3.69(m,2H),3.65-3.50(m,12H),3.49-3.45(m,2H),2.96-2.80(m,2H),2.61-2.58(m,3H),2.55(s,3H),2.39-2.33(m,2H),1.65(d,J=7.0Hz,3H).
化合物9
1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),8.40(d,J=42.3Hz,1H),8.00(d,J=8.0Hz,1H),7.78(d,J=8.4Hz,1H),7.51(s,1H),7.38(d,J=8.8Hz,1H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.76-5.72(m,1H),5.65(s,1H),5.12(dd,J=12.9,5.4Hz,1H),4.23(d,J=13.5Hz,2H),3.96(s,3H),3.76-3.69(m,2H),3.65-3.50(m,16H),3.49-3.45(m,2H),2.96-2.80(m,2H),2.61-2.58(m,3H),2.55(s,3H),2.39-2.33(m,2H),1.65(d,J=7.0Hz,3H).
化合物10
1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),8.40(d,J=42.3Hz,1H),8.00(d,J=8.0Hz,1H),7.78(d,J=8.4Hz,1H),7.51(s,1H),7.38(d,J=8.8Hz,1H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.76-5.72(m,1H),5.65(s,1H),5.12(dd,J=12.9,5.4Hz,1H),4.23(d,J=13.5Hz,2H),3.96(s,3H),3.76-3.69(m,2H),3.65-3.50(m,16H),3.52-3.46(m,6H),2.96-2.80(m,2H),2.61-2.58(m,3H),2.55(s,3H),2.39-2.33(m,2H),1.65(d,J=7.0Hz,3H).
实施例11:化合物11的制备
(1)中间体11-1合成路线
向反应瓶中依次加入化合物戊二酸(736.43mg,5.49mmol,3.0eq)和二氯甲烷,0℃加入草酰氯(1.51g,11.90mmol,6.5eq),加毕,室温搅拌反应3小时,体系减压浓缩后,将其滴加到化合物1-4a(500mg,1.83mmol,1.0eq)与四氢呋喃(20mL)的混合液中,加毕,升温至80℃,搅拌反应
45分钟,反应体系降至室温后加入水(50mL),再加入二氯甲烷:乙腈=10:1(50mL)萃取3次,无水硫酸钠干燥过滤和浓缩得到粗品,粗品通过柱层析纯化(洗脱剂:二氯甲烷/甲醇=15/1),得到化合物11-1a(475mg);MS:m/z 388.2[M+1]+;
向反应瓶中依次加入化合物11-1a(118.3mg,0.31mmol,1.5eq),二甲基甲酰胺(5mL),HATU(116.12mg,0.31mmol,1.5eq),二异丙基乙胺(105mg,0.80mmol,4.0eq),室温搅拌5分钟后,加入化合物1-3(100mg,0.20mol,1.0eq),加毕,室温搅拌过夜,向体系加入水(30mL),再加入乙酸乙酯(30mL)萃取3次,饱和氯化钠溶液(50mL)洗涤2次后,加入无水硫酸钠干燥、过滤、浓缩得到粗品,所得粗品经柱层析纯化(洗脱剂:二氯甲烷/甲醇=15/1),得到化合物11-1(75mg);MS:m/z 861.4[M+1]+。
(2)化合物11的制备
向反应瓶中依次加入化合物11-1(75mg,0.09mmol,1.0eq),四氢呋喃(10ml),20%钯碳(15mg),在氢气围下控温30℃反应过夜,将反应液过滤,滤液旋干,进行反相柱层析纯化(Shim-pack GIS-C1820*250nm,5μm;0.01%甲酸-水/乙腈),得到化合物11(5.0mg);1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),8.40(d,J=42.3Hz,1H),8.00(d,J=8.0Hz,1H),7.78(d,J=8.4Hz,1H),7.51(s,1H),7.38(d,J=8.8Hz,1H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.76-5.72(m,1H),5.65(s,1H),5.12(dd,J=12.9,5.4Hz,1H),4.23(d,J=13.5Hz,2H),3.96(s,3H),3.76-3.69(m,2H),3.64-3.56(m,2H),3.49-3.45(m,2H),2.96-2.80(m,2H),2.66-2.63(m,2H),2.61-2.58(m,3H),2.55(s,3H),2.39-2.33(m,2H),2.25-2.23(m,2H),1.66(d,J=7.0Hz,3H);MS:m/z 831.2[M+1]+。
实施例12-16:化合物12-16的制备
按照与实施例11基本相似的操作,合成化合物12-16。
化合物12-16的核磁数据如下:
化合物12
1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),8.40(d,J=42.3Hz,1H),8.00(d,J=8.0Hz,1H),7.78(d,J=8.4Hz,1H),7.51(s,1H),7.38(d,J=8.8Hz,1H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.76-5.72(m,1H),5.65(s,1H),5.12(dd,J=12.9,5.4Hz,1H),4.23(d,J=13.5Hz,2H),3.96(s,3H),3.76-3.69(m,2H),3.64-3.56(m,2H),3.49-3.45(m,2H),2.96-2.80(m,2H),2.66-2.63(m,2H),2.61-2.58(m,3H),2.55(s,3H),2.39-2.33(m,2H),2.25-2.23(m,2H),1.73-1.70(m,2H),1.66(d,J=7.0Hz,3H).
化合物13
1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),8.40(d,J=42.3Hz,1H),8.00(d,J=8.0Hz,1H),7.78(d,J=8.4Hz,1H),7.51(s,1H),7.38(d,J=8.8Hz,1H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.76-5.72(m,1H),5.65(s,1H),5.12(dd,J=12.9,5.4Hz,1H),4.23(d,J=13.5Hz,2H),3.96(s,3H),3.76-3.69(m,2H),3.64-3.56(m,2H),3.49-3.45(m,2H),2.96-2.80(m,2H),2.66-2.63(m,2H),2.61-2.58(m,3H),2.55(s,3H),2.39-2.33(m,2H),2.25-2.23(m,2H),1.75-1.71(m,4H),1.66(d,J=7.0Hz,3H).
化合物14
1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),8.40(d,J=42.3Hz,1H),8.00(d,J=8.0Hz,1H),7.78(d,J=8.4Hz,1H),7.51(s,1H),7.38(d,J=8.8Hz,1H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.76-5.72(m,1H),5.65(s,1H),5.12(dd,J=12.9,5.4Hz,1H),4.23(d,J=13.5Hz,2H),3.96(s,3H),3.76-3.69(m,2H),3.64-3.56(m,2H),3.49-3.45(m,2H),2.96-2.80(m,2H),2.66-2.63(m,2H),2.61-2.58(m,3H),2.55(s,3H),2.39-2.33(m,2H),2.25-2.23(m,2H),1.74-1.68(m,6H),1.66(d,J=7.0Hz,3H).
化合物15
1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),8.40(d,J=42.3Hz,1H),8.00(d,J=8.0Hz,1H),7.78(d,J=8.4Hz,1H),7.51(s,1H),7.38(d,J=8.8Hz,1H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.76-5.72(m,1H),5.65(s,1H),5.12(dd,J=12.9,5.4Hz,1H),4.23(d,J=13.5Hz,2H),3.96(s,3H),3.76-3.69(m,2H),3.64-3.56(m,2H),3.49-3.45(m,2H),2.96-2.80(m,2H),2.66-2.63(m,2H),2.61-2.58(m,3H),2.55(s,3H),2.39-2.33(m,2H),2.25-2.23(m,2H),1.74-1.68(m,4H),1.66(d,J=7.0Hz,3H),1.57-1.48(m,4H).
化合物16
1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),8.40(d,J=42.3Hz,1H),8.00(d,J=8.0Hz,1H),7.78(d,J=8.4Hz,1H),7.51(s,1H),7.38(d,J=8.8Hz,1H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.76-5.72(m,1H),5.65(s,1H),5.12(dd,J=12.9,5.4Hz,1H),4.23(d,J=13.5Hz,2H),3.96(s,3H),3.76-3.69(m,2H),3.64-3.56(m,2H),3.49-3.45(m,2H),2.96-2.80(m,2H),2.66-2.63(m,2H),2.61-2.58(m,3H),2.55(s,3H),2.39-2.33(m,2H),2.25-2.23(m,2H),1.74-1.68(m,4H),1.66(d,J=7.0Hz,3H),1.60-1.45(m,6H).
实施例17:化合物17的制备
(1)中间体17-1合成路线
向反应瓶中依次加入化合物1-3(1.2g,2.44mmol,1.0eq),溴乙酸叔丁酯(710.90mg,3.66mmol,1.5eq),二异丙基乙胺(947.32mg,7.33mmol,3.0eq),二甲基甲酰胺(20mL),加毕,升温至70℃搅拌反应6h。将反应体系冷却至室温加入水(50mL),乙酸乙酯(50mL)萃取2次,饱和氯化钠溶液(100mL)洗涤2次,无水硫酸钠干燥过滤,浓缩得到粗品,粗品通过柱层析纯化(洗脱剂:二氯甲烷/甲醇=20/1),得到化合物17-1a(800mg);MS:m/z 606.2[M+1]+;
向反应瓶中依次加入化合物17-1a(800mg,0.46mmol,1.0eq),1,4-二氧六环(5mL),4N盐酸(2mL),加毕,室温搅拌反应过夜,体系减压浓缩,得到化合物17-1b(780mg),不经纯化,直接投入下一步反应;MS:m/z 550.2.0[M+1]+;
向反应瓶中依次加入化合物17-1b(225.0mg,0.41mmol,1.0eq),二甲基甲酰胺(5mL),HATU(233.67mg,0.61mmol,1.5eq),二异丙基乙胺(211.80mg,1.64mmol,4.0eq),室温搅拌5分钟后加入化合物17-2(192.8mg,0.61mol,1.5eq),加毕室温搅拌过夜,向体系加入水(30mL),乙酸乙
酯(30mL)萃取3次,饱和氯化钠溶液(50mL)洗涤2次,无水硫酸钠干燥过滤,浓缩得到粗品,粗品通过柱层析纯化(洗脱剂:二氯甲烷/甲醇=10/1),得到化合物17-1(98mg);MS:m/z 847.3[M+1]+;
(2)中间体17-2合成路线
向反应瓶中依次加入化合物1-1a(300mg,1.09mmol,1.0eq),N-叔丁氧羰基-1,2-乙二胺(208.2mg,1.31mmol,1.2eq),二异丙基乙胺(842.2mg,6.52mmol,6.0eq),二甲基甲酰胺(20mL),加毕,升温至100℃搅拌反应过夜,将反应体系冷却室温加入水(50mL),再加入乙酸乙酯(50mL)萃取3次,饱和氯化钠溶液(100mL)洗涤2次,无水硫酸钠干燥过滤,浓缩得到粗品,粗品通过柱层析纯化(洗脱剂:二氯甲烷/甲醇=20/1),得到化合物17-2a(500mg);MS:m/z 417.2[M+1]+;
向反应瓶中依次加入化合物17-2a(800mg,0.46mmol,1.0eq),1,4-二氧六环(5mL),4N盐酸(2mL),加毕室温搅拌反应过夜,体系减压浓缩,得到化合物17-2(425mg),不经纯化,直接投入下一步反应;MS:m/z 317.2.0[M+1]+;
(3)化合物17的制备
向反应瓶中依次加入化合物17-1(98mg,0.12mmol,1.0eq),四氢呋喃(10ml),20%钯碳(20mg),在氢气氛围下控温30℃反应过夜,反应液过滤,滤液旋干,进行反相柱层析纯化(Shim-pack GIS-C1820*250nm,5μm;0.01%甲酸-水/乙腈),得到化合物17(0.6mg);1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),8.40(d,J=42.3Hz,1H),8.00(d,J=8.0Hz,1H),7.88(s,1H),7.78(d,J=8.4Hz,1H),7.51(s,1H),7.38(d,J=8.8Hz,1H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.76-5.72(m,1H),5.65(s,1H),5.12(dd,J=12.9,5.4Hz,1H),4.23(d,J=13.5Hz,2H),3.96(s,3H),3.85-3.81(m,2H),3.76-3.69(m,2H),3.66-3.52(m,4H),3.49-3.45(m,2H),2.96-2.80(m,2H),2.66-2.63(m,2H),2.61-2.58(m,3H),2.55(s,3H),1.66(d,J=7.0Hz,3H);MS:m/z 818.4[M+1]+。
实施例18-21:化合物18-21的制备
中间体18-2至中间体21-2的制备
按照与中间体17-2基本相似的操作,合成中间体18-2至中间体21-2。
按照与实施例17基本相似的操作,合成化合物18-21。
化合物18-21的核磁数据如下:
化合物18
1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),8.40(d,J=42.3Hz,1H),8.00(d,J=8.0Hz,1H),7.88(s,1H),7.78(d,J=8.4Hz,1H),7.51(s,1H),7.38(d,J=8.8Hz,1H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.76-5.72(m,1H),5.65(s,1H),5.12(dd,J=12.9,5.4Hz,1H),4.23(d,J=13.5Hz,2H),3.96(s,3H),3.85-3.81(m,2H),3.76-3.69(m,2H),3.66-3.52(m,4H),3.49-3.45(m,2H),2.96-2.80(m,2H),2.66-2.63(m,2H),2.61-2.58(m,3H),2.55(s,3H),2.12-1.95(m,2H),1.66(d,J=7.0
Hz,3H).
化合物19
1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),8.40(d,J=42.3Hz,1H),8.00(d,J=8.0Hz,1H),7.88(s,1H),7.78(d,J=8.4Hz,1H),7.51(s,1H),7.38(d,J=8.8Hz,1H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.76-5.72(m,1H),5.65(s,1H),5.12(dd,J=12.9,5.4Hz,1H),4.23(d,J=13.5Hz,2H),3.96(s,3H),3.85-3.81(m,2H),3.76-3.69(m,2H),3.66-3.52(m,4H),3.49-3.45(m,2H),2.96-2.80(m,2H),2.66-2.63(m,2H),2.61-2.58(m,3H),2.55(s,3H),1.64-1.48(m,7H).
化合物20
1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),8.40(d,J=42.3Hz,1H),8.00(d,J=8.0Hz,1H),7.88(s,1H),7.78(d,J=8.4Hz,1H),7.51(s,1H),7.38(d,J=8.8Hz,1H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.76-5.72(m,1H),5.65(s,1H),5.12(dd,J=12.9,5.4Hz,1H),4.23(d,J=13.5Hz,2H),3.96(s,3H),3.85-3.81(m,2H),3.76-3.69(m,2H),3.66-3.52(m,4H),3.49-3.45(m,2H),2.96-2.80(m,2H),2.66-2.63(m,2H),2.61-2.58(m,3H),2.55(s,3H),1.64-1.48(m,7H),1.42-1.31(m,2H).
化合物21
1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),8.40(d,J=42.3Hz,1H),8.00(d,J=8.0Hz,1H),7.88(s,1H),7.78(d,J=8.4Hz,1H),7.51(s,1H),7.38(d,J=8.8Hz,1H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.76-5.72(m,1H),5.65(s,1H),5.12(dd,J=12.9,5.4Hz,1H),4.23(d,J=13.5Hz,2H),3.96(s,3H),3.85-3.81(m,2H),3.76-3.69(m,2H),3.66-3.52(m,4H),3.49-3.45(m,2H),2.96-2.80(m,2H),2.66-2.63(m,2H),2.61-2.58(m,3H),2.55(s,3H),1.64-1.48(m,7H),1.45-1.32(m,4H).
实施例22:化合物22的制备
(1)中间体22-1合成路线
向反应瓶中依次加入化合物1-3(1.2g,2.44mmol,1.0eq),3-溴丙酸叔丁酯(765.23mg,3.66mmol,1.5eq),二异丙基乙胺(947.32mg,7.33mmol,3.0eq),二甲基甲酰胺(20mL),加毕,升温至70℃搅拌反应6h,将反应体系冷却至室温加入水(50mL),乙酸乙酯(50mL)萃取2次,饱和氯化钠溶
液(100mL)洗涤2次,无水硫酸钠干燥过滤,浓缩得到粗品,粗品通过柱层析纯化(洗脱剂:二氯甲烷/甲醇=20/1),得到化合物22-1a(800mg);MS:m/z 620.2[M+1]+;
向反应瓶中依次加入化合物22-1a(800mg,0.46mmol,1.0eq),1,4-二氧六环(5mL),4N盐酸(2mL),加毕,室温搅拌反应过夜,体系减压浓缩,得到化合物22-1b(780mg),不经纯化,直接投入下一步反应;MS:m/z 564.20[M+1]+;
向反应瓶中依次加入化合物22-1b(225.0mg,0.40mmol,1.0eq),二甲基甲酰胺(5mL),HATU(228mg,0.60mmol,1.5eq),二异丙基乙胺(208mg,0.80mmol,4.0eq),室温搅拌5分钟后,加入化合物17-2(189.7mg,0.60mol,1.5eq),加毕,室温搅拌过夜,向体系加入水(30mL),乙酸乙酯(30mL)萃取3次,饱和氯化钠溶液(50mL)洗涤2次,无水硫酸钠干燥过滤,浓缩得到粗品,粗品通过柱层析纯化(洗脱剂:二氯甲烷/甲醇=10/1),得到化合物22-1(100mg);MS:m/z 862.4[M+1]+;
(2)化合物22的制备
向反应瓶中依次加入化合物22-1(10mg,0.12mmol,1.0eq),四氢呋喃(10ml),20%钯碳(20mg),在氢气氛围下控温30℃反应过夜,反应液过滤,滤液旋干,进行反相柱层析纯化(Shim-pack GIS-C1820*250nm,5μm;0.01%甲酸-水/乙腈),得到化合物22(6.0mg);1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),8.40(d,J=42.3Hz,1H),8.00(d,J=8.0Hz,1H),7.88(s,1H),7.78(d,J=8.4Hz,1H),7.51(s,1H),7.38(d,J=8.8Hz,1H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.76-5.72(m,1H),5.65(s,1H),5.12(dd,J=12.9,5.4Hz,1H),4.23(d,J=13.5Hz,2H),3.96(s,3H),3.85-3.81(m,2H),3.76-3.69(m,2H),3.66-3.52(m,4H),3.49-3.45(m,2H),2.96-2.80(m,2H),2.66-2.63(m,2H),2.62-2.56(m,5H),2.55(s,3H),1.66(d,J=7.0Hz,3H);MS:m/z 832.4[M+1]+。
实施例23-26:化合物23-26的制备
按照与实施例22基本相似的操作,合成化合物23-26。
化合物23-26的核磁数据如下:
化合物23
1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),8.40(d,J=42.3Hz,1H),8.00(d,J=8.0Hz,1H),7.88(s,1H),7.78(d,J=8.4Hz,1H),7.51(s,1H),7.38(d,J=8.8Hz,1H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.76-5.72(m,1H),5.65(s,1H),5.12(dd,J=12.9,5.4Hz,1H),4.23(d,J=13.5Hz,2H),3.96(s,3H),3.85-3.81(m,2H),3.76-3.69(m,2H),3.66-3.52(m,4H),3.49-3.45(m,2H),2.96-2.80(m,2H),2.66-2.63(m,2H),2.62-2.56(m,5H),2.55(s,3H),2.13-2.05(m,2H),1.66(d,J=7.0Hz,3H).
化合物24
1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),8.40(d,J=42.3Hz,1H),8.00(d,J=8.0Hz,1H),7.88(s,1H),7.78(d,J=8.4Hz,1H),7.51(s,1H),7.38(d,J=8.8Hz,1H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.76-5.72(m,1H),5.65(s,1H),5.12(dd,J=12.9,5.4Hz,1H),4.23(d,J=13.5Hz,2H),3.96(s,3H),3.85-3.81(m,2H),3.76-3.69(m,2H),3.66-3.52(m,4H),3.49-3.45(m,2H),2.96-2.80(m,2H),2.66-2.63(m,2H),2.62-2.56(m,5H),2.55(s,3H),2.08-1.85(m,4H),1.66(d,J=7.0Hz,3H).
化合物25
1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),8.40(d,J=42.3Hz,1H),8.00(d,J=8.0Hz,1H),7.88(s,1H),7.78(d,J=8.4Hz,1H),7.51(s,1H),7.38(d,J=8.8Hz,1H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.76-5.72(m,1H),5.65(s,1H),5.12(dd,J=12.9,5.4Hz,1H),4.23(d,J=13.5Hz,2H),3.96(s,3H),3.85-3.81(m,2H),3.76-3.69(m,2H),3.66-3.52(m,4H),3.49-3.45(m,2H),2.96-2.80(m,2H),2.66-2.63(m,2H),2.62-2.56(m,5H),2.55(s,3H),2.08-1.85(m,4H),1.66(d,J=7.0Hz,3H),1.44-1.36(m,2H).
化合物26
1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),8.40(d,J=42.3Hz,1H),8.00(d,J=8.0Hz,1H),7.88(s,1H),7.78(d,J=8.4Hz,1H),7.51(s,1H),7.38(d,J=8.8Hz,1H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.76-5.72(m,1H),5.65(s,1H),5.12(dd,J=12.9,5.4Hz,1H),4.23(d,J=13.5Hz,2H),3.96(s,3H),3.85-3.81(m,2H),3.76-3.69(m,2H),3.66-3.52(m,4H),3.49-3.45(m,2H),2.96-2.80(m,2H),2.66-2.63(m,2H),2.62-2.56(m,5H),2.55(s,3H),1.85-1.63(m,2H),1.66(d,J=7.0Hz,3H),1.44-1.36(m,6H).
实施例27:化合物27的制备
(1)中间体27-1合成路线
向反应瓶中依次加入化合物1-1a(3.0g,10.86mmol,1.0eq),(2-(2-氨基乙氧基)乙基)氨基甲酸叔丁酯(1.90g,11.95mmol,1.1eq),二异丙基乙胺(2.80g,21.72mmol,2.0eq),N-甲基吡咯烷酮(50mL),加毕,升温至100℃,搅拌反应过夜,反应体系冷却至室温后加入水(50mL),再加入乙酸乙酯(50mL)萃取3次,有机相用饱和氯化钠溶液(100mL)洗涤2次后,加入无水硫酸钠干燥、过滤和浓缩得到粗品,粗品经柱层析纯化(洗脱剂:石油醚/乙酸乙酯=1/1),得到化合物27-1a(4.30g);MS:m/z 461.2[M+1]+;
向反应瓶中依次加入化合物27-1a(1.0g,2.40mmol,1.0eq),三氟乙酸(3mL),二氯甲烷(15mL),加毕,室温搅拌反应过夜,体系减压浓缩,得到化合物27-1b(750.6mg),不经纯化,直接投入下一步反应;MS:m/z 361.1[M+1]+;
向反应瓶中依次加入化合物17-1b(228.74mg,0.42mmol,1.5eq),二甲基甲酰胺(5mL),HATU(158.37mg,0.42mmol,1.5eq),二异丙基乙胺(143.54mg,1.11mmol,4.0eq),室温搅拌5分钟后,加入化合物27-1b(100mg,0.28mol,1.0eq),加毕,室温搅拌过夜,向体系加入水(30mL),乙酸乙酯(30mL)萃取3次,饱和氯化钠溶液(50mL)洗涤2次,无水硫酸钠干燥过滤,浓缩得到粗品,粗品通过柱层析纯化(洗脱剂:二氯甲烷/甲醇=10/1),得到化合物27-1(50mg);MS:m/z 892.4[M+1]+;
(2)化合物27的制备
向反应瓶中依次加入化合物27-1(50mg,0.056mmol,1.0eq),四氢呋喃(10ml),20%钯碳(10mg),在氢气氛围下控温30℃反应过夜,反应液过滤,滤液旋干,进行反相柱层析纯化(Shim-pack GIS-C1820*250nm,5μm;0.01%甲酸-水/乙腈),得到化合物27(1.0mg);1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),8.40(d,J=42.3Hz,1H),8.00(d,J=8.0Hz,1H),7.88(s,1H),7.78(d,J=8.4Hz,1H),7.51(s,1H),7.38(d,J=8.8Hz,1H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.76-5.72(m,1H),5.65(s,1H),5.12(dd,J=12.9,5.4Hz,1H),4.23(d,J=13.5Hz,2H),3.96(s,3H),3.85-3.81(m,2H),3.76-3.69(m,4H),3.66-3.52(m,4H),3.49-3.45(m,4H),2.96-2.80(m,2H),2.66-2.63(m,2H),2.61-2.58(m,3H),2.55(s,3H),1.65(d,J=7.0Hz,3H);MS:m/z 862.4[M+1]+。
实施例28-29:化合物28-29的制备
按照与实施例27基本相似的操作,合成化合物28-29。
化合物28-29的核磁数据如下:
化合物28
1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),8.40(d,J=42.3Hz,1H),8.00(d,J=8.0Hz,1H),7.88(s,1H),7.78(d,J=8.4Hz,1H),7.51(s,1H),7.38(d,J=8.8Hz,1H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.76-5.72(m,1H),5.65(s,1H),5.12(dd,J=12.9,5.4Hz,1H),4.23(d,J=13.5Hz,2H),3.96(s,3H),3.85-3.81(m,2H),3.76-3.69(m,4H),3.68-3.50(m,8H),3.49-3.45(m,4H),2.96-2.80(m,2H),2.66-2.63(m,2H),2.61-2.58(m,3H),2.55(s,3H),1.65(d,J=7.0Hz,3H).
化合物29
1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),8.40(d,J=42.3Hz,1H),8.00(d,J=8.0Hz,1H),7.88(s,1H),7.78(d,J=8.4Hz,1H),7.51(s,1H),7.38(d,J=8.8Hz,1H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.76-5.72(m,1H),5.65(s,1H),5.12(dd,J=12.9,5.4Hz,1H),4.23(d,J=13.5Hz,2H),3.96(s,3H),3.85-3.81(m,2H),3.76-3.69(m,4H),3.68-3.49(m,12H),3.49-3.45(m,4H),2.96-2.80(m,2H),2.66-2.63(m,2H),2.61-2.58(m,3H),2.55(s,3H),1.65(d,J=7.0Hz,3H).
实施例30:化合物30的制备
(1)中间体30-2合成路线
氮气保护下,向反应瓶中依次加入30-2a(45.00g,211.24mmol,1.0eq),1-叔丁氧羰基哌嗪(39.34g,211.24mmol,1.0eq),二氧六环(500mL),三(二亚苄基丙酮)二钯(0)(19.34g,21.12mmol,0.10eq),Xantphos(12.22g,21.12mmol,0.10eq)和碳酸钾(89.68g,422.48mmol,2.0eq),加毕,加热至100℃,搅拌过夜,趁热过滤,用二氯甲烷洗涤滤渣,浓缩,趁热加入乙酸乙酯(50mL)和石油醚(100mL)的混合液,搅拌,冷却,过滤,得到的固体在烘箱中烘干,得到化合物30-2b(50g);MS:m/z 319.2[M+1]+;
向反应瓶中依次加入化合物30-2b(47.8g,150.14mmol,1.0eq),四氢呋喃(150mL),甲醇(150mL)和水(150mL),再加入氢氧化钠(24.0g,600mmol,4eq),加毕,室温下搅拌1h后,加入水(400mL),用乙醚(200mL)洗涤,水相用2M盐酸中和至pH=4-5,继续搅拌直到产生大量沉淀,过滤,滤饼用水洗涤,得到的固体在烘箱中烘干,得到化合物30-2c(40g);MS:m/z 337.2[M+1]+;
向反应瓶中依次加入化合物30-2c(20g,59.46mmol,1.0eq)加入甲醇(100mL)和乙酸乙酯(100mL),冰浴冷却至-10℃,缓慢滴加TMSCH2N2(2.0M,89mL,3.0eq)。加毕,室温下搅拌30min后,加入水(200mL)分液,水相用乙酸乙酯(200mL)萃取2次,合并有机相,用饱和氯化钠溶液(200mL)洗涤1次,硫酸钠干燥,过滤并浓缩,得到化合物30-2d(20.84g);MS:m/z 351.2[M+1]+;
向反应瓶中依次加入化合物30-2d(20.84g,59.47mmol,1.0eq)、干燥四氢呋喃(200mL)和四溴化碳(29.58g,89.21mmol,1.5eq),在冰浴冷却下,分批加入三苯基膦(23.4g,89.21mmol,1.5eq),加毕,在室温下继续搅拌1h,减压浓缩出去大部分四氢呋喃后,加入水(200mL),用乙酸乙酯(200mL)萃取3次,合并有机相,用饱和食盐水(200mL)洗涤,无水硫酸钠干燥,过滤浓缩,柱层析纯化(洗脱剂:石油醚/乙酸乙酯=15/1),得到化合物30-2e(12.0g);MS:m/z 413.1[M+1]+;
向反应瓶中依次加入化合物30-2e(12.0g,29.03mmol,1.0eq),二异丙基乙胺(11.26g,87.09mmol,3.0eq),3-氨基哌啶-2,6-二酮盐酸盐(7.17g,43.55mmol,1.5eq)和乙腈(300mL),加毕,加热至80℃,搅拌72小时,趁热过滤,滤液浓缩,趁热加入乙酸乙酯(100mL),搅拌、冷却至室温,过滤、干燥,得到化合物30-2f(6.0g);MS:m/z 429.2[M+1]+;
向反应瓶中依次加入化合物30-2f(6.0g,14.0mmol,1.0eq),二氯甲烷(50mL),在冰浴冷却条件下,滴加三氟乙酸(10mL),室温下搅拌2h后,减压旋干二氯甲烷和三氟乙酸,得到化合物30-2(5g),不经纯化,直接投入下一步反应;MS:m/z 329.2[M+1]+;
(2)中间体30-1合成路线
向反应瓶中依次加入化合物1-3(500.0mg,1.02mmol,1.0eq),二异丙基乙胺(394.68mg,3.05mmol,3.0eq),4-溴丁醛乙二缩醛(298.43mg,1.53mmol,1.5eq),二甲基甲酰胺(5mL),100℃微波反应1小时,冷却至室温后,加入水(30mL),再加入乙酸乙酯(30mL)萃取3次,用饱和氯化钠溶液(50mL)洗涤2次,加入无水硫酸钠干燥、过滤和浓缩,所得粗品经柱层析纯化(洗脱剂:石油醚/乙酸乙酯=1/1),得到化合物30-1a(360.0mg);MS:m/z 606.8[M+1]+;
向反应瓶中依次加入化合物30-1a(360.0mg,0.59mmol,1.0eq),四氢呋喃(5mL),水(0.5mL),三氟乙酸(134.54mg,1.18mmol,2.0eq),100℃微波反应1小时,冷却至室温后,饱和碳酸氢钠调
节pH至7后,加入乙酸乙酯(50mL)萃取3次,加入无水硫酸钠干燥、过滤和浓缩,所得粗品经柱层析纯化(洗脱剂:二氯甲烷/甲醇=20/1),得到化合物30-1b(100.0mg);MS:m/z 562.6[M+1]+;
向反应瓶中依次加入化合物30-1b(100.0mg,0.18mmol,1.0eq),化合物30-2(59.07mg,0.18mmol,1.0eq),二氯甲烷(10mL),甲醇(1mL),无水乙酸钠(2.42mg,0.02mmol,0.1eq)和醋酸(1.21mg,0.02mmol,0.1eq),室温搅拌反应1小时,0℃下加入氰基硼氢化钠(55.99mg,0.89mmol,5.0eq),加毕,升至室温,搅拌反应过夜,加入水(30mL),乙酸乙酯(30mL)萃取3次,加入无水硫酸钠干燥、过滤和浓缩得到粗品,粗品经柱层析纯化(洗脱剂:二氯甲烷/甲醇=10/1),得到化合物30-1(30.0mg);MS:m/z 874.4[M+1]+;
(3)化合物30的制备
向反应瓶中依次加入化合物30-1(30.0mg,0.03mmol,1.0eq),四氢呋喃(5mL),20%钯碳(6mg),在氢气氛围下控温30℃反应过夜,反应液过滤,滤液旋干,进行反相柱层析纯化(Shim-pack GIS-C1820*250nm,5μm;0.01%甲酸-水/乙腈),得到化合物30(0.5mg);1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),8.40(d,J=42.3Hz,1H),8.00(d,J=8.0Hz,1H),7.78(d,J=8.4Hz,1H),7.51(s,1H),7.38(d,J=8.8Hz,1H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.76-5.72(m,1H),5.65(s,1H),5.12(dd,J=12.9,5.4Hz,1H),4.23(d,J=13.5Hz,2H),3.96(s,3H),3.76-3.69(m,2H),3.64-3.56(m,4H),3.49-3.45(m,8H),3.15(s,4H),3.03(s,2H),2.96-2.80(m,3H),2.39-2.33(m,2H),2.14-1.98(m,2H),1.88-1.69(m,2H),1.67(d,J=7.0Hz,3H);MS:m/z 844.4[M+1]+。
实施例31:化合物31的制备
按照与实施例30基本相似的操作,合成化合物31。
化合物31的核磁数据如下:
1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),8.40(d,J=42.3Hz,1H),8.00(d,J=8.0Hz,1H),7.78(d,J=8.4Hz,1H),7.51(s,1H),7.38(d,J=8.8Hz,1H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.76-5.72(m,1H),5.65(s,1H),5.12(dd,J=12.9,5.4Hz,1H),4.23(d,J=13.5Hz,2H),3.96(s,3H),3.76-3.69(m,2H),3.64-3.56(m,4H),3.49-3.45(m,8H),3.15(s,4H),3.03(s,2H),2.96-2.80(m,3H),2.39-2.33(m,2H),2.14-1.98(m,2H),1.63-1.40(m,7H).
实施例32:化合物32的制备
(1)中间体32-1合成路线
向反应瓶中依次加入化合物17-1b(251.03mg,0.46mmol,1.5eq),二甲基甲酰胺(5mL),HATU(173.81mg,0.46mmol,1.5eq),二异丙基乙胺(157.54mg,1.22mmol,4.0eq),室温搅拌5分钟后,加入化合物30-2(100mg,0.30mol,1.0eq),加毕,室温搅拌过夜,向体系加入水(30mL),乙酸乙酯(30mL)萃取3次,饱和氯化钠溶液(50mL)洗涤2次,无水硫酸钠干燥过滤,浓缩得到粗品,粗品通过柱层析纯化(洗脱剂:二氯甲烷/甲醇=10/1),得到化合物32-1(55.0mg);MS:m/z 860.4[M+1]+;
(2)化合物32的制备
向反应瓶中依次加入化合物32-1(55.0mg,0.06mmol,1.0eq),四氢呋喃(5mL),20%钯碳(11mg),在氢气氛围下控温30℃反应过夜,反应液过滤,滤液旋干,进行反相柱层析纯化(Shim-pack GIS-C1820*250nm,5μm;0.01%甲酸-水/乙腈),得到化合物32(2.1mg);1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),8.40(d,J=42.3Hz,1H),8.00(d,J=8.0Hz,1H),7.78(d,J=8.4Hz,1H),7.51(s,1H),7.38(d,J=8.8Hz,1H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.76-5.72(m,1H),5.65(s,1H),5.12(dd,J=12.9,5.4Hz,1H),4.23(d,J=13.5Hz,2H),3.96(s,3H),3.76-3.69(m,2H),3.64-3.56(m,4H),3.49-3.45(m,4H),3.35-3.28(m,4H),3.03(s,2H),2.96-2.80(m,3H),2.39-2.33(m,2H),2.14-1.98(m,2H),1.65(d,J=7.0Hz,3H);MS:m/z 830.4[M+1]+。
实施例33-35:化合物33-35的制备
按照与实施例32基本相似的操作,合成化合物33-35。
化合物33-35的核磁数据如下:
化合物33
1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),8.40(d,J=42.3Hz,1H),8.00(d,J=8.0Hz,1H),7.78(d,J=8.4Hz,1H),7.51(s,1H),7.38(d,J=8.8Hz,1H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.76-5.72(m,1H),5.65(s,1H),5.12(dd,J=12.9,5.4Hz,1H),4.23(d,J=13.5Hz,2H),3.96(s,3H),3.76-3.69(m,2H),3.64-3.56(m,4H),3.49-3.45(m,4H),3.35-3.28(m,4H),3.03(s,2H),2.96-2.80(m,3H),2.62-2.48(m,2H),2.39-2.33(m,2H),2.14-1.98(m,2H),1.65(d,J=7.0Hz,3H).
化合物34
1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),8.40(d,J=42.3Hz,1H),8.00(d,J=8.0Hz,1H),7.78(d,J=8.4Hz,1H),7.51(s,1H),7.38(d,J=8.8Hz,1H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.76-5.72(m,1H),5.65(s,1H),5.12(dd,J=12.9,5.4Hz,1H),4.23(d,J=13.5Hz,2H),3.96(s,3H),3.76-3.69(m,2H),3.64-3.56(m,4H),3.49-3.45(m,4H),3.35-3.28(m,4H),3.03(s,2H),2.96-2.80(m,3H),2.62-2.48(m,2H),2.39-2.33(m,2H),2.14-1.88(m,4H),1.65(d,J=7.0Hz,3H).
化合物35
1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),8.40(d,J=42.3Hz,1H),8.00(d,J=8.0Hz,1H),7.78(d,J=8.4Hz,1H),7.51(s,1H),7.38(d,J=8.8Hz,1H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.76-5.72(m,1H),5.65(s,1H),5.12(dd,J=12.9,5.4Hz,1H),4.23(d,J=13.5Hz,2H),3.96(s,3H),3.76-3.69(m,2H),3.64-3.56(m,4H),3.49-3.45(m,4H),3.35-3.28(m,4H),3.03(s,2H),2.96-2.80(m,3H),2.62-2.48(m,2H),2.39-2.33(m,2H),2.14-1.88(m,4H),1.65(d,J=7.0Hz,3H),1.58-1.45(m,2H).
实施例36:化合物36的制备
(1)中间体36-1合成路线
向反应瓶中依次加入化合物36-1a(5.0g,18.10mmol,1.0eq)、N-叔丁氧羰基哌嗪(3.71g,19.90mmol,1.1eq)、二异丙基乙胺(7.0g,54.30mmol,6.0eq)、N-甲基吡咯烷酮(30mL),加毕,
升温至140℃搅拌反应6h,将反应体系冷却至室温加入水(100mL),乙酸乙酯(100mL)萃取2次,饱和氯化钠溶液(100mL)洗涤2次,无水硫酸钠干燥过滤,浓缩得到粗品,粗品通过柱层析纯化(洗脱剂:石油醚/乙酸乙酯=1/1),得到化合物36-1b(6.0g);MS:m/z 443.2[M+1]+;
向反应瓶中依次加入化合物36-1b(6.0g,13.57mmol,1.0eq)、4N盐酸/1,4-二氧六环(50mL),加毕,室温搅拌反应2h,体系减压浓缩,得到化合物36-1c(5.5g),不经纯化,直接投入下一步;MS:m/z 343.0[M+1]+;
向反应瓶中依次加入化合物36-1c(.5g,4.38mmol,1.0eq),4-(2-氧代乙基)哌啶-1-甲酸叔丁酯(1.5g,6.58mmol,1.5eq),无水乙酸钠(7.2g,87.69mmol,20.0eq)、二氯甲烷:甲醇=10:1(100mL),室温搅拌反应30分钟后,分批加入氰基硼氢化钠(2.76g,43.84mmol,10.0eq),加毕,室温搅拌反应2h,加入水(150mL),乙酸乙酯(150mL)萃取2次,无水硫酸钠干燥过滤,浓缩得到粗品,粗品通过柱层析纯化(洗脱剂:石油醚/乙酸乙酯=1/1),得到化合物36-1d(2.5g);MS:m/z 554.2[M+1]+;
向反应瓶中依次加入化合物36-1d(2.5g,4.52mmol,1.0eq),4N盐酸/1,4-二氧六环(20mL),加毕,室温搅拌反应2h,体系减压浓缩,得到化合物36-1e(2.5g),不经纯化,直接投入下一步;MS:m/z 454.2[M+1]+;
向反应瓶中依次加入化合物36-1e(270.0mg,0.60mmol,1.0eq),3-溴丙酸叔丁酯(249.1mg,1.19mmol,2.0eq),二异丙基乙胺(154.0mg,1.19mmol,2.0eq),二甲基甲酰胺(10mL),加毕,升温至50℃搅拌反应6h,质谱显示主要为原料,补加二异丙基乙胺(154.0mg,1.19mmol,2.0eq),50℃搅拌反应过夜,反应体系降至室温,加入水(50mL),乙酸乙酯(50mL)萃取2次,饱和氯化钠溶液(50mL)洗涤2次,无水硫酸钠干燥过滤,浓缩得到粗品,粗品通过柱层析纯化(洗脱剂:二氯甲烷/甲醇=15/1),得到化合物36-1f(183mg);MS:m/z 582.4[M+1]+;
向反应瓶中依次加入化合物36-1f(183mg,0.31mmol,1.0eq),浓盐酸(5mL),加毕,室温搅拌反应2h,体系减压浓缩,得到化合物36-1g(154mg),不经纯化,直接投入下一步;MS:m/z 526.2[M+1]+;
向反应瓶中依次加入化合物36-1g(154.0mg,0.27mmol,1.0eq),二甲基甲酰胺(5mL),HOBT(54.1mg,0.40mmol,1.5eq),EDCI(76.7mg,0.40mmol,1.5eq),二异丙基乙胺(241.3mg,1.86mmol,7.0eq),室温搅拌反应2小时后,加入化合物1-3(131.0mg,0.27mmol,1.0eq),加毕,升温至30℃搅拌反应过夜,反应体系降至室温,加入水(50mL),乙酸乙酯(50mL)萃取2次,饱和氯化钠溶液(50mL)洗涤2次,无水硫酸钠干燥过滤,浓缩得到粗品,粗品通过柱层析纯化(洗脱剂:二氯甲烷/甲醇=10/1),得到化合物36-1(250mg);MS:m/z 999.4[M+1]+;
(2)化合物36的制备
向反应瓶中依次加入化合物36-1(250mg,0.25mmol,1.0eq),四氢呋喃(10ml),20%钯碳(50mg),在氢气氛围下控温至30℃搅拌反应过夜,反应液过滤,滤液旋干,进行反相柱层析纯化(Shim-packGIS-C18 20*250nm,5μm;0.01%甲酸-水/乙腈),得到化合物36(12.8mg);1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),8.40(d,J=42.3Hz,1H),8.00(d,J=8.0Hz,1H),7.78(d,J=8.4Hz,1H),7.51(s,1H),7.38(d,J=8.8Hz,1H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),
5.76-5.72(m,1H),5.65(s,1H),5.12(dd,J=12.9,5.4Hz,1H),4.23(d,J=13.5Hz,2H),3.96(s,3H),3.76-3.69(m,2H),3.64-3.56(m,4H),3.49-3.45(m,5H),3.15(s,4H),3.03(s,2H),2.96-2.80(m,3H),2.61-2.58(m,6H),2.39-2.33(m,2H),2.26-2.22(m,1H),2.14-1.98(m,2H),1.88(d,J=12.8Hz,2H),1.78-1.69(m,5H),1.62(d,J=7.0Hz,3H);MS:m/z 969.4[M+1]+。
实施例37-38及实施例75-82:化合物37-38及化合物75-82的制备
按照与实施例36基本相似的操作,合成化合物37-38及化合物75-82。
化合物37-38和75-82的核磁数据如下:
化合物37
1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),8.40(d,J=42.3Hz,1H),8.00(d,J=8.0Hz,1H),7.78(d,J=8.4Hz,1H),7.51(s,1H),7.38(d,J=8.8Hz,1H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.76-5.72(m,1H),5.65(s,1H),5.12(dd,J=12.9,5.4Hz,1H),4.23(d,J=13.5Hz,2H),3.96(s,3H),3.76-3.69(m,2H),3.64-3.56(m,4H),3.49-3.45(m,5H),3.15(s,4H),3.03(s,2H),2.96-2.80(m,3H),2.61-2.58(m,6H),2.39-2.33(m,2H),2.26-2.22(m,1H),2.14-1.98(m,2H),1.88(d,J=12.8Hz,2H),1.78-1.69(m,5H),1.62-1.48(m,5H).
化合物38
1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),8.40(d,J=42.3Hz,1H),8.00(d,J=8.0Hz,1H),7.78(d,J=8.4Hz,1H),7.51(s,1H),7.38(d,J=8.8Hz,1H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.76-5.72(m,1H),5.65(s,1H),5.12(dd,J=12.9,5.4Hz,1H),4.23(d,J=13.5Hz,2H),3.96(s,3H),3.76-3.69(m,2H),3.64-3.56(m,4H),3.49-3.45(m,5H),3.15(s,4H),3.03(s,2H),2.96-2.80(m,3H),2.61-2.58(m,6H),2.39-2.33(m,2H),2.26-2.22(m,1H),2.14-1.98(m,2H),1.88(d,J=12.8Hz,2H),1.78-1.69(m,5H),1.62-1.48(m,7H).
化合物75
1H NMR(400MHz,DMSO-d6):δ11.10(s,1H),8.26(d,J=2.6Hz,1H),8.00(d,J=8.0Hz,1H),7.80(d,J=16.0Hz,1H),7.69(d,J=8.5Hz,1H),7.34(d,J=2.5Hz,1H),7.26-7.23(m,1H),7.08(d,J=4.0Hz,1H),6.88(d,J=9.3Hz,2H),6.71(s,1H),5.64-5.56(m,3H),5.25-5.01(m,2H),4.15(s,1H),4.08(d,J=8.2Hz,2H),3.88(d,J=2.1Hz,3H),3.76-3.45(m,12H),2.98-2.77(m,4H),2.46-2.42(m,5H),2.37(d,J=3.1Hz,3H),2.33-2.29(m,4H),2.12(d,J=8.4Hz,1H),2.08-1.95(m,3H),1.89(t,J=11.5Hz,1H),1.62-1.57(m,6H).
化合物76
1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),8.40(d,J=42.3Hz,1H),8.00(d,J=8.0Hz,1H),7.78(d,J=8.4Hz,1H),7.51(s,1H),7.38(d,J=8.8Hz,1H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.76-5.72(m,1H),5.65(s,1H),5.12(dd,J=12.9,5.4Hz,1H),4.23(d,J=13.5Hz,2H),3.96(s,3H),3.76-3.69(m,2H),3.64-3.56(m,4H),3.49-3.45(m,3H),3.15(s,4H),3.03(s,2H),2.96-2.80(m,3H),2.61-2.58(m,8H),2.26-2.22(m,1H),2.14-1.98(m,2H),1.88(d,J=12.8Hz,2H),1.78-1.69(m,7H),1.62-1.48(m,5H).
化合物77
1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),8.40(d,J=42.3Hz,1H),8.00(d,J=8.0Hz,1H),7.78(d,J=8.4Hz,1H),7.51(s,1H),7.38(d,J=8.8Hz,1H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.76-5.72(m,1H),5.65(s,1H),5.12(dd,J=12.9,5.4Hz,1H),4.46-4.41(s,4H),4.23(d,J=13.5Hz,2H),3.96(s,3H),3.76-3.69(m,2H),3.64-3.56(m,4H),3.49-3.45(m,3H),3.15(s,4H),3.03(s,2H),2.96-2.80(m,3H),2.61-2.58(m,4H),2.26-2.22(m,1H),2.14-1.98(m,2H),1.88(d,J=12.8Hz,2H),1.78-1.69(m,7H),1.62-1.48(m,5H).
化合物78
1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),8.49(s,1H),7.87-7.84(m,1H),7.38(d,J=8.8Hz,1H),7.26(d,J=4.1Hz,1H),7.08-7.07(m,1H),6.89-6.87(m,2H),6.71(s,1H),5.76-5.72(m,1H),5.65(s,1H),5.12(dd,J=12.9,5.4Hz,1H),4.23(d,J=13.5Hz,2H),3.96(s,3H),3.76-3.69(m,2H),3.64-3.56(m,4H),3.49-3.45(m,3H),3.15(s,4H),3.03(s,2H),2.96-2.80(m,3H),2.61-2.58(m,8H),2.39-2.33(m,2H),2.26-2.22(m,1H),2.14-1.98(m,2H),1.88(d,J=12.8Hz,2H),1.78-1.69(m,5H),1.62-1.48(m,7H).
化合物79
1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),8.49(s,1H),7.87-7.84(m,1H),7.38(d,J=8.8Hz,1H),7.26(d,J=4.1Hz,1H),7.08-7.07(m,1H),6.89-6.87(m,2H),6.71(s,1H),6.40(d,J=6.2Hz,2H),5.76-5.72(m,1H),5.65(s,1H),5.12(dd,J=12.9,5.4Hz,1H),4.23(d,J=13.5Hz,2H),3.96(s,3H),3.76-3.69(m,2H),3.64-3.56(m,4H),3.49-3.45(m,3H),3.15(s,4H),3.03(s,2H),2.96-2.80(m,3H),2.61-2.58(m,6H),2.26-2.22(m,1H),2.14-1.98(m,2H),1.88(d,J=12.8Hz,2H),1.78-1.69(m,3H),1.62-1.48(m,5H).
化合物80
1H NMR(400MHz,DMSO-d6):δ11.10(s,1H),8.18(s,1H),7.98(d,J=8.1Hz,1H),7.69(d,J=8.5Hz,1H),7.62(d,J=4.4Hz,1H),7.35(d,J=2.1Hz,1H),7.27(d,J=8.9Hz,1H),7.05(d,J=2.0Hz,1H),6.88(d,J=15.5Hz,2H),6.71(s,1H),5.59-5.53(m,3H),5.15-5.00(m,2H),4.34-4.31(m,1H),4.04-3.94(m,1H),3.88(s,3H),3.76-3.45(m,12H),3.37-3.21(m,5H),3.18-3.04(m,1H),2.98-2.88(m,2H),2.87-2.80(m,3H),2.70(d,J=10.2Hz,1H),2.63-2.56(m,2H),2.40-2.33(m,5H),2.18-2.16(m,2H),2.07-2.01(m,2H),1.95-1.85(m,2H),1.76-1.64(m,5H),1.57(d,J=7.0Hz,3H),1.43-1.38(m,2H).
化合物81
1H NMR(400MHz,DMSO-d6):δ11.10(s,1H),8.18(s,1H),7.98(d,J=8.1Hz,1H),7.69(d,J=8.5Hz,1H),7.62(d,J=4.4Hz,1H),7.35(d,J=2.1Hz,1H),7.27(d,J=8.9Hz,1H),7.05(d,J=2.0Hz,1H),6.88(d,J=15.5Hz,2H),6.71(s,1H),5.59-5.53(m,3H),5.15-5.00(m,2H),4.34-4.31(m,1H),4.04-3.94(m,1H),3.88(s,3H),3.76-3.45(m,10H),3.37-3.21(m,5H),3.18-3.04(m,1H),2.98-2.88(m,2H),2.87-2.80(m,3H),2.70(d,J=10.2Hz,1H),2.63-2.56(m,2H),2.40-2.33(m,5H),2.18-2.16(m,2H),2.07-2.01(m,2H),1.95-1.85(m,2H),1.57(d,J=7.0Hz,3H),1.76-1.64(m,5H),1.43-1.38(m,2H).
化合物82
1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),9.32(s,1H),8.40(d,J=42.3Hz,1H),8.00(d,J=8.0Hz,1H),7.78(d,J=8.4Hz,1H),7.63(s,1H),7.51(s,1H),7.38(d,J=8.8Hz,1H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.76-5.72(m,1H),5.65(s,1H),5.12(dd,J=12.9,5.4Hz,
1H),4.23(d,J=13.5Hz,2H),3.76-3.69(m,4H),3.64-3.56(m,4H),3.49-3.45(m,5H),3.15(s,4H),3.03(s,2H),2.96-2.80(m,3H),2.61-2.58(m,6H),2.26-2.22(m,1H),2.14-1.98(m,2H),1.88(d,J=12.8Hz,2H),1.78-1.69(m,5H),1.62-1.48(m,7H).
实施例86及实施例88:化合物86和88的制备
按照与实施例36基本相似的操作,合成化合物86和88。
化合物86和88的核磁数据如下:
化合物86
1H NMR(400MHz,DMSO-d6):δ11.10(s,1H),8.20(s,1H),8.17-8.10(m,3H),8.04(t,J=2.2Hz,1H),7.69(d,J=8.4Hz,2H),7.63-7.55(m,1H),7.52(t,J=7.3Hz,1H),7.35(s,1H),7.27(d,J=2.0Hz,1H),7.14(d,J=1.9Hz,1H),5.83-5.73(m,1H),5.35(d,J=5.5Hz,1H),5.09(dd,J=12.9,5.4Hz,1H),3.84(s,1H),3.70-3.71(m,4H),3.49-3.42(m,9H),2.94-2.86(m,4H),2.35-2.23(m,6H),2.09-1.85(m,5H),1.70-1.60(m,4H),1.48-1.39(m,5H),1.26-1.12(m,6H).
化合物88
1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),8.49(s,1H),7.87-7.84(m,1H),7.38(d,J=8.8Hz,1H),7.26(d,J=4.1Hz,1H),7.08-7.07(m,1H),6.89-6.87(m,2H),6.71(s,1H),5.76-5.72(m,1H),5.65(s,1H),5.12(dd,J=12.9,5.4Hz,1H),4.23(d,J=13.5Hz,2H),3.96(s,3H),3.76-3.69(m,2H),3.64-3.56(m,4H),3.49-3.45(m,5H),3.15(s,4H),3.03(s,2H),2.96-2.80(m,3H),2.61-2.58(m,6H),2.39-2.33(m,2H),2.26-2.22(m,1H),2.14-1.98(m,2H),1.88(d,J=12.8Hz,2H),1.78-1.69(m,5H),1.62-1.48(m,7H).
实施例39:化合物39的制备
(1)中间体39-2合成路线
氮气保护下,向反应瓶中依次加入化合物39-2a(20.00g,106.36mmol,1.0eq),四氢呋喃(150mL),
叔丁基亚磺酰胺(19.31g,159.54mmol,1.5eq)和钛酸四乙酯(74.65g,327.26mmol,2.0eq),加毕,升温至80℃,搅拌反应4小时,反应体系冷却至室温后,加入水(150mL),再加入乙酸乙酯(150mL)萃取2次,有机相用无水硫酸钠干燥,浓缩,柱层析纯化(洗脱剂:石油醚/乙酸乙酯=5/1),得到化合物39-2b(28.0g);MS:m/z 292.1[M+1]+;
向反应瓶中依次加入化合物39-2b(28.00g,96.19mmol,1.0eq),四氢呋喃(400mL)和水(6mL),降温至-60~-50℃后,缓慢加入硼氢化钠(6.58g,173.14mmol,1.8eq),加毕,升温至-5~0℃并控温继续搅拌30分钟,向体系加入水(300mL)淬灭反应,再加入乙酸乙酯(300mL)萃取2次,有机相用无水硫酸钠干燥,浓缩,柱层析纯化(洗脱剂:石油醚/乙酸乙酯=5/1),得到化合物39-2c(22.2g);MS:m/z 294.1[M+1]+;
向反应瓶中依次加入化合物39-2c(22.20g,75.76mmol,1.0eq),二氧六环(50mL)和4M盐酸(40mL),加毕,室温搅拌反应2小时,使用1M氢氧化钠溶液将体系pH调节至8-9,再加入乙酸乙酯(100mL)2次,有机相用无水硫酸钠干燥,浓缩,所得固体使用石油醚打浆,得到中间体39-2(10.0g);MS:m/z 190.1[M+1]+;
(2)中间体39-3合成路线
向反应瓶中依次加入化合物39-3a(15.00g,65.23mmol,1.0eq)和乙酸酐(90ml),加毕,升温至70℃,搅拌反应过夜,反应体系冷却至室温后,加入水(50ml),用饱和碳酸钠水溶液将体系pH调节至8-9,再加入乙酸乙酯(500ml)萃取2次,有机相合并用水(200ml)洗一次,饱和氯化钠水溶液(200ml)洗一次,有机相无水硫酸钠干燥,浓缩,柱层析纯化(洗脱液:石油醚/乙酸乙酯=5/1),得到化合物39-3b(9.01g);MS:m/z 273.0[M+1]+;
向反应瓶中依次加入化合物39-3b(9.00g,33.09mmol,1.0eq)和氨水(90ml),升温至30℃,搅拌反应过夜,反应体系降至室温,体系旋干,加入二氯甲烷(100ml),打浆0.5小时,过滤,滤饼用二氯甲烷(50ml)洗2次,滤饼烘干,得到化合物39-3c(6.56g);MS:m/z 240.0[M+1]+;
向反应瓶中依次加入化合物39-3c(6.07g,25.40mmol,1.0eq),乙腈(70ml),N,N-二异丙基乙胺(16.40g,127.01mmol,5.0eq)和三氯氧磷(11.68g,76.20mmol,3.0eq),升温至80℃,反应搅拌3小时,体系旋干,加入乙酸乙酯(100ml),在冰浴条件下用饱和碳酸钠水溶液将体系pH调节至8-9,分液,有机相用水(50ml)洗一次,饱和氯化钠水溶液(50ml)洗一次,有机相用无水硫酸钠干燥,旋干,得到化合物39-3d(6.53g);MS:m/z 258.0[M+1]+;
向反应瓶中依次加入化合物39-3d(6.53g),化合物39-2(7.77g,38.10mmol,1.5eq),N,N-二乙基乙胺(9.84g,76.20mmol,3.0eq)和四氢呋喃(70ml),室温搅拌反应过夜,体系降至室温,旋干,加入水(50ml),加入乙酸乙酯(100ml)萃取2次,有机相合并用水(50ml)洗一次,饱和氯化钠水溶液(50ml)洗一次,有机相用无水硫酸钠干燥,旋干,柱层析纯化(洗脱液:石油醚/乙酸乙酯=1/1),得到化合物39-3e(7.0g);MS:m/z 411.0[M+1]+;
氮气保护下,向反应瓶中依次加入化合物39-3e(7g,17.07mmol,1.0eq),N-叔丁氧羰基哌嗪(21.02g,85.36mmol,5.0eq),碘化亚铜(325.13mg,1.71mmol,0.1eq),磷酸钾(10.87g,51.21mmol,3.0eq),异丙醇(70ml)和乙二醇(70ml),加毕,升温至80℃,搅拌反应过夜,反应体系冷却至室温后加入水(150mL),再加入乙酸乙酯(150mL)萃取2次,有机相用无水硫酸钠干燥,浓缩,柱层析纯化(洗脱剂:石油醚/乙酸乙酯=1/1),得到化合物39-3f(7.5g);MS:m/z 517.3[M+1]+;
向反应瓶中依次加入化合物39-3f(7.5g,14.53mmol,1.0eq),1,4-二氧六环(50mL),4N盐酸(20mL),加毕,室温搅拌反应过夜,体系减压浓缩,得到化合物39-3(6.8g),不经纯化,直接投入下一步反应;MS:m/z 417.2[M+1]+;
(3)中间体38-1b的制备
按照与中间体36-1基本相似的操作,合成中间体38-1b。
(4)化合物39的制备
向反应瓶中依次加入化合物38-1b(199.41mg,0.36mmol,1.5eq),二甲基甲酰胺(5mL),HOBT(48.70mg,0.36mmol,1.5eq),EDCI(70.89mg,0.36mmol,1.5eq),二异丙基乙胺(124.21mg,0.96mmol,4.0eq),室温搅拌反应2小时后,加入化合物39-3(100.0mg,0.24mmol,1.0eq),加毕,升温至30℃搅拌反应过夜,反应体系降至室温,加入水(50mL),乙酸乙酯(50mL)萃取2次,饱和氯化钠溶液(50mL)洗涤2次,无水硫酸钠干燥过滤,浓缩得到粗品,粗品进行反相柱层析纯化(Shim-pack GIS-C18 20*250nm,5μm;0.01%甲酸-水/乙腈),得到化合物39(8.6mg);1H NMR(400MHz,DMSO-d6):δ11.10(s,1H),8.97(s,1H),8.67(s,1H),7.92(s,1H),7.73-7.70(m,1H),7.58(t,J=7.2Hz,1H),7.44-7.32(m,3H),7.30-7.18(m,2H),5.99(t,J=7.2Hz,1H),5.10(dd,J=12.9,5.4Hz,1H),3.77-3.58(m,8H),3.53-3.47(m,8H),2.78-2.59(m,4H),2.55(d,J=2.0Hz,3H),2.46-2.28(m,8H),2.07-2.01(m,2H),1.75(d,J=7.0Hz,3H),1.65-1.43(m,11H);MS:m/z 952.5[M+1]+。
实施例40:化合物40的制备
(1)中间体40-1的制备
氮气保护下,向反应瓶中依次加入化合物39-3e(360mg,0.88mmol,1.0eq),3,6-二氢-2H-噻喃-4-硼酸频哪醇酯(297.81mg,1.32mmol,1.5eq),四(三苯基膦)钯(152.18mg,0.13mmol,0.15eq),碳酸钠(232.12mg,2.19mmol,2.5eq),二氧六环(8mL)和水(2mL)加毕,升温至90℃搅拌反应6小时,降至室温后,加入水(50mL),乙酸乙酯(50mL)萃取2次,有机相用无水硫酸钠干燥,过滤和浓缩,柱层析纯化(洗脱剂:石油醚/乙酸乙酯=1/1),得到化合物40-1a(210.0mg);MS:m/z 431.1[M+1]+;
向反应瓶中依次加入化合物40-1a(200mg,0.46mmol,1.0eq),二氯甲烷(4mL)和间氯过氧苯甲酸(79.38mg,0.46mmol,1.0eq),加毕,室温搅拌反应1.5小时,加入亚硫酸钠溶液(30mL)淬灭反应,二氯甲烷(50mL)萃取2次,有机相用无水硫酸镁干燥,过滤和浓缩,柱层析纯化(洗脱剂:二氯甲烷/甲醇=10/1),得到化合物40-1b(140.0mg);MS:m/z 447.2[M+1]+;
氮气保护下,向反应瓶中依次加入化合物40-1b(140.0mg,0.31mmol,1.0eq)、二聚醋酸铑(5.55mg,0.01mmol,0.04eq)、碘苯二乙酯(152.23mg,0.47mmol,1.5eq)、三氟乙酸胺(71.12mg,0.62mmol,2.0eq)、氧化镁(51.07mg,1.24mmol,4.0eq)和二氯甲烷(4mL),加毕,室温搅拌反应48小时,体系过滤后,滤液减压浓缩,柱层析纯化(洗脱剂:二氯甲烷/甲醇=10/1),得到化合物40-1c(90.0mg);MS:m/z 557.2[M+1]+;
向反应瓶中依次加入化合物40-1c(80.0mg,0.14mmol,1.0eq),碳酸钾(99.16mg,0.72mmol,5.0eq)和甲醇(4mL)加毕,室温搅拌反应2小时,体系过滤后,向滤液中加入水(10mL),乙酸乙酯(10mL)萃取3次,有机相用无水硫酸钠干燥,过滤和浓缩,得到化合物40-1(60.0mg),不经纯化,直接投入下一步;MS:m/z 461.2[M+1]+;
(2)化合物40的制备
向反应瓶中依次加入化合物38-1b(179.97mg,0.33mmol,1.5eq),二甲基甲酰胺(5mL),HOBt
(43.95mg,0.33mmol,1.5eq),EDCI(63.98mg,0.33mmol,1.5eq),二异丙基乙胺(112.10mg,0.87mmol,4.0eq),室温搅拌反应2小时后,加入化合物40-1(100.0mg,0.22mmol,1.0eq),加毕,升温至30℃搅拌反应过夜,反应体系降至室温,加入水(50mL),乙酸乙酯(50mL)萃取2次,饱和氯化钠溶液(50mL)洗涤2次,无水硫酸钠干燥过滤,浓缩得到粗品,粗品进行反相柱层析纯化(Shim-pack GIS-C18 20*250nm,5μm;0.01%甲酸-水/乙腈),得到化合物40(4.3mg);1H NMR(400MHz,DMSO-d6):δ11.10(s,1H),8.97(s,1H),8.67(s,1H),7.92(s,1H),7.73-7.70(m,1H),7.58(t,J=7.2Hz,1H),7.44-7.32(m,3H),7.30-7.18(m,2H),5.99(t,J=7.2Hz,1H),5.83(t,J=14.4Hz,1H),5.10(dd,J=12.9,5.4Hz,1H),3.77-3.58(m,8H),3.47(d,J=8.4Hz,2H),2.78-2.59(m,8H),2.55(d,J=2.0Hz,3H),2.46-2.28(m,8H),2.07-2.01(m,3H),1.75(d,J=7.0Hz,3H),1.65-1.43(m,11H);MS:m/z997.4[M+1]+。
实施例41:化合物41的制备
(1)中间体41-1的制备
向反应瓶中依次加入化合物36-1c(1.5g,4.38mmol,1.0eq),4-甲酰基哌啶-1-甲酸叔丁酯(1.4g,6.58mmol,1.5eq),无水乙酸钠(7.2g,87.69mmol,20.0eq),二氯甲烷:MeOH=10:1(100mL),室温搅拌反应30分钟后,分批加入氰基硼氢化钠(2.76g,43.84mmol,10.0eq),加毕,室温搅拌反应2h,加入水(150mL),乙酸乙酯(150mL)萃取2次,无水硫酸钠干燥过滤,浓缩得到粗品,粗品通过柱层析纯化(洗脱剂:石油醚/乙酸乙酯=1/1),得到化合物41-1a(2.3g);MS:m/z 540.4[M+1]+;
向反应瓶中依次加入化合物41-1a(2.3g,4.27mmol,1.0eq),4N盐酸/1,4-二氧六环(20mL),加毕,室温搅拌反应2h,体系减压浓缩,得到化合物41-1b(2.2g),不经纯化,直接投入下一步;MS:m/z 440.3[M+1]+;
向反应瓶中依次加入化合物41-1b(300.0mg,0.68mmol,1.0eq),3-溴丙酸叔丁酯(285.62mg,1.36mmol,2.0eq)、二异丙基乙胺(175.77mg,1.36mmol,2.0eq),二甲基甲酰胺(10mL),加毕,升温至50℃搅拌反应6h,质谱显示主要为原料,补加二异丙基乙胺(175.77mg,1.36mmol,2.0eq),50℃搅拌反应过夜。反应体系降至室温,加入水(50mL),乙酸乙酯(50mL)萃取2次,饱和氯化
钠溶液(50mL)洗涤2次,无水硫酸钠干燥过滤,浓缩得到粗品,粗品通过柱层析纯化(洗脱剂:二氯甲烷/甲醇=10/1),得到化合物41-1c(195.0mg);MS:m/z 568.2[M+1]+;
向反应瓶中依次加入化合物41-1c(195.0mg,0.34mmol,1.0eq),浓盐酸(5mL),加毕,室温搅拌反应2h,体系减压浓缩,得到化合物41-1d(190.0mg),不经纯化,直接投入下一步;MS:m/z 512.4[M+1]+;
向反应瓶中依次加入化合物41-1d(190.0mg,0.37mmol,1.5eq),二甲基甲酰胺(5mL),HOBT(50.1mg,0.37mmol,1.5eq),EDCI(72.78mg,0.37mmol,1.5eq),二异丙基乙胺(226.17mg,1.75mmol,7.0eq),室温搅拌反应2小时后,加入化合物1-3(121.70mg,0.25mmol,1.0eq),加毕,升温至30℃搅拌反应过夜,反应体系降至室温,加入水(50mL),乙酸乙酯(50mL)萃取2次,饱和氯化钠溶液(50mL)洗涤2次,无水硫酸钠干燥过滤,浓缩得到粗品,粗品通过柱层析纯化(洗脱剂:二氯甲烷/甲醇=10/1),得到化合物41-1(112.0mg);MS:m/z 985.4[M+1]+;
(2)化合物41的制备
向反应瓶中依次加入化合物41-1(112mg,0.11mmol,1.0eq),四氢呋喃(10ml),20%钯碳(22.4mg),在氢气氛围下控温至30℃搅拌反应过夜,反应液过滤,滤液旋干,进行反相柱层析纯化(Shim-packGIS-C18 20*250nm,5μm;0.01%甲酸-水/乙腈),得到化合物41(5.6mg);1H NMR(400MHz,DMSO-d6):δ11.10(s,1H),8.40(d,J=42.3Hz,1H),8.13(d,J=19.0Hz,1H),7.71(d,J=8.4Hz,1H),7.38(s,1H),7.29(d,J=8.6Hz,1H),7.18(s,1H),6.95(s,1H),6.90(s,1H),6.74(s,1H),5.72-5.54(m,3H),5.41-5.20(m,1H),5.09(dd,J=12.9,5.4Hz,1H),3.92(s,3H),3.78-3.56(m,4H),3.48-3.44(m,7H),3.02(s,3H),2.94-2.78(m,3H),2.63-2.55(m,6H),2.43-2.29(m,3H),2.29-2.15(m,2H),2.07-2.01(m,2H),1.92-1.90(m,2H),1.78-1.70(m,2H),1.65(d,J=7.0Hz,3H),1.59-1.55(m,2H);MS:m/z 955.5[M+1]+。
实施例42-43:化合物42-43的制备
按照与实施例41基本相似的操作,合成化合物42-43。
化合物42-43的核磁数据如下:
化合物42
1H NMR(400MHz,DMSO-d6):δ11.10(s,1H),8.40(d,J=42.3Hz,1H),8.13(d,J=19.0Hz,1H),7.71(d,J=8.4Hz,1H),7.38(s,1H),7.29(d,J=8.6Hz,1H),7.18(s,1H),6.95(s,1H),6.90(s,1H),6.74
(s,1H),5.72-5.54(m,3H),5.41-5.20(m,1H),5.09(dd,J=12.9,5.4Hz,1H),3.92(s,3H),3.78-3.56(m,4H),3.48-3.44(m,7H),3.02(s,3H),2.94-2.78(m,3H),2.63-2.55(m,6H),2.43-2.29(m,3H),2.29-2.15(m,2H),2.07-2.01(m,2H),1.92-1.90(m,2H),1.78-1.70(m,2H),1.65(d,J=7.0Hz,3H),1.59-1.55(m,2H),1.50-1.42(s,2H).
化合物43
1H NMR(400MHz,DMSO-d6):δ11.10(s,1H),8.40(d,J=42.3Hz,1H),8.13(d,J=19.0Hz,1H),7.71(d,J=8.4Hz,1H),7.38(s,1H),7.29(d,J=8.6Hz,1H),7.18(s,1H),6.95(s,1H),6.90(s,1H),6.74(s,1H),5.72-5.54(m,3H),5.41-5.20(m,1H),5.09(dd,J=12.9,5.4Hz,1H),3.92(s,3H),3.78-3.56(m,4H),3.48-3.44(m,7H),3.02(s,3H),2.94-2.78(m,3H),2.63-2.55(m,6H),2.43-2.29(m,3H),2.29-2.15(m,2H),2.07-2.01(m,2H),1.92-1.90(m,2H),1.78-1.70(m,2H),1.65(d,J=7.0Hz,3H),1.59-1.55(m,2H),1.50-1.42(s,2H),1.33-1.25(m,2H).
实施例44:化合物44的制备
(1)中间体44-1合成路线
向反应瓶中依次加入化合物36-1c(300.0mg,0.88mmol,1.0eq),溴乙酸叔丁酯(265.5mg,1.37mmol,1.5eq),二异丙基乙胺(177.1mg,1.37mmol,1.5eq),二甲基甲酰胺(10mL),加毕,升温至50℃搅拌反应6h,质谱显示主要为原料,补加二异丙基乙胺(177.1mg,1.37mmol,1.5eq)、二甲基甲酰胺(10mL),50℃搅拌反应过夜,反应体系降至室温,加入水(50mL),乙酸乙酯(50mL)萃取2次,饱和氯化钠溶液(50mL)洗涤2次,无水硫酸钠干燥过滤,浓缩得到粗品,粗品通过柱层析纯化(洗脱剂:二氯甲烷/甲醇=15/1),得到化合物44-1a(400mg);MS:m/z 457.2[M+1]+;
向反应瓶中依次加入化合物44-1a(400g,0.70mmol,1.0eq),浓盐酸(5mL),加毕,室温搅拌反应2h,体系减压浓缩,得到化合物44-1b(338.0mg),不经纯化,直接投入下一步;MS:m/z 401.2.0[M+1]+;
向反应瓶中依次加入化合物44-1b(122.2mg,0.31mmol,1.5eq),二甲基甲酰胺(5mL),HATU(116.12mg,0.31mmol,1.5eq),二异丙基乙胺(105mg,0.80mmol,4.0eq),室温搅拌反应2小时后,加入化合物1-3(100mg,0.20mol,1.0eq),加毕,升温至30℃搅拌反应过夜,反应体系降至室温,加入水(50mL),乙酸乙酯(50mL)萃取2次,饱和氯化钠溶液(50mL)洗涤2次,无水硫酸钠干燥过滤,浓缩得到粗品,粗品通过柱层析纯化(洗脱剂:二氯甲烷/甲醇=10/1),得到化合物44-1(170.0mg);MS:m/z 874.4[M+1]+;
(2)化合物44的制备
向反应瓶中依次加入化合物44-1(170mg,0.19mmol,1.0eq),四氢呋喃(10ml),20%钯碳(34mg),在氢气氛围下控温至30℃搅拌反应过夜,反应液过滤,滤液旋干,进行反相柱层析纯化(Shim-packGIS-C18 20*250nm,5μm;0.01%甲酸-水/乙腈),得到化合物44(2.0mg);1H NMR(400MHz,DMSO-d6):δ11.10(s,1H),8.40(s,1H),7.71(d,J=8.5Hz,1H),7.37(t,J=2.8Hz,1H),7.28-7.25(m,2H),7.20(s,1H),7.12(s,1H),6.94(s,1H),6.71(s,1H),5.79-5.73(m,1H),5.38(d,J=45.0Hz,1H),5.10(dd,J=12.9,5.4Hz,1H),3.71-3.59(m,8H),3.53-3.38(m,10H),2.95-2.85(m,1H),2.66-2.57(m,5H),2.27-2.20(m,2H),2.08-1.98(m,2H),1.77-1.68(m,3H);MS:m/z 844.4[M+1]+。
实施例45-47:化合物45-47的制备
按照与实施例44基本相似的操作,合成化合物45-47。
化合物45-47的核磁数据如下:
化合物45
1H NMR(400MHz,DMSO-d6):δ11.10(s,1H),8.40(s,1H),7.71(d,J=8.5Hz,1H),7.37(t,J=2.8Hz,1H),7.28-7.25(m,2H),7.20(s,1H),7.12(s,1H),6.94(s,1H),6.71(s,1H),5.79-5.73(m,1H),5.38(d,J=45.0Hz,1H),5.10(dd,J=12.9,5.4Hz,1H),3.71-3.59(m,8H),3.53-3.38(m,10H),2.95-2.85(m,1H),2.78-2.69(m,2H),2.66-2.57(m,5H),2.27-2.20(m,2H),2.08-1.98(m,2H),1.77-1.68(m,3H).
化合物46
1H NMR(400MHz,DMSO-d6):δ11.10(s,1H),8.40(s,1H),7.71(d,J=8.5Hz,1H),7.37(t,J=2.8Hz,1H),7.28-7.25(m,2H),7.20(s,1H),7.12(s,1H),6.94(s,1H),6.71(s,1H),5.79-5.73(m,1H),5.38(d,J=45.0Hz,1H),5.10(dd,J=12.9,5.4Hz,1H),3.71-3.59(m,8H),3.53-3.38(m,10H),2.95-2.85(m,1H),2.78-2.69(m,2H),2.66-2.57(m,5H),2.27-2.20(m,2H),2.08-1.98(m,4H),1.77-1.68(m,3H).
化合物47
1H NMR(400MHz,DMSO-d6):δ11.10(s,1H),8.40(s,1H),7.71(d,J=8.5Hz,1H),7.37(t,J=2.8
Hz,1H),7.28-7.25(m,2H),7.20(s,1H),7.12(s,1H),6.94(s,1H),6.71(s,1H),5.79-5.73(m,1H),5.38(d,J=45.0Hz,1H),5.10(dd,J=12.9,5.4Hz,1H),3.71-3.59(m,8H),3.53-3.38(m,10H),2.95-2.85(m,1H),2.78-2.69(m,2H),2.66-2.57(m,5H),2.27-2.20(m,2H),2.08-1.98(m,4H),1.77-1.68(m,3H),1.58-1.43(m,2H).
实施例48:化合物48的制备
(1)中间体48-1合成路线
向反应瓶中依次加入化合物36-1c(400.0mg,1.17mmol,1.0eq)、丁二酸酐(140.4mg,1.40mmol,1.2eq)、二异丙基乙胺(453.3mg,3.51mmol,3.0eq),四氢呋喃(20mL),加毕,升温至50℃搅拌反应2h。反应体系降至室温,加入水(50mL),乙酸乙酯(50mL)萃取2次,饱和氯化钠溶液(50mL)洗涤2次,无水硫酸钠干燥过滤,浓缩得到粗品,粗品通过柱层析纯化(洗脱剂:二氯甲烷/甲醇=10/1),得到化合物48-1a(515mg);MS:m/z 443.2[M+1]+;
向反应瓶中依次加入化合物48-1a(288.4mg,0.65mmol,1.2eq),二甲基甲酰胺(5mL),HOBT(110.1mg,0.81mmol,1.5eq),EDCI(156.1mg,0.81mmol,1.5eq),二异丙基乙胺(491.2mg,3.80mmol,7.0eq),室温搅拌1小时后,加入化合物1-3(267.0mg,0.54mol,1.0eq),加毕,升温至30℃搅拌反应过夜,反应体系降至室温,加入水(50mL),乙酸乙酯(50mL)萃取2次,饱和氯化钠溶液(50mL)洗涤2次,无水硫酸钠干燥过滤,浓缩得到粗品,粗品通过柱层析纯化(洗脱剂:二氯甲烷/甲醇=10/1),得到化合物48-1(109mg);MS:m/z 916.4[M+1]+;
(2)化合物48的制备
向反应瓶中依次加入化合物48-1(170mg,0.19mmol,1.0eq),四氢呋喃(10ml),20%钯碳(34mg),在氢气氛围下控温至30℃搅拌反应过夜,反应液过滤,滤液旋干,进行反相柱层析纯化(Shim-packGIS-C18 20*250nm,5μm;0.01%甲酸-水/乙腈),得到化合物48(2.0mg);1H NMR(400MHz,DMSO-d6):δ11.10(s,1H),8.40(s,1H),7.71(d,J=8.5Hz,1H),7.37(t,J=2.8Hz,1H),7.28-7.25(m,2H),7.20(s,1H),7.12(s,1H),6.94(s,1H),6.71(s,1H),5.79-5.73(m,1H),5.38(d,J=45.0Hz,1H),5.10(dd,J=12.9,5.4Hz,1H),3.71-3.59(m,8H),3.53-3.38(m,10H),2.95-2.85(m,1H),2.78-2.69(m,4H),2.66-2.57(m,
5H),2.27-2.20(m,2H),1.77-1.68(m,3H);MS:m/z 886.4[M+1]+。
实施例49:化合物49的制备
(1)中间体49-1合成路线
向反应瓶中依次加入化合物36-1c(300.0mg,0.88mmol,1.5eq),二甲基甲酰胺(10mL),戊二酸(173.7mg,1.32mmol,1.5eq),二异丙基乙胺(340.0mg,2.63mmol,3.0eq),室温搅拌5分钟后,分批加入HATU(317.0mg,1.04mol,1.5eq),升温至30℃搅拌反应2h,反应体系降至室温,加入水(50mL),二氯甲烷:乙腈=10:1(50mL)萃取2次,饱和氯化钠溶液(50mL)洗涤2次,无水硫酸钠干燥过滤,浓缩得到粗品,粗品通过柱层析纯化(洗脱剂:二氯甲烷/甲醇=10/1),得到化合物49-1a(478mg);MS:m/z 457.2[M+1]+;
向反应瓶中依次加入化合物49-1a(237.0mg,0.52mmol,1.5eq),二甲基甲酰胺(5mL),HATU(198.0mg,0.52mmol,1.5eq),二异丙基乙胺(90.0mg,0.70mmol,2.0eq),室温搅拌5分钟后,加入化合物1-3(170.0mg,0.35mol,1.0eq),加毕,升温至30℃搅拌反应过夜,反应体系降至室温,加入水(50mL),乙酸乙酯(50mL)萃取2次,饱和氯化钠溶液(50mL)洗涤2次,无水硫酸钠干燥过滤,浓缩得到粗品,粗品通过柱层析纯化(洗脱剂:二氯甲烷/甲醇=10/1),得到化合物49-1(188.0mg);MS:m/z 930.4[M+1]+;
(2)化合物49的制备
向反应瓶中依次加入化合物49-1(188.0mg,0.20mmol,1.0eq),四氢呋喃(10ml),20%钯碳(37.6mg),在氢气氛围下控温至30℃搅拌反应过夜,反应液过滤,滤液旋干,进行反相柱层析纯化(Shim-pack GIS-C18 20*250nm,5μm;0.01%甲酸-水/乙腈),得到化合物49(18.4mg);1H NMR(400MHz,DMSO-d6):δ11.10(s,1H),8.40(s,1H),7.71(d,J=8.5Hz,1H),7.37(t,J=2.8Hz,1H),7.28-7.25(m,2H),7.20(s,1H),7.12(s,1H),6.94(s,1H),6.71(s,1H),5.79-5.73(m,1H),5.38(d,J=45.0Hz,1H),5.10(dd,J=12.9,5.4Hz,1H),3.71-3.59(m,8H),3.53-3.38(m,10H),2.95-2.85(m,1H),2.78-2.69(m,4H),2.66-2.57(m,5H),2.27-2.18(m,4H),1.77-1.68(m,3H);MS:m/z 900.4[M+1]+。
实施例50-51:化合物50-51的制备
按照与实施例49基本相似的操作,合成化合物50-51。
化合物50-51的核磁数据如下:
化合物50
1H NMR(400MHz,DMSO-d6):δ11.10(s,1H),8.40(s,1H),7.71(d,J=8.5Hz,1H),7.37(t,J=2.8Hz,1H),7.28-7.25(m,2H),7.20(s,1H),7.12(s,1H),6.94(s,1H),6.71(s,1H),5.79-5.73(m,1H),5.38(d,J=45.0Hz,1H),5.10(dd,J=12.9,5.4Hz,1H),3.71-3.59(m,8H),3.53-3.38(m,10H),2.95-2.85(m,1H),2.78-2.69(m,4H),2.66-2.57(m,5H),2.27-2.20(m,4H),1.77-1.68(m,5H).
化合物51
1H NMR(400MHz,DMSO-d6):δ11.10(s,1H),8.40(s,1H),7.71(d,J=8.5Hz,1H),7.37(t,J=2.8Hz,1H),7.28-7.25(m,2H),7.20(s,1H),7.12(s,1H),6.94(s,1H),6.71(s,1H),5.79-5.73(m,1H),5.38(d,J=45.0Hz,1H),5.10(dd,J=12.9,5.4Hz,1H),3.71-3.59(m,8H),3.53-3.38(m,10H),2.95-2.85(m,1H),2.78-2.69(m,4H),2.66-2.57(m,5H),2.27-2.20(m,4H),1.77-1.68(m,5H),1.52-1.48(m,2H).
实施例52:化合物52的制备
(1)中间体52-1合成路线
向反应瓶中依次加入化合物52-1a(5.0g,37.31mmol,1.0eq),苄溴(6.38g,37.31mmol,1.0eq),三乙胺(4.89g,48.50mmol,1.3eq),乙腈(80mL),加毕,室温搅拌反应过夜,反应液过滤,减压浓缩后,加入饱和碳酸氢钠调节滤液的pH至8,乙酸乙酯(50mL)萃取2次后,盐酸调节水相pH至2,二氯甲烷(50mL)萃取,无水硫酸镁干燥过滤,浓缩得到化合物52-1b(4.0g);MS:m/z 225.1[M+1]+;
向反应瓶中依次加入化合物52-1b(626.30mg,2.80mmol,1.2eq),二甲基甲酰胺(5mL),HOBT(473.96mg,3.51mmol,1.5eq),EDCI(689.88mg,3.51mmol,1.5eq),二异丙基乙胺(1.21g,9.35mmol,4.0eq),化合物36-1c(800.0mg,2.33mmol,1.0eq),加毕,室温搅拌反应2小时,加入水(50mL),乙酸乙酯(50mL)萃取2次,饱和氯化钠溶液(50mL)洗涤2次,无水硫酸钠干燥过滤,浓缩得到粗品,粗品通过柱层析纯化(洗脱剂:二氯甲烷/甲醇=20/1),得到化合物52-1c(620mg);MS:m/z 549.2[M+1]+;
向反应瓶中依次加入化合物52-1c(300mg,0.55mmol,1.0eq),二甲基甲酰胺(10ml),40%钯碳(120.0mg),在氢气氛围下控温至50℃搅拌反应过夜,反应液过滤,滤液旋干,得到化合物52-1d(254.0mg);MS:m/z 459.1[M+1]+;
向反应瓶中依次加入化合物52-1d(123.6mg,0.27mmol,1.0eq),二甲基甲酰胺(5mL),HOBT(54.1mg,0.40mmol,1.5eq),EDCI(76.7mg,0.40mmol,1.5eq),二异丙基乙胺(241.3mg,1.86mmol,7.0eq),室温搅拌反应2小时后,加入化合物1-3(131.0mg,0.27mmol,1.0eq),加毕,升温至30℃搅拌反应过夜,反应体系降至室温,加入水(50mL),乙酸乙酯(50mL)萃取2次,饱和氯化钠溶液(50mL)洗涤2次,无水硫酸钠干燥过滤,浓缩得到粗品,粗品通过柱层析纯化(洗脱剂:二氯甲烷/甲醇=10/1),得到化合物52-1(65.0mg);MS:m/z 932.3[M+1]+;
(2)化合物52的制备
向反应瓶中依次加入化合物52-1(65.0mg,0.07mmol,1.0eq),四氢呋喃(10ml),20%钯碳(13.0mg),在氢气氛围下控温至30℃搅拌反应过夜,反应液过滤,滤液旋干,进行反相柱层析纯化(Shim-packGIS-C18 20*250nm,5μm;0.01%甲酸-水/乙腈),得到化合物52(1.4mg);1H NMR(400MHz,DMSO-d6):δ11.10(s,1H),8.40(s,1H),7.71(d,J=8.5Hz,1H),7.37(t,J=2.8Hz,1H),7.28-7.25(m,2H),7.20(s,1H),7.12(s,1H),6.94(s,1H),6.71(s,1H),5.79-5.73(m,1H),5.38(d,J=45.0Hz,1H),5.10(dd,J=12.9,5.4Hz,1H),4.40-4.26(m,4H),3.71-3.59(m,8H),3.53-3.41(m,8H),2.95-2.85(m,1H),2.66-2.57(m,5H),2.27-2.20(m,2H),2.08-1.98(m,2H),1.77-1.68(m,3H);MS:m/z 902.4[M+1]+。
实施例53:化合物53的制备
按照与实施例52基本相似的操作,合成化合物53。
化合物53的核磁数据如下:
1H NMR(400MHz,DMSO-d6):δ11.10(s,1H),8.23-8.05(m,1H),7.82(d,J=17.6Hz,1H),7.69(d,J=8.4Hz,1H),7.36(d,J=2.5Hz,1H),7.23(d,J=8.6Hz,1H),7.08(d,J=2.8Hz,1H),6.88(d,J=9.9Hz,2H),6.72(s,1H),5.73-5.51(m,3H),5.18-5.01(m,2H),4.25(s,1H),4.19(d,J=2.1Hz,2H),4.14(d,J=4.7Hz,1H),3.88(s,3H),3.72-3.45(m,16H),2.95-2.86(m,1H),2.66-2.55(m,2H),2.39(d,J=2.9Hz,3H),2.29-2.24(m,1H),2.15-2.10(m,1H),2.05-1.99(m,1H),1.60-1.57(m,3H).
实施例54:化合物54的制备
(1)中间体54-1合成路线
向反应瓶中依次加入化合物36-1a(3.0g,10.87mmol,1.0eq),2-叔丁氧羰基-2,7-二氮杂螺[3.5]壬烷(2.69g,11.96mmol,1.1eq),二异丙基乙胺(4.21g,32.61mmol,3.0eq),N-甲基吡咯烷酮(30mL),加毕,升温至140℃搅拌反应6h,将反应体系冷却至室温加入水(100mL),乙酸乙酯(100mL)萃取2次,饱和氯化钠溶液(100mL)洗涤2次,无水硫酸钠干燥过滤,浓缩得到粗品,粗品通过柱层析纯化(洗脱剂:石油醚/乙酸乙酯=1/1),得到化合物54-1a(5.0g);MS:m/z 483.2[M+1]+;
向反应瓶中依次加入化合物54-1a(5.0g,10.34mmol,1.0eq)、4N盐酸/1,4-二氧六环(50mL),加毕,室温搅拌反应2h,体系减压浓缩,得到化合物54-1b(4.5g),不经纯化,直接投入下一步;MS:m/z 383.2[M+1]+;
向反应瓶中依次加入化合物54-1b(800.0mg,2.09mmol,1.0eq)、丁二酸酐(251.21mg,2.51mmol,1.2eq)、二异丙基乙胺(810.33mg,6.27mmol,3.0eq),四氢呋喃(20mL),加毕,升温至50℃搅拌反应2h,反应体系降至室温,加入水(50mL),乙酸乙酯(50mL)萃取2次,饱和氯化钠溶液(50mL)洗涤2次,无水硫酸钠干燥过滤,浓缩得到粗品,粗品通过柱层析纯化(洗脱剂:二氯甲烷/甲醇=10/1),得到化合物54-1c(630.0mg);MS:m/z 483.2[M+1]+;
向反应瓶中依次加入化合物54-1c(314.53mg,0.65mmol,1.2eq),二甲基甲酰胺(5mL),HOBT(110.1mg,0.81mmol,1.5eq),EDCI(156.1mg,0.81mmol,1.5eq),二异丙基乙胺(491.2mg,3.80mmol,7.0eq),室温搅拌1小时后,加入化合物1-3(267.0mg,0.54mol,1.0eq),加毕,升温至30℃搅拌反应过夜,反应体系降至室温,加入水(50mL),乙酸乙酯(50mL)萃取2次,饱和氯化钠溶液(50mL)洗涤2次,无水硫酸钠干燥过滤,浓缩得到粗品,粗品通过柱层析纯化(洗脱剂:二氯甲烷/甲醇=10/1),得到化合物54-1(121.0mg);MS:m/z 956.4[M+1]+;
(2)化合物54的制备
向反应瓶中依次加入化合物54-1(121.0mg,0.13mmol,1.0eq),四氢呋喃(10ml),20%钯碳(24.2mg),在氢气氛围下控温至30℃搅拌反应过夜,反应液过滤,滤液旋干,进行反相柱层析纯化(Shim-pack GIS-C18 20*250nm,5μm;0.01%甲酸-水/乙腈),得到化合物54(1.4mg);1H NMR(400MHz,DMSO-d6):δ11.10(s,1H),8.40(s,1H),7.71(d,J=8.5Hz,1H),7.37(t,J=2.8Hz,1H),7.28-7.25(m,2H),7.20(s,1H),7.12(s,1H),6.94(s,1H),6.71(s,1H),5.79-5.73(m,1H),5.38(d,J=45.0Hz,1H),
5.10(dd,J=12.9,5.4Hz,1H),3.97(s,4H),3.71-3.59(m,8H),3.53-3.38(m,10H),2.95-2.85(m,1H),2.78-2.69(m,4H),2.66-2.57(m,5H),2.27-2.20(m,2H),1.77-1.68(m,3H);MS:m/z 926.4[M+1]+。
实施例55:化合物55的制备
(1)中间体51-1a合成路线
按照与中间体49-1a基本相似的操作,合成中间体51-1a。
(2)化合物55的制备
向反应瓶中依次加入化合物51-1a(349.02mg,0.72mmol,1.5eq),二甲基甲酰胺(5mL),HOBT(97.29mg,0.72mmol,1.5eq),EDCI(141.62mg,0.72mmol,1.5eq),二异丙基乙胺(248.14mg,1.92mmol,4.0eq),室温搅拌1小时后,加入化合物39-3(200.0mg,0.48mol,1.0eq),加毕,升温至30℃搅拌反应过夜,反应体系降至室温,加入水(50mL),乙酸乙酯(50mL)萃取2次,饱和氯化钠溶液(50mL)洗涤2次,无水硫酸钠干燥过滤,浓缩得到粗品,粗品通过反相柱层析纯化(Shim-packGIS-C18 20*250nm,5μm;0.01%甲酸-水/乙腈),得到化合物55(1.0mg);1H NMR(400MHz,DMSO-d6):δ11.10(s,1H),8.97(s,1H),8.67(s,1H),7.92(s,1H),7.73-7.70(m,1H),7.58(t,J=7.2Hz,1H),7.44-7.32(m,3H),7.30-7.18(m,2H),5.99(t,J=7.2Hz,1H),5.10(dd,J=12.9,5.4Hz,1H),3.77-3.58(m,8H),3.53-3.47(m,8H),2.55(d,J=2.0Hz,3H),2.46-2.28(m,6H),2.07-2.01(m,2H),1.75(d,J=7.0Hz,3H),1.65-1.43(m,6H);MS:m/z 883.4[M+1]+。
实施例56:化合物56的制备
(1)中间体56-1合成路线
向反应瓶中依次加入化合物36-1a(550.00mg,1.99mmol,1.0eq),3-(2-氨基乙氧基)丙酸叔丁酯(452.2mg,2.39mmol,1.2eq),二异丙基乙胺(1.54g,11.94mmol,6.0eq),N-甲基吡咯烷酮(10mL),
加毕,升温至加热到100℃,搅拌反应过夜,反应体系降至室温,加入水(50mL),再加入乙酸乙酯(50mL)萃取3次,有机相用饱和氯化钠溶液(100mL),洗涤2次后,加入无水硫酸钠干燥、过滤和浓缩,粗品经柱层析纯化(洗脱剂:二氯甲烷/甲醇=20/1),得到化合物56-1a(621.0mg);MS:m/z446.2[M+1]+;
向反应瓶中依次加入化合物56-1a(621mg,1.39mmol,1.0eq),4N盐酸/二氧六环(10mL),加毕,室温搅拌反应2h,体系减压浓缩,得到化合物56-1b(675mg),不经纯化,直接投入下一步;MS:m/z 390.2[M+1]+;
向反应瓶中依次加入化合物56-1b(310.0mg,0.80mmol,1.5eq),二甲基甲酰胺(5mL),HOBT(107.0mg,0.80mmol,1.5eq),EDCI(152.2mg,0.80mmol,1.5eq),二异丙基乙胺(478.9mg,3.71mmol,7.0eq),加毕,室温搅拌反应2小时后,加入化合物1-3(260.0mg,0.53mol,1.0eq),升温至30℃搅拌反应过夜,反应体系降至室温,加入水(50mL),乙酸乙酯(50mL)萃取2次,饱和氯化钠溶液(50mL)洗涤2次,无水硫酸钠干燥过滤,浓缩得到粗品,粗品通过柱层析纯化(洗脱剂:二氯甲烷/甲醇=10/1),得到化合物56-1(144.0mg);MS:m/z 863.2[M+1]+;
(2)化合物56的制备
向反应瓶中依次加入化合物56-1(144mg,0.02mmol,1.0eq),四氢呋喃(10ml),20%钯碳(28.8mg),在氢气氛围下控温至30℃搅拌反应过夜,反应液过滤,滤液旋干,进行反相柱层析纯化(Shim-packGIS-C18 20*250nm,5μm;0.01%甲酸-水/乙腈),得到化合物56(5.0mg);1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),8.40(d,J=42.3Hz,1H),8.00(d,J=8.0Hz,1H),7.78(d,J=8.4Hz,1H),7.51(s,1H),7.38(d,J=8.8Hz,1H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.76-5.72(m,1H),5.65(s,1H),5.12(dd,J=12.9,5.4Hz,1H),4.23(d,J=13.5Hz,2H),3.96(s,3H),3.85-3.81(m,2H),3.76-3.69(m,4H),3.66-3.52(m,4H),3.49-3.45(m,2H),2.96-2.80(m,2H),2.66-2.63(m,2H),2.61-2.58(m,3H),2.55(s,3H),1.65(d,J=7.0Hz,3H);MS:m/z 833.4[M+1]+。
实施例57-59:化合物57-59的制备
按照与实施例56基本相似的操作,合成化合物57-59。
化合物57-59的核磁数据如下:
化合物57
1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),8.40(d,J=42.3Hz,1H),8.00(d,J=8.0Hz,1H),7.78(d,J=8.4Hz,1H),7.51(s,1H),7.38(d,J=8.8Hz,1H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.76-5.72(m,1H),5.65(s,1H),5.12(dd,J=12.9,5.4Hz,1H),4.23(d,J=13.5Hz,2H),3.96(s,3H),3.85-3.81(m,4H),3.76-3.69(m,6H),3.66-3.52(m,4H),3.49-3.45(m,2H),2.96-2.80(m,2H),2.66-2.63(m,2H),2.61-2.58(m,3H),2.55(s,3H),1.65(d,J=7.0Hz,3H).
化合物58
1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),8.40(d,J=42.3Hz,1H),8.00(d,J=8.0Hz,1H),7.78(d,J=8.4Hz,1H),7.51(s,1H),7.38(d,J=8.8Hz,1H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.76-5.72(m,1H),5.65(s,1H),5.12(dd,J=12.9,5.4Hz,1H),4.23(d,J=13.5Hz,2H),3.96(s,3H),3.85-3.81(m,4H),3.76-3.69(m,8H),3.66-3.52(m,6H),3.49-3.45(m,2H),2.96-2.80(m,2H),2.66-2.63(m,2H),2.61-2.58(m,3H),2.55(s,3H),1.65(d,J=7.0Hz,3H).
化合物59
1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),8.40(d,J=42.3Hz,1H),8.00(d,J=8.0Hz,1H),7.78(d,J=8.4Hz,1H),7.51(s,1H),7.38(d,J=8.8Hz,1H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.76-5.72(m,1H),5.65(s,1H),5.12(dd,J=12.9,5.4Hz,1H),4.23(d,J=13.5Hz,2H),3.96(s,3H),3.85-3.81(m,4H),3.74-3.69(m,12H),3.66-3.52(m,6H),3.49-3.45(m,2H),2.96-2.80(m,2H),2.66-2.63(m,2H),2.61-2.58(m,3H),2.55(s,3H),1.65(d,J=7.0Hz,3H).
实施例60:化合物60的制备
(1)中间体60-1合成路线
向反应瓶中依次加入化合物1-3(500mg,1.01mmol,1.0eq),6-溴己酸叔丁酯(383.52mg,1.53mmol,1.5eq),二异丙基乙胺(263.12mg,2.04mmol,2.0eq),二甲基甲酰胺(10mL),加毕,升温至70℃搅拌反应2h,将反应体系冷却至室温加入水(50mL),乙酸乙酯(50mL)萃取2次,饱和氯化钠溶液(100mL)洗涤2次,无水硫酸钠干燥过滤,浓缩得到粗品,粗品通过柱层析纯化(洗脱剂:二氯
甲烷/甲醇=20/1),得到化合物60-1a(481.0mg);MS:m/z 662.3[M+1]+;
向反应瓶中依次加入化合物60-1a(481.0mg,0.73mmol,1.0eq),1,4-二氧六环(5mL),4N盐酸(2mL),加毕室温搅拌反应过夜,体系减压浓缩,得到化合物60-1b(380.0mg),不经纯化,直接投入下一步反应;MS:m/z 606.3[M+1]+;
向反应瓶中依次加入化合物60-1b(354.71mg,0.73mmol,1.5eq),二甲基甲酰胺(5mL),HATU(278.42mg,0.73mmol,1.5eq),三乙胺(148.31mg,1.47mmol,3.0eq),室温搅拌5分钟后,加入化合物60-2(210.0mg,0.49mol,1.0eq),加毕,室温搅拌过夜,向体系加入水(30mL),乙酸乙酯(30mL)萃取3次,饱和氯化钠溶液(50mL)洗涤2次,无水硫酸钠干燥过滤,浓缩得到粗品,粗品通过柱层析纯化(洗脱剂:二氯甲烷/甲醇=10/1),得到化合物60-1(377.0mg);MS:m/z 1018.5[M+1]+;
(2)化合物60的制备
向反应瓶中依次加入化合物60-1(377mg,0.37mmol,1.0eq),四氢呋喃(10ml),20%钯碳(75.4mg),在氢气氛围下控温至30℃搅拌反应过夜,反应液过滤,滤液旋干,进行反相柱层析纯化(Shim-packGIS-C18 20*250nm,5μm;0.01%甲酸-水/乙腈),得到化合物60(2.5mg);1H NMR(400MHz,DMSO-d6):δ9.15(s,1H),8.53(s,1H),8.40(d,J=42.3Hz,1H),7.78(d,J=8.4Hz,1H),7.49-7.44(m,4H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.76-5.72(m,1H),5.65(s,1H),5.12(dd,J=12.9,5.4Hz,1H),4.59(t,J=8.0Hz,1H),4.51-4.49(m,1H),4.47-4.35(m,3H),4.23(d,J=13.5Hz,2H),3.96(s,3H),3.79-3.76(m,2H),3.64-3.56(m,2H),3.49-3.45(m,2H),2.96-2.80(m,2H),2.61-2.59(m,2H),2.55(s,3H),2.51(s,3H),2.28-2.22(m,4H),2.08-2.02(m,1H),1.75-1.68(m,6H),1.65(d,J=7.0Hz,3H),1.43(s,9H);MS:m/z 988.5[M+1]+。
实施例61:化合物61的制备
按照与实施例60基本相似的操作,合成化合物61。
化合物61的核磁数据如下:
1H NMR(400MHz,DMSO-d6):δ9.15(s,1H),8.53(s,1H),8.40(d,J=42.3Hz,1H),7.78(d,J=8.4Hz,1H),7.49-7.44(m,4H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.76-5.72(m,1H),5.65(s,1H),5.12(dd,J=12.9,5.4Hz,1H),4.59(t,J=8.0Hz,1H),4.51-4.49(m,1H),4.47-4.35(m,3H),4.23(d,J=13.5Hz,2H),3.96(s,3H),3.79-3.76(m,2H),3.64-3.56(m,2H),3.49-3.45(m,2H),
2.96-2.80(m,2H),2.61-2.59(m,2H),2.55(s,3H),2.51(s,3H),2.28-2.22(m,4H),2.08-2.02(m,1H),1.75-1.68(m,6H),1.65(d,J=7.0Hz,3H),1.46-1.42(s,13H).
实施例101-105、实施例124及实施例129-138:化合物101-105、124和129-138的制备
按照与实施例60基本相似的操作,合成化合物101-105、124和129-138。
化合物101
1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),9.15(s,1H),8.40(d,J=42.3Hz,1H),8.25(d,J=8.2Hz,1H),8.04-7.98(m,2H),7.49-7.44(m,4H),7.33-7.26(m,2H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.83(t,J=14.4Hz,1H),5.76-5.72(m,1H),5.65(s,1H),4.59(t,J=8.0Hz,1H),4.51-4.49(m,1H),4.47-4.35(m,3H),4.23-4.21(m,1H),3.79-3.76(m,2H),3.76-3.69(m,2H),3.51-3.49(m,1H),3.40(s,2H),3.09-3.06(m,2H),2.51(s,3H),2.28-2.22(m,3H),2.08-2.02(m,1H),1.54(s,3H),1.43(s,9H).
化合物102
1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),9.15(s,1H),8.40(d,J=42.3Hz,1H),8.25(d,J=8.2Hz,1H),8.04-7.98(m,2H),7.49-7.44(m,4H),7.33-7.26(m,2H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.83(t,J=14.4Hz,1H),5.76-5.72(m,1H),5.65(s,1H),4.59(t,J=8.0Hz,1H),4.51-4.49(m,1H),4.47-4.35(m,3H),4.23-4.21(m,1H),3.79-3.76(m,4H),3.76-3.69(m,2H),3.51-3.49(m,1H),3.09-3.06(m,2H),2.49-2.46(m,5H),2.28-2.22(m,3H),2.08-2.02(m,1H),1.54(s,3H),1.43(s,9H).
化合物103
1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),9.15(s,1H),8.40(d,J=42.3Hz,1H),8.25(d,J=8.2Hz,1H),8.04-7.98(m,2H),7.49-7.44(m,4H),7.33-7.26(m,2H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.83(t,J=14.4Hz,1H),5.76-5.72(m,1H),5.65(s,1H),4.59(t,J=8.0Hz,1H),4.51-4.49(m,1H),4.47-4.35(m,3H),4.23-4.21(m,1H),3.79-3.76(m,2H),3.76-3.69(m,2H),3.51-3.49(m,1H),3.09-3.06(m,2H),2.64-2.62(m,2H),2.49-2.46(m,3H),2.28-2.22(m,5H),2.08-2.02(m,1H),1.95-1.93(m,2H),1.54(s,3H),1.43(s,9H).
化合物104
1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),9.15(s,1H),8.40(d,J=42.3Hz,1H),8.25(d,J=8.2Hz,1H),8.04-7.98(m,2H),7.49-7.44(m,4H),7.33-7.26(m,2H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.83(t,J=14.4Hz,1H),5.76-5.72(m,1H),5.65(s,1H),4.59(t,J=8.0Hz,1H),4.51-4.49(m,1H),4.47-4.35(m,3H),4.23-4.21(m,1H),3.79-3.76(m,2H),3.76-3.69(m,2H),3.51-3.49(m,1H),3.09-3.06(m,2H),2.64-2.62(m,2H),2.49-2.46(m,3H),2.28-2.22(m,5H),2.08-2.02(m,1H),1.75-1.73(m,2H),1.56-1.54(m,5H),1.43(s,9H).
化合物105
1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),9.15(s,1H),8.40(d,J=42.3Hz,1H),8.25(d,J=8.2Hz,1H),8.04-7.98(m,2H),7.49-7.44(m,4H),7.33-7.26(m,2H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.83(t,J=14.4Hz,1H),5.76-5.72(m,1H),5.65(s,1H),4.59(t,J=8.0Hz,1H),4.51-4.49(m,1H),4.47-4.35(m,3H),4.23-4.21(m,1H),3.79-3.76(m,2H),3.76-3.69(m,2H),3.51-3.49(m,1H),3.09-3.06(m,2H),2.64-2.62(m,2H),2.49-2.46(m,3H),2.28-2.22(m,5H),2.08-2.02(m,1H),1.56-1.53(m,7H),1.49-1.47(m,2H),1.43(s,9H).
化合物124
1H NMR(400MHz,DMSO-d6):δ11.10(s,1H),10.12(s,1H),9.36(s,1H),8.45-8.33(m,2H),7.74-7.72(m,1H),7.51(dd,J=7.6,1.2Hz,1H),7.47(s,1H),7.25(t,J=7.6Hz,1H),7.08-6.92(m,3H),5.65-5.61(m,1H),5.06-5.04(m,1H),3.82(s,2H),3.50(s,2H),3.36(t,J=5.6Hz,2H),3.09-3.01(m,2H),2.75(d,J=7.6Hz,6H),2.66-2.36(m,2H),2.11-1.94(m,2H),1.65(d,J=7.2Hz,3H).
化合物129
1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),10.35(s,1H),8.40(d,J=42.3Hz,1H),8.25(d,J=8.2Hz,1H),8.04-7.98(m,2H),7.78(d,J=8.4Hz,1H),7.51(s,1H),7.33-7.26(m,2H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.83(t,J=14.4Hz,1H),5.76-5.72(m,1H),5.65(s,1H),5.12(dd,J=12.9,5.4Hz,1H),4.20-4.18(m,1H),3.49-3.45(m,4H),2.96-2.80(m,2H),2.39-2.33(m,2H),2.26-2.22(m,4H),1.55(d,J=7.0Hz,3H).
化合物130
1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),10.35(s,1H),8.40(d,J=42.3Hz,1H),8.25(d,J=8.2Hz,1H),8.04-7.98(m,2H),7.78(d,J=8.4Hz,1H),7.51(s,1H),7.33-7.26(m,2H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.83(t,J=14.4Hz,1H),5.76-5.72(m,1H),5.65(s,1H),5.12(dd,J=12.9,5.4Hz,1H),4.20-4.18(m,1H),3.87-3.85(m,2H),3.49-3.45(m,2H),2.96-2.80(m,2H),2.73-2.71(m,2H),2.39-2.33(m,2H),2.26-2.22(m,4H),1.55(d,J=7.0Hz,3H).
化合物131
1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),10.35(s,1H),8.40(d,J=42.3Hz,1H),8.25(d,J=8.2Hz,1H),8.04-7.98(m,2H),7.78(d,J=8.4Hz,1H),7.51(s,1H),7.33-7.26(m,2H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.83(t,J=14.4Hz,1H),5.76-5.72(m,1H),5.65(s,1H),5.12(dd,J=12.9,5.4Hz,1H),4.20-4.18(m,1H),3.49-3.45(m,2H),2.96-2.80(m,2H),2.65-2.61(m,4H),2.39-2.33(m,2H),2.26-2.22(m,4H),2.00-1.98(m,2H),1.55(d,J=7.0Hz,3H).
化合物132
1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),10.35(s,1H),8.40(d,J=42.3Hz,1H),8.25(d,J=8.2Hz,1H),8.04-7.98(m,2H),7.78(d,J=8.4Hz,1H),7.51(s,1H),7.33-7.26(m,2H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.83(t,J=14.4Hz,1H),5.76-5.72(m,1H),5.65(s,1H),5.12(dd,J=12.9,5.4Hz,1H),4.20-4.18(m,1H),3.49-3.45(m,2H),2.96-2.80(m,2H),2.65-2.61(m,4H),2.39-2.33(m,2H),2.26-2.22(m,4H),1.82-1.79(m,2H),1.55-1.52(m,5H).
化合物133
1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),10.35(s,1H),8.40(d,J=42.3Hz,1H),8.25(d,J=8.2Hz,1H),8.04-7.98(m,2H),7.78(d,J=8.4Hz,1H),7.51(s,1H),7.33-7.26(m,2H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.83(t,J=14.4Hz,1H),5.76-5.72(m,1H),5.65(s,1H),5.12(dd,J=12.9,5.4Hz,1H),4.20-4.18(m,1H),3.49-3.45(m,2H),2.96-2.80(m,2H),2.65-2.61(m,4H),2.39-2.33(m,2H),2.26-2.22(m,4H),1.82-1.79(m,2H),1.55-1.52(m,7H).
化合物134
1H NMR(400MHz,DMSO-d6)δ11.11(s,1H),8.40(d,J=42.3Hz,1H),8.25(d,J=8.2Hz,1H),8.04-7.98(m,2H),7.78(d,J=8.4Hz,1H),7.51(s,1H),7.33-7.26(m,2H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.83(t,J=14.4Hz,1H),5.76-5.72(m,1H),5.65(s,1H),5.12(dd,J=
12.9,5.4Hz,1H),4.20-4.18(m,1H),368-3.64(m,4H),3.49-3.45(m,8H),2.96-2.80(m,2H),2.39-2.33(m,2H),2.26-2.22(m,4H),1.55(d,J=7.0Hz,3H).
化合物135
1H NMR(400MHz,DMSO-d6)δ11.11(s,1H),8.40(d,J=42.3Hz,1H),8.25(d,J=8.2Hz,1H),8.04-7.98(m,2H),7.78(d,J=8.4Hz,1H),7.51(s,1H),7.33-7.26(m,2H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.83(t,J=14.4Hz,1H),5.76-5.72(m,1H),5.65(s,1H),5.12(dd,J=12.9,5.4Hz,1H),4.20-4.18(m,1H),368-3.64(m,4H),3.49-3.45(m,8H),2.96-2.80(m,2H),2.63-2.60(m,2H),2.39-2.33(m,2H),2.26-2.22(m,4H),1.55(d,J=7.0Hz,3H).
化合物136
1H NMR(400MHz,DMSO-d6)δ11.11(s,1H),8.40(d,J=42.3Hz,1H),8.25(d,J=8.2Hz,1H),8.04-7.98(m,2H),7.78(d,J=8.4Hz,1H),7.51(s,1H),7.33-7.26(m,2H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.83(t,J=14.4Hz,1H),5.76-5.72(m,1H),5.65(s,1H),5.12(dd,J=12.9,5.4Hz,1H),4.20-4.18(m,1H),368-3.64(m,4H),3.49-3.45(m,8H),2.96-2.80(m,2H),2.63-2.60(m,2H),2.39-2.33(m,2H),2.26-2.22(m,4H),1.70-1.68(m,2H),1.55(d,J=7.0Hz,3H).
化合物137
1H NMR(400MHz,DMSO-d6)δ11.11(s,1H),8.40(d,J=42.3Hz,1H),8.25(d,J=8.2Hz,1H),8.04-7.98(m,2H),7.78(d,J=8.4Hz,1H),7.51(s,1H),7.33-7.26(m,2H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.83(t,J=14.4Hz,1H),5.76-5.72(m,1H),5.65(s,1H),5.12(dd,J=12.9,5.4Hz,1H),4.20-4.18(m,1H),368-3.64(m,4H),3.49-3.45(m,8H),2.96-2.80(m,2H),2.63-2.60(m,2H),2.39-2.33(m,2H),2.26-2.22(m,4H),1.70-1.68(m,2H),1.55(d,J=7.0Hz,3H),1.45-1.43(m,2H).
化合物138
1H NMR(400MHz,DMSO-d6)δ11.11(s,1H),8.40(d,J=42.3Hz,1H),8.25(d,J=8.2Hz,1H),8.04-7.98(m,2H),7.78(d,J=8.4Hz,1H),7.51(s,1H),7.33-7.26(m,2H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.83(t,J=14.4Hz,1H),5.76-5.72(m,1H),5.65(s,1H),5.12(dd,J=12.9,5.4Hz,1H),4.20-4.18(m,1H),368-3.64(m,4H),3.49-3.45(m,8H),2.96-2.80(m,2H),2.63-2.60(m,2H),2.39-2.33(m,2H),2.26-2.22(m,4H),1.70-1.68(m,2H),1.55(d,J=7.0Hz,3H),1.45-1.43(m,2H),1.38-1.35(m,2H).
实施例62:化合物62的制备
向反应瓶中依次加入化合物7-1b(140.25mg,0.36mmol,1.5eq),二甲基甲酰胺(5mL),HATU(137.04mg,0.36mmol,1.5eq),二异丙基乙胺(93.05mg,0.72mmol,3.0eq),室温搅拌5分钟后,加入化合物39-3(100.0mg,0.24mol,1.0eq),加毕室温搅拌过夜,向体系加入水(30mL),乙酸乙酯(30mL)萃取3次,饱和氯化钠溶液(50mL)洗涤2次,无水硫酸钠干燥过滤,浓缩得到粗品,
粗品通过柱层析纯化(洗脱剂:二氯甲烷/甲醇=10/1),得到化合物62(6.8mg);1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),8.90(d,J=2.9Hz,1H),8.46(d,J=7.2Hz,1H),8.09(d,J=2.9Hz,1H),7.68(t,J=7.5Hz,1H),7.58(dd,J=8.5,7.1Hz,1H),7.52(t,J=7.2Hz,1H),7.31(t,J=7.7Hz,1H),7.26(t,J=52.0Hz,1H),7.13(d,J=8.2Hz,1H),7.05(d,J=7.0Hz,1H),6.60(t,J=5.8Hz,1H),5.84-5.87(m,1H),5.10-5.05(m,1H),3.71-3.67(m,5H),3.61(t,J=5.4Hz,2H),3.57-3.50(m,5H),3.30(s,2H),2.95-2.86(m,1H),2.65(q,J=6.0,5.4Hz,3H),2.36(s,3H),2.08-1.98(m,2H),1.63(d,J=7.1Hz,3H);MS:m/z 788.3[M+1]+。
实施例63-66:化合物63-66的制备
按照与实施例62基本相似的操作,合成化合物63-66。
化合物63-66的核磁数据如下:
化合物63
1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),8.90(d,J=2.9Hz,1H),8.46(d,J=7.2Hz,1H),8.09(d,J=2.9Hz,1H),7.68(t,J=7.5Hz,1H),7.58(dd,J=8.5,7.1Hz,1H),7.52(t,J=7.2Hz,1H),7.31(t,J=7.7Hz,1H),7.26(t,J=52.0Hz,1H),7.13(d,J=8.2Hz,1H),7.05(d,J=7.0Hz,1H),6.60(t,J=5.8Hz,1H),5.84-5.87(m,1H),5.10-5.05(m,1H),3.71-3.67(m,7H),3.61(t,J=5.4Hz,2H),3.57-3.50(m,5H),3.46(q,J=5.6Hz,2H),3.30(s,2H),2.95-2.86(m,1H),2.65(q,J=6.0,5.4Hz,3H),2.36(s,3H),2.08-1.98(m,2H),1.63(d,J=7.1Hz,3H).
化合物64
1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),8.90(d,J=2.9Hz,1H),8.46(d,J=7.2Hz,1H),8.09(d,J=2.9Hz,1H),7.68(t,J=7.5Hz,1H),7.58(dd,J=8.5,7.1Hz,1H),7.52(t,J=7.2Hz,1H),7.31(t,J=7.7Hz,1H),7.26(t,J=52.0Hz,1H),7.13(d,J=8.2Hz,1H),7.05(d,J=7.0Hz,1H),6.60(t,J=5.8Hz,1H),5.84-5.87(m,1H),5.10-5.05(m,1H),3.71-3.67(m,7H),3.61(t,J=5.4Hz,2H),3.57-3.50(m,9H),3.46(q,J=5.6Hz,2H),3.30(s,2H),2.95-2.86(m,1H),2.65(q,J=6.0,5.4Hz,3H),2.36(s,3H),2.08-1.98(m,2H),1.63(d,J=7.1Hz,3H).
化合物65
1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),8.90(d,J=2.9Hz,1H),8.46(d,J=7.2Hz,1H),8.09(d,J=2.9Hz,1H),7.68(t,J=7.5Hz,1H),7.58(dd,J=8.5,7.1Hz,1H),7.52(t,J=7.2Hz,1H),7.31(t,J=7.7Hz,1H),7.25(t,J=52.0Hz,1H),7.13(d,J=8.2Hz,1H),7.05(d,J=7.0Hz,1H),6.61(t,J=5.8Hz,1H),5.84-5.77(m,1H),5.07(dd,J=12.9,5.4Hz,1H),3.71-3.66(m,6H),3.62(t,J=5.4Hz,2H),3.59-3.53(m,3H),3.53-3.44(m,13H),3.30(s,2H),2.95-2.86(m,1H),2.67(t,J=6.6Hz,3H),2.36(s,3H),2.10-1.94(m,2H),1.63(d,J=7.1Hz,3H).
化合物66
1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),8.90(d,J=2.9Hz,1H),8.46(d,J=7.2Hz,1H),8.26(d,J=2.6Hz,1H),8.09(d,J=2.9Hz,1H),7.58(dd,J=8.5,7.1Hz,1H),7.52(t,J=7.2Hz,1H),7.48(s,1H),7.26(t,J=52.0Hz,1H),7.19(d,J=8.2Hz,1H),7.05(d,J=7.0Hz,1H),6.60(t,J=5.8Hz,1H),5.84-5.87(m,1H),5.10-5.05(m,1H),3.71-3.67(m,5H),3.61(t,J=5.4Hz,2H),3.57-3.50(m,5H),3.30(s,2H),2.95-2.86(m,1H),2.65(q,J=6.0,5.4Hz,3H),2.36(s,3H),2.08-1.98(m,2H),1.63(d,J=7.1Hz,3H).
实施例67:化合物67的制备
向反应瓶中依次加入化合物7-1b(136.42mg,0.33mmol,1.5eq),二甲基甲酰胺(5mL),HATU(133.12mg,0.33mmol,1.5eq),二异丙基乙胺(85.30mg,0.66mmol,3.0eq),室温搅拌5分钟后,加入化合物40-1(100.0mg,0.22mol,1.0eq),加毕室温搅拌过夜,向体系加入水(30mL),乙酸乙酯(30mL)萃取3次,饱和氯化钠溶液(50mL)洗涤2次,无水硫酸钠干燥过滤,浓缩得到粗品,粗品通过柱层析纯化(洗脱剂:二氯甲烷/甲醇=10/1),得到化合物67(4.2mg);1H NMR(400MHz,DMSO-d6):δ11.10(s,1H),8.97(s,1H),8.67(s,1H),7.92(s,1H),7.73-7.70(m,1H),7.58(t,J=7.2Hz,1H),7.44-7.32(m,3H),7.30-7.18(m,2H),5.99(t,J=7.2Hz,1H),5.83(t,J=14.4Hz,1H),5.10(dd,J=12.9,5.4Hz,1H),3.47(d,J=8.4Hz,2H),2.78-2.59(m,6H),2.55(d,J=2.0Hz,3H),2.46-2.28(m,8H),2.07-2.01(m,3H),1.75(d,J=7.0Hz,3H);MS:m/z 833.3[M+1]+。
实施例68:化合物68合成路线
向反应瓶中依次加入化合物68-1a(293mg,1mmol,1.0eq,参照WO2022017339A1合成),Boc酸酐(218mg,1mmol,1.0eq),三乙胺(202mg,2mmol,2.0eq),四氢呋喃(3mL),加毕,室温搅拌过夜,向体系加入水(5mL),乙酸乙酯(5mL)萃取3次,饱和氯化钠溶液(3mL)洗涤2次,无水硫酸钠干燥过滤,浓缩得到粗品,粗品通过柱层析纯化(洗脱剂:石油醚/乙酸乙酯=5/1),得到化合物68-1b(335mg);MS:m/z 394.3[M+1]+;
氮气保护下,向反应瓶中依次加入中间体68-1b(335mg,0.85mmol,1.0eq),甲苯(10mL),化合物39-2(402.8mg,2.12mmol,2.5eq),Pd(dba)3(293mg,0.51mmol,0.6eq),Xantphos(589mg,1.02mmol,1.2eq)和磷酸三钾(1081mg,5.1mmol,6.0eq),反应体系升温至110℃,反应24h,浓缩除去溶剂,加入水和乙酸乙酯萃取,分液,有机相浓缩干,粗品经柱层析纯化(洗脱剂:石油醚/乙酸乙酯=2/1),得到化合物68-1c(125mg);MS:m/z 547.2[M+H]+;
向反应瓶中依次加入中间体68-1c(125mg,0.23mmol),二氧六环(4mL),2N盐酸(1mL),加毕,室温搅拌反应2小时,体系浓缩近干,得到化合物68-1d(93mg),不经纯化,直接投入下一步;
向反应瓶中依次加入化合物38-1g(105.0mg,0.20mmol,1.0eq),二甲基甲酰胺(5mL),HOBT(40.5mg,0.30mmol,1.5eq),EDCI(57.6mg,0.30mmol,1.5eq),二异丙基乙胺(180.6mg,1.40mmol,7.0eq),室温搅拌反应2小时后,加入化合物68-1d(90.0mg,0.20mmol,1.0eq),加毕,升温至30℃搅拌反应过夜,反应体系降至室温,加入水(20mL),乙酸乙酯(20mL)萃取2次,饱和氯化钠溶液(20mL)洗涤2次,无水硫酸钠干燥过滤,浓缩得到粗品,进行反相柱层析纯化(Shim-pack GIS-C1820*250nm,5μm;0.01%甲酸-水/乙腈),得到化合物68(13mg);1H NMR(400MHz,DMSO-d6):δ11.10(s,1H),8.97(s,1H),8.67(s,1H),7.92(s,1H),7.73-7.70(m,1H),7.58(t,J=7.2Hz,1H),7.44-7.32(m,3H),7.30-7.18(m,2H),5.99(t,J=7.2Hz,1H),5.12(dd,J=12.9,5.4Hz,1H),3.96(s,3H),3.76-3.69(m,2H),3.64-3.56(m,4H),3.49-3.45(m,6H),3.15(s,4H),3.03(s,2H),2.96-2.80(m,3H),2.61-2.58(m,6H),2.39-2.33(m,2H),2.26-2.22(m,1H),2.14-1.98(m,2H),1.88(d,J=12.8Hz,2H),1.78-1.69(m,5H),1.62-1.48(m,7H);MS:m/z 982.4[M+1]+。
实施例69-74:化合物69-74的制备
按照与实施例68基本相似的操作,合成化合物69-74。
化合物69-74的核磁数据如下:
化合物69
1H NMR(400MHz,DMSO-d6):δ11.10(s,1H),8.97(s,1H),8.67(s,1H),8.35(s,1H),7.92(s,1H),7.58(t,J=7.2Hz,1H),7.44-7.32(m,3H),7.30-7.18(m,2H),5.99(t,J=7.2Hz,1H),5.12(dd,J=12.9,5.4Hz,1H),3.76-3.69(m,2H),3.64-3.56(m,6H),3.49-3.45(m,8H),3.15(s,4H),3.03(s,2H),2.96-2.80(m,2H),2.61-2.58(m,6H),2.26-2.22(m,1H),2.14-1.98(m,2H),1.88(d,J=12.8Hz,2H),1.78-1.69(m,5H),1.62-1.48(m,7H).
化合物70
1H NMR(400MHz,DMSO-d6):δ11.10(s,1H),8.97(s,1H),8.67(s,1H),8.35(s,1H),7.92(s,1H),7.58(t,J=7.2Hz,1H),7.44-7.32(m,3H),7.30-7.18(m,2H),5.12(dd,J=12.9,5.4Hz,1H),3.76-3.69(m,2H),3.64-3.56(m,6H),3.49-3.45(m,8H),3.15(s,4H),3.03(s,2H),2.96-2.80(m,2H),2.61-2.58(m,
9H),2.26-2.22(m,1H),2.14-1.98(m,2H),1.88(d,J=12.8Hz,2H),1.78-1.69(m,5H),1.62-1.48(m,7H).
化合物71
1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),8.40(d,J=42.3Hz,1H),7.78(d,J=8.4Hz,1H),7.38(d,J=8.8Hz,1H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.76-5.72(m,1H),5.65(s,1H),5.12(dd,J=12.9,5.4Hz,1H),4.23(d,J=13.5Hz,2H),3.76-3.69(m,2H),3.64-3.56(m,6H),3.49-3.45(m,7H),3.15(s,4H),3.03(s,2H),2.96-2.80(m,3H),2.61-2.58(m,6H),2.39-2.33(m,2H),2.26-2.22(m,1H),2.14-1.98(m,2H),1.88(d,J=12.8Hz,2H),1.78-1.69(m,5H),1.62-1.48(m,11H).
化合物72
1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),8.40(d,J=42.3Hz,1H),8.22-8.16(m,3H),7.78(d,J=8.4Hz,1H),7.38(d,J=8.8Hz,1H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.76-5.72(m,1H),5.65(s,1H),5.12(dd,J=12.9,5.4Hz,1H),4.23(d,J=13.5Hz,2H),3.76-3.69(m,2H),3.64-3.56(m,4H),3.49-3.45(m,4H),3.15(s,4H),3.09-3.06(m,2H),3.03(s,2H),2.96-2.80(m,3H),2.61-2.58(m,6H),2.39-2.33(m,2H),2.26-2.22(m,1H),2.14-1.98(m,2H),1.88(d,J=12.8Hz,2H),1.78-1.69(m,5H),1.62-1.48(m,7H).
化合物73
1H NMR(400MHz,DMSO-d6):δ11.50(s,1H),11.11(s,1H),8.40(d,J=42.3Hz,1H),7.78(d,J=8.4Hz,1H),7.51(s,1H),7.38(d,J=8.8Hz,1H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.83(t,J=14.4Hz,1H),5.76-5.72(m,1H),5.65(s,1H),5.12(dd,J=12.9,5.4Hz,1H),4.23(d,J=13.5Hz,2H),3.76-3.69(m,2H),3.64-3.56(m,4H),3.49-3.45(m,2H),3.15(s,4H),3.09-3.06(m,2H),3.03(s,2H),2.96-2.80(m,3H),2.61-2.58(m,6H),2.39-2.33(m,2H),2.26-2.22(m,1H),2.14-1.98(m,3H),1.88(d,J=12.8Hz,2H),1.78-1.69(m,5H),1.62-1.48(m,6H).
化合物74
1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),8.40(d,J=42.3Hz,1H),8.00(d,J=8.0Hz,1H),7.78(d,J=8.4Hz,1H),7.51(s,1H),7.38(d,J=8.8Hz,1H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.76-5.72(m,1H),5.65(s,1H),5.12(dd,J=12.9,5.4Hz,1H),4.23(d,J=13.5Hz,2H),3.76-3.69(m,4H),3.64-3.56(m,4H),3.49-3.45(m,5H),3.15(s,4H),3.03(s,2H),2.96-2.80(m,7H),2.61-2.58(m,6H),2.26-2.22(m,1H),2.14-1.98(m,4H),1.88(d,J=12.8Hz,2H),1.78-1.69(m,5H),1.62-1.48(m,7H).
实施例83:化合物83合成路线
向反应瓶中依次加入化合物83-1a(2.76g,10mmol,1.0eq),乙腈(10mL),中间体1-2(2.34g,10mmol,1.0eq),二异丙基乙胺(2.58g,20mmol,2.0eq),加毕室温搅拌反应12h,向体系加入水(30mL),乙酸乙酯(30mL)萃取3次,饱和氯化钠溶液(50mL)洗涤2次,无水硫酸钠干燥过滤,浓缩得到粗品,粗品通过柱层析纯化(洗脱剂:石油醚烷/乙酸乙酯=5/1),得到化合物83-1b(4.2g);MS:m/z 475.0[M+1]+;
向反应瓶中依次加入化合物83-1b(237mg,0.5mmol,1.0eq),乙腈(4mL),氨基乙醛缩二甲醇(2mL),加毕微波130℃搅拌反应5h,向体系加入水(10mL),乙酸乙酯(10mL)萃取3次,饱和氯化钠溶液(10mL)洗涤2次,无水硫酸钠干燥过滤,浓缩得到粗品,粗品通过柱层析纯化(洗脱剂:石油醚烷/乙酸乙酯=3/1),得到化合物83-1c(130mg);MS:m/z 544.1[M+1]+;
向反应瓶中依次加入化合物83-1c(130mg),醋酸(3mL),加毕微波160℃搅拌反应3h,浓缩得到粗品,粗品通过柱层析纯化(洗脱剂:石油醚烷/乙酸乙酯=2/1),得到化合物83-1d(83mg);MS:m/z 462.1[M+1]+;
氮气保护下,向反应瓶中依次加入化合物83-1d(83mg,0.18mmol,1.0eq),N-Boc-1,2,5,6-四氢吡啶-4-硼酸频哪醇酯(67mg,0.22mmol,1.2eq),四(三苯基膦)钯(31.2mg,0.027mmol,0.15eq),碳酸钠(47.7mg,0.45mmol,2.5eq),二氧六环(4mL)和水(1mL)加毕,升温至90℃搅拌反应6小时,降至室温后,加入水(5mL),乙酸乙酯(5mL)萃取2次,有机相用无水硫酸钠干燥,过滤和浓缩,柱层析纯化(洗脱剂:石油醚/乙酸乙酯=1/1),得到化合物83-1e(61mg);MS:m/z 583.1[M+1]+;
向反应瓶中依次加入化合物83-1e(61mg,0.13mmol,1.0eq),二氯甲烷(4mL),三氟乙酸(1mL),加毕室温搅拌反应3h,浓缩得到粗品83-1f,直接投下一步;
向上述含有粗品83-1f反应瓶中依次加入二甲基甲酰胺(2mL),HOBT(27mg,0.20mmol,1.5eq),EDCI(38mg,0.20mmol,1.5eq),二异丙基乙胺(117mg,0.91mmol,7.0eq),室温搅拌反应2小时后,加入羧酸(72mg,0.13mmol,1.0eq),加毕,升温至30℃搅拌反应过夜,反应体系降至室温,加入水(10mL),乙酸乙酯(10mL)萃取2次,饱和氯化钠溶液(10mL)洗涤2次,无水硫酸钠干燥过滤,浓缩得到粗品,粗品通过柱层析纯化(洗脱剂:二氯甲烷/甲醇=10/1),得到化合物83-1g(32mg);MS:m/z 1018.4[M+1]+;
向反应瓶中依次加入化合物83-1g(32mg),四氢呋喃(3ml),20%钯碳(6.4mg),在氢气氛围下控温至30℃搅拌反应过夜,反应液过滤,滤液旋干,进行反相柱层析纯化(Shim-pack GIS-C1820*250nm,5μm;0.01%甲酸-水/乙腈),得到化合物83(6.9mg);1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),8.40(d,J=42.3Hz,1H),8.25(d,J=8.2Hz,1H),8.04-7.98(m,2H),7.78(d,J=8.4Hz,1H),7.51(s,1H),7.33-7.26(m,2H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.83(t,J=14.4Hz,1H),5.76-5.72(m,1H),5.65(s,1H),5.12(dd,J=12.9,5.4Hz,1H),4.23(d,J=13.5Hz,2H),3.76-3.69(m,2H),3.64-3.56(m,4H),3.49-3.45(m,2H),3.15(s,4H),3.09-3.06(m,2H),3.03(s,2H),2.96-2.80(m,3H),2.61-2.58(m,3H),2.39-2.33(m,2H),2.26-2.22(m,1H),2.14-1.98(m,3H),1.88(d,J=12.8Hz,2H),1.78-1.69(m,5H),1.62-1.48(m,6H);MS:m/z 988.5[M+1]+。
实施例84-85:化合物84-85的制备
按照与实施例83基本相似的操作,合成化合物84-85。
化合物84-85的核磁数据如下:
化合物84
1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),8.40(d,J=42.3Hz,1H),8.25(d,J=8.2Hz,1H),8.04-7.98(m,2H),7.76-7.73(m,2H),7.51(s,1H),7.33-7.26(m,3H),7.26(d,J=4.1Hz,1H),7.23-7.21(m,1H),6.99(s,1H),6.92(s,1H),5.83(t,J=14.4Hz,1H),5.76-5.72(m,1H),5.12(dd,J=12.9,5.4Hz,1H),4.23(d,J=13.5Hz,2H),3.76-3.69(m,2H),3.64-3.56(m,4H),3.49-3.45(m,2H),3.15(s,4H),3.09-3.06(m,2H),3.03(s,2H),2.96-2.80(m,3H),2.61-2.58(m,3H),2.39-2.33(m,2H),2.26-2.22(m,1H),2.14-1.98(m,3H),1.88(d,J=12.8Hz,2H),1.78-1.69(m,5H),1.62-1.48(m,6H).
化合物85
1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),8.40(d,J=42.3Hz,1H),8.25(d,J=8.2Hz,1H),8.04-7.98(m,2H),7.76-7.73(m,2H),7.51(s,1H),7.33-7.26(m,3H),7.26(d,J=4.1Hz,1H),7.23-7.21(m,1H),6.99(s,1H),6.92(s,1H),5.99(t,J=7.2Hz,1H),5.83(t,J=14.4Hz,1H),5.76-5.72(m,1H),5.12(dd,J=12.9,5.4Hz,1H),4.23(d,J=13.5Hz,2H),3.76-3.69(m,2H),3.64-3.56(m,4H),3.49-3.45(m,2H),3.15(s,4H),3.09-3.06(m,2H),3.03(s,2H),2.96-2.80(m,3H),2.39-2.33(m,2H),2.26-2.22(m,1H),2.14-1.98(m,3H),1.88(d,J=12.8Hz,2H),1.78-1.69(m,5H),1.62-1.48(m,6H).
实施例87:化合物87的合成路线
向反应瓶中依次加入化合物1-1a(5.0g,18.1mmol,1.0eq.)、1-Boc-哌嗪(3.71g,19.9mmol,1.1eq.)、DIPEA(7.0g,54.3mmol,6.0eq.)、N-甲基吡咯烷酮(30mL),加毕,升温至140℃搅拌反应6h。将反应体系冷却至室温加入水(100mL),乙酸乙酯(100mL×2)萃取,饱和氯化钠溶液(100mL×2)洗涤,无水硫酸钠干燥、过滤、浓缩得到粗品,粗品通过柱层析纯化(洗脱剂:石油醚/乙酸乙酯=1/1),得到化合物87a(6.0g);MS:m/z 443.2[M+1]+。
向反应瓶中依次加入化合物87a(6.0g,13.57mmol,1.0eq.)、4N盐酸1,4-二氧六环(50mL),加毕,室温搅拌反应2h。体系减压浓缩,得到化合物87b(5.5g)不经纯化,直接投下一步;MS:m/z343.0[M+1]+。
向反应瓶中依次加入化合物87b(1.5g,4.38mmol,1.0eq.)、1-叔丁氧羰基哌啶-4-甲醛(1.4g,6.58mmol,1.5eq.)、无水乙酸钠(7.2g,87.69mmol,20.0eq.)、DCM/MeOH=10:1(100mL),室温
搅拌反应30分钟后,分批加入氰基硼氢化钠(2.76g,43.84mmol,10.0eq.),加毕,室温搅拌反应2h。加入水(150mL),乙酸乙酯(150mL×2)萃取,无水硫酸钠干燥、过滤,浓缩得到粗品,粗品经柱层析纯化(石油醚/乙酸乙酯=1/1),得到化合物87c(2.3g);MS:m/z 540.4[M+1]+。
向反应瓶中依次加入化合物87c(2.3g,4.27mmol,1.0eq.),4N盐酸1,4-二氧六环(20mL),加毕,室温搅拌反应2h。体系减压浓缩,得到化合物87d(2.2g)不经纯化,直接投下一步;MS:m/z 440.3[M+1]+。
向反应瓶中依次加入化合物87d(500mg,1.14mmol,1.0eq.)、1-叔丁氧羰基哌啶-4-甲醛(362.01mg,1.71mmol,1.5eq.)、无水乙酸钠(1.81g,22.81mmol,20.0eq))、DCM/MeOH=10:1(100mL),室温搅拌反应30分钟后,分批加入氰基硼氢化钠(693.23mg,11.41mmol,10.0eq.),加毕,室温搅拌反应2h。加入水(150mL),乙酸乙酯(150mL×2)萃取,无水硫酸钠干燥、过滤、浓缩得到粗品,粗品经柱层析纯化(石油醚/乙酸乙酯=1/1),得到化合物87e(601mg);MS:m/z 637.4[M+1]+。
向反应瓶中依次加入化合物87e(601mg,0.94mmol,1.0eq.),TFA:DCM=2:1(15mL),加毕,室温搅拌反应2h。体系减压浓缩,得到化合物87f(2.5g),不经纯化,直接投下一步;MS:m/z537.3[M+1]+。
向反应瓶中依次加入化合物17-1b(170.0mg,0.31mmol,1.0eq.),DMF(5mL),HOBT(104.57mg,0.77mmol,2.5eq.),EDCI(152.21mg,0.77mmol,2.5eq.),DIPEA(200.03mg,1.55mmol,5.0eq.),室温搅拌反应2小时后加入化合物87f(199.22mg,0.37mmol,1.2eq.),加毕,升温至30℃搅拌反应过夜。反应体系降至室温,加入水(50mL),乙酸乙酯(50mL×2)萃取,饱和氯化钠溶液(50mL×2)洗涤,无水硫酸钠干燥过滤,浓缩得到粗品,粗品通过柱层析纯化(洗脱剂:二氯甲烷/甲醇=10/1),得到化合物87g(111.0mg);MS:m/z 1069.0[M+1]+。
向反应瓶中依次加入化合物87g(111mg,0.10mmol,1.0eq.)、乙醇(10mL)、氯化亚锡(54.07mg,0.68mmol,6.5eq.),升温至80℃搅拌2h。降至室温后,饱和碳酸氢钠调节PH至7,过滤后,滤液用EA(20mL×3)萃取,无水硫酸钠干燥、过滤、浓缩得到粗品,粗品经反相柱层析纯化(Shim-packGIS-C18 20×250nm,5μm;0.01%甲酸-水/乙腈),得到纯的化合物87(17.9mg);1H NMR(400MHz,DMSO-d6):δ11.10(s,1H),8.18(s,1H),7.98(d,J=8.1Hz,1H),7.69(d,J=8.5Hz,1H),7.62(d,J=4.4Hz,1H),7.35(d,J=2.1Hz,1H),7.27(d,J=8.9Hz,1H),7.05(d,J=2.0Hz,1H),6.88(d,J=15.5Hz,2H),6.71(s,1H),5.59-5.53(m,3H),5.15-5.00(m,2H),4.34-4.31(m,1H),4.04-3.94(m,1H),3.88(s,3H),3.76-3.45(m,12H),3.37-3.21(m,5H),3.18-3.04(m,1H),2.98-2.88(m,2H),2.87-2.80(m,3H),2.70(d,J=10.2Hz,1H),2.63-2.56(m,2H),2.40-2.33(m,5H),2.18-2.16(m,2H),2.07-2.01(m,2H),1.95-1.85(m,2H),1.76-1.64(m,3H),1.57(d,J=7.0Hz,3H),1.43-1.38(m,2H);MS:m/z 1039.0[M+1]+。
实施例89-100及实施例125:化合物89-100和125的合成路线
按照与实施例87基本相似的操作,合成化合物89-100和125。
化合物89
1H NMR(400MHz,DMSO-d6):δ11.10(s,1H),8.18(s,1H),7.98(d,J=8.1Hz,1H),7.69(d,J=8.5Hz,1H),7.62(d,J=4.4Hz,1H),7.35(d,J=2.1Hz,1H),7.27(d,J=8.9Hz,1H),7.05(d,J=2.0Hz,1H),6.88(d,J=15.5Hz,2H),6.71(s,1H),5.59-5.53(m,3H),5.15-5.00(m,2H),4.34-4.31(m,1H),4.04-3.94(m,1H),3.88(s,3H),3.76-3.45(m,12H),3.37-3.21(m,5H),3.18-3.04(m,1H),2.98-2.88(m,2H),2.87-2.80(m,3H),2.70(d,J=10.2Hz,1H),2.63-2.56(m,2H),2.40-2.33(m,5H),2.18-2.16(m,2H),2.07-2.01(m,2H),1.95-1.85(m,2H),1.57(d,J=7.0Hz,3H),1.76-1.64(m,5H),1.43-1.38(m,2H).
化合物90
1H NMR(400MHz,DMSO-d6):δ11.12(s,1H),7.79(d,J=8.5Hz,1H),7.52(s,1H),7.39(d,J=8.7Hz,1H),7.30(s,2H),7.17(s,1H),7.04(s,1H),6.95(s,1H),6.91(s,1H),6.78(s,1H),5.86-5.69(m,2H),5.50-5.29(m,3H),5.12(dd,J=12.9,5.3Hz,2H),4.68-4.50(m,5H),4.26(d,J=12.6Hz,4H),4.00(s,4H),3.79-3.75(m,4H),3.63-3.60(m,3H),3.49-3.46(m,4H),3.19-3.11(m,1H),3.03-2.85(m,2H),2.62(s,6H),2.16-2.13(m,2H),2.07-1.99(m,3H),1.94-1.91(m,2H),1.68(d,J=7.1Hz,3H),1.54-1.48(m,5H).
化合物91
1H NMR(400MHz,DMSO-d6):δ11.12(s,1H),7.79(d,J=8.5Hz,1H),7.52(s,1H),7.39(d,J=8.7Hz,1H),7.30(s,2H),7.17(s,1H),7.04(s,1H),6.95(s,1H),6.91(s,1H),6.78(s,1H),5.85-5.70(m,1H),5.11(dd,J=12.9,5.4Hz,1H),4.60-4.48(m,3H),4.34(s,2H),4.23-4.19(m,3H),3.98(s,5H),3.83-3.80(m,7H),3.20-3.06(m,7H),2.98-2.82(m,6H),2.62(d,J=3.1Hz,5H),2.29-1.88(m,10H),1.76-1.72(m,5H).
化合物92
1H NMR(400MHz,DMSO-d6):δ11.10(s,1H),7.97(d,J=8.1Hz,1H),7.70(d,J=8.5Hz,1H),7.62(d,J=3.6Hz,1H),7.35(d,J=2.2Hz,1H),7.26(d,J=9.1Hz,1H),7.05(s,1H),6.90(s,2H),6.86(s,1H),6.71(d,J=1.9Hz,1H),5.65-5.49(m,4H),5.14-5.03(m,3H),4.31(s,2H),4.03-3.93(m,2H),3.88(s,6H),3.49(s,2H),3.14-3.04(m,2H),2.99-2.86(m,6H),2.48(s,7H),2.37(s,8H),2.18(d,J=7.1Hz,3H),2.09-1.94(m,5H),1.86(s,2H),1.57(d,J=7.1Hz,5H).
化合物93
1H NMR(400MHz,DMSO-d6):δ11.10(s,1H),7.97(d,J=8.1Hz,1H),7.70(d,J=8.5Hz,1H),7.62(d,J=3.6Hz,1H),7.35(d,J=2.2Hz,1H),7.26(d,J=9.1Hz,1H),7.05(s,1H),6.90(s,2H),6.86(s,1H),6.71(d,J=1.9Hz,1H),5.65-5.49(m,4H),5.14-5.03(m,3H),4.31(s,2H),4.03-3.93(m,2H),3.88(s,6H),3.49(s,2H),3.14-3.04(m,2H),2.99-2.86(m,6H),2.48(s,7H),2.37(s,8H),2.18(d,J=7.1Hz,3H),2.09-1.94(m,3H),1.86(s,2H),1.57(d,J=7.1Hz,5H).
化合物94
1H NMR(400MHz,DMSO-d6):δ11.10(s,1H),7.97(d,J=8.1Hz,1H),7.70(d,J=8.5Hz,1H),7.62(d,J=3.6Hz,1H),7.35(d,J=2.2Hz,1H),7.26(d,J=9.1Hz,1H),7.05(s,1H),6.90(s,2H),6.86(s,1H),6.71(d,J=1.9Hz,1H),5.65-5.49(m,4H),5.14-5.03(m,3H),4.31(s,2H),4.03-3.93(m,2H),3.88(s,6H),3.49(s,2H),3.14-3.04(m,2H),2.99-2.86(m,6H),2.48(s,7H),2.37(s,6H),2.18(d,J=7.1Hz,3H),2.09-1.94(m,3H),1.86(s,2H),1.57(d,J=7.1Hz,5H).
化合物95
1H NMR(400MHz,DMSO-d6):δ11.10(s,1H),8.18(s,1H),7.98(d,J=8.1Hz,1H),7.69(d,J=8.5Hz,1H),7.62(d,J=4.4Hz,1H),7.35(d,J=2.1Hz,1H),7.27(d,J=8.9Hz,1H),7.05(d,J=2.0Hz,1H),6.88(d,J=15.5Hz,2H),6.71(s,1H),5.59-5.53(m,3H),5.15-5.00(m,2H),4.34-4.31(m,1H),4.04-3.94(m,1H),3.88(s,3H),3.76-3.45(m,12H),3.37-3.21(m,5H),3.18-3.04(m,1H),2.98-2.88(m,2H),2.87-2.80(m,3H),2.70(d,J=10.2Hz,1H),2.63-2.56(m,2H),2.40-2.33(m,5H),2.18-2.16(m,2H),2.07-2.01(m,2H),1.95-1.85(m,2H),1.57(d,J=7.0Hz,3H),1.76-1.64(m,5H),1.43-1.38(m,5H).
化合物96
1H NMR(400MHz,DMSO-d6):δ11.10(s,1H),7.97(d,J=8.1Hz,1H),7.70(d,J=8.5Hz,1H),7.62(d,J=3.6Hz,1H),7.35(d,J=2.2Hz,1H),7.26(d,J=9.1Hz,1H),7.05(s,1H),6.90(s,2H),6.86(s,1H),6.71(d,J=1.9Hz,1H),5.65-5.49(m,4H),5.14-5.03(m,3H),4.31(s,2H),4.03-3.93(m,2H),3.88(s,6H),3.49(s,2H),3.14-3.04(m,2H),2.99-2.86(m,6H),2.48(s,7H),2.37(s,8H),2.18(d,J=7.1Hz,3H),2.09-1.94(m,3H),1.86(s,2H),1.57-1.43(m,5H).
化合物97
1H NMR(400MHz,DMSO-d6):δ11.10(s,1H),7.97(d,J=8.1Hz,1H),7.70(d,J=8.5Hz,1H),7.62(d,J=3.6Hz,1H),7.35(d,J=2.2Hz,1H),7.26(d,J=9.1Hz,1H),7.05(s,1H),6.90(s,2H),6.86(s,1H),6.71(d,J=1.9Hz,1H),5.65-5.49(m,4H),5.14-5.03(m,3H),4.31(s,2H),4.03-3.93(m,2H),3.88(s,6H),3.49(s,2H),3.14-3.04(m,2H),2.99-2.86(m,6H),2.48(s,7H),2.37(s,8H),2.18(d,J=7.1Hz,3H),2.09-1.94(m,3H),1.86(s,2H),1.57-1.44(m,5H).
化合物98
1H NMR(400MHz,DMSO-d6):δ11.10(s,1H),7.97(d,J=8.1Hz,1H),7.70(d,J=8.5Hz,1H),7.62(d,J=3.6Hz,1H),7.35(d,J=2.2Hz,1H),7.26(d,J=9.1Hz,1H),7.05(s,1H),6.90(s,2H),6.86(s,1H),6.71(d,J=1.9Hz,1H),5.65-5.49(m,4H),5.14-5.03(m,3H),4.31(s,2H),4.03-3.93(m,2H),3.88(s,6H),3.14-3.04(m,2H),2.99-2.86(m,6H),2.48(s,7H),2.37(s,8H),2.18(d,J=7.1Hz,3H),2.09-1.94(m,3H),1.86(s,2H),1.57-1.44(m,5H).
化合物99
1H NMR(400MHz,DMSO-d6):δ11.10(s,1H),7.97(d,J=8.1Hz,1H),7.70(d,J=8.5Hz,1H),7.62(d,J=3.6Hz,1H),7.35(d,J=2.2Hz,1H),7.26(d,J=9.1Hz,1H),7.05(s,1H),6.90(s,2H),6.86(s,1H),6.71(d,J=1.9Hz,1H),5.65-5.49(m,4H),5.14-5.03(m,3H),4.31(s,2H),4.03-3.93(m,2H),3.88(s,6H),3.49(s,2H),3.14-3.04(m,2H),2.99-2.86(m,6H),2.48(s,7H),2.37(s,8H),2.18(d,J=7.1Hz,3H),2.09-1.94(m,3H),1.86(s,2H),1.57-1.43(m,7H).
化合物100
1H NMR(400MHz,DMSO-d6):δ11.10(s,1H),7.97(d,J=8.1Hz,1H),7.70(d,J=8.5Hz,1H),7.62(d,J=3.6Hz,1H),7.35(d,J=2.2Hz,1H),7.26(d,J=9.1Hz,1H),7.05(s,1H),6.90(s,2H),6.86(s,1H),6.71(d,J=1.9Hz,1H),5.65-5.49(m,4H),5.14-5.03(m,3H),4.31(s,2H),4.03-3.93(m,2H),3.88(s,6H),3.49(s,2H),3.14-3.04(m,2H),2.99-2.86(m,6H),2.52-2.46(m,9H),2.37(s,8H),2.18(d,J=7.1Hz,3H),2.09-1.94(m,3H),1.86(s,2H),1.57-1.43(m,7H).
化合物125
1H NMR(400MHz,DMSO-d6):δ11.10(s,1H),10.12(s,1H),9.36(s,1H),8.45-8.33(m,2H),7.74-7.72(m,1H),7.51(dd,J=7.6,1.2Hz,1H),7.47(s,1H),7.25(t,J=7.6Hz,1H),7.08-6.92(m,3H),5.65-5.61(m,1H),5.06-5.04(m,1H),3.82(s,2H),3.75-3.71(m,4H),3.60-3.58(m,12H),3.50(s,2H),3.36(t,J=5.6Hz,2H),3.09-3.01(m,2H),2.75(d,J=7.6Hz,6H),2.66-2.36(m,2H),2.27-2.24(m,2H),2.18-2.15(m,2H),2.11-1.94(m,2H),1.90-1.88(m,4H),1.68-1.66(m,5H),1.65(d,J=7.2Hz,3H),1.63-1.60(m,1H).
实施例106:化合物106的合成路线
向反应瓶中依次加入化合物83-1f(500mg,1.0eq.)、乙醇(10mL)、氯化亚锡(6.5eq.),升温至80℃搅拌2h。降至室温后,饱和碳酸氢钠调节PH至7,过滤后,滤液用EA(100mL×3)萃取,无水硫酸钠干燥、过滤、浓缩得到粗品,粗品经柱层析纯化得到化合物106-P1。
将己二酸(30mg,1.0eq.)加入反应瓶中,氯化亚砜(2mL)做溶剂,再加入一滴DMF催化,80℃反应1.5h,将反应体系旋干,再加入DCM(3mL)做溶剂,依次加入TEA(113mg,6eq.)、化合物60-2(81mg,1.0eq.),室温反应1h,反应完毕将反应体系倒入10mL水中,EA萃取(10mL×2),水相冻干,得到粗产品化合物106a(130mg),无需纯化,直接进行下一步。
将化合物106a(130mg,1.0eq.),HOBt(61mg,2.0eq.),EDCI(87mg,2.0eq.),DIEA(117mg,4.0eq.)加入反应瓶中,DMF(3mL)做溶剂,室温反应0.5h,再加入化合物106-P1(103mg,1.0eq.),加完室温反应2h,反应完毕将反应体系倒入30mL水中,EA萃取(10mL×3),合并有机相,有机相经无水硫酸钠干燥、过滤、浓缩得粗品,粗品经薄层层析纯化(DCM/MeOH=5:1)、制备纯化,得到目标产品化合物106;1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),9.15(s,1H),8.40(d,J=42.3Hz,1H),8.25(d,J=8.2Hz,1H),8.04-7.98(m,2H),7.49-7.44(m,4H),7.33-7.26(m,2H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.83(t,J=14.4Hz,1H),5.76-5.72(m,1H),5.65(s,1H),4.59(t,J=8.0Hz,1H),4.51-4.49(m,1H),4.47-4.35(m,3H),4.23-4.21(m,1H),3.79-3.76(m,2H),3.76-3.69(m,2H),3.51-3.49(m,1H),3.09-3.06(m,2H),2.49-2.46(m,5H),2.28-2.22(m,5H),2.08-2.02(m,1H),1.62-1.60(m,4H),1.56-1.53(m,3H),1.43(s,9H);MS:m/z 993.4[M+1]+。
实施例107-114:化合物107-114的合成路线
按照与实施例106基本相似的操作,合成化合物107-114。
化合物107
1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),9.15(s,1H),8.40(d,J=42.3Hz,1H),8.25(d,J=8.2Hz,1H),8.04-7.98(m,2H),7.49-7.44(m,4H),7.33-7.26(m,2H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.83(t,J=14.4Hz,1H),5.76-5.72(m,1H),5.65(s,1H),4.59(t,J=8.0Hz,1H),4.51-4.49(m,1H),4.47-4.35(m,3H),4.23-4.21(m,1H),3.79-3.76(m,2H),3.76-3.69(m,2H),3.51-3.49(m,1H),3.09-3.06(m,2H),2.49-2.46(m,5H),2.28-2.22(m,5H),2.08-2.02(m,1H),1.62-1.60(m,4H),1.56-1.53(m,3H),1.46-1.44(m,2H),1.43(s,9H).
化合物108
1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),9.15(s,1H),8.40(d,J=42.3Hz,1H),8.25(d,J=8.2Hz,1H),8.04-7.98(m,2H),7.49-7.44(m,4H),7.33-7.26(m,2H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.83(t,J=14.4Hz,1H),5.76-5.72(m,1H),5.65(s,1H),4.59(t,J=8.0Hz,1H),4.51-4.49(m,1H),4.47-4.35(m,3H),4.23-4.21(m,1H),3.79-3.76(m,2H),3.76-3.69(m,2H),3.51-3.49(m,1H),3.09-3.06(m,2H),2.49-2.46(m,5H),2.28-2.22(m,5H),2.08-2.02(m,1H),1.62-1.60(m,4H),1.56-1.53(m,7H),1.43(s,9H).
化合物109
1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),9.15(s,1H),8.40(d,J=42.3Hz,1H),8.25(d,J=8.2Hz,1H),8.04-7.98(m,2H),7.49-7.44(m,4H),7.33-7.26(m,2H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.83(t,J=14.4Hz,1H),5.76-5.72(m,1H),5.65(s,1H),4.59(t,J=8.0Hz,1H),4.51-4.49(m,1H),4.47-4.35(m,3H),4.23-4.21(m,1H),3.79-3.76(m,2H),3.76-3.69(m,2H),3.51-3.49(m,1H),3.09-3.06(m,2H),2.49-2.46(m,5H),2.28-2.22(m,5H),2.08-2.02(m,1H),1.62-1.60(m,4H),1.56-1.53(m,7H),1.46-1.44(m,2H),1.43(s,9H).
化合物110
1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),9.15(s,1H),8.40(d,J=42.3Hz,1H),8.25(d,J=8.2Hz,1H),8.04-7.98(m,2H),7.49-7.44(m,4H),7.33-7.26(m,2H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.83(t,J=14.4Hz,1H),5.76-5.72(m,1H),5.65(s,1H),4.59(t,J=8.0Hz,1H),4.51-4.49(m,1H),4.47-4.35(m,3H),4.23-4.21(m,1H),3.79-3.76(m,2H),3.76-3.69(m,2H),3.51-3.49(m,1H),3.09-3.06(m,2H),2.49-2.46(m,5H),2.28-2.22(m,5H),2.08-2.02(m,1H),1.62-1.60(m,4H),1.56-1.53(m,3H),1.50-1.46(m,8H),1.43(s,9H).
化合物111
1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),9.15(s,1H),8.40(d,J=42.3Hz,1H),8.25(d,J=8.2Hz,1H),8.04-7.98(m,2H),7.49-7.44(m,4H),7.33-7.26(m,2H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.83(t,J=14.4Hz,1H),5.76-5.72(m,1H),5.65(s,1H),4.59(t,J=8.0Hz,1H),4.51-4.49(m,1H),4.47-4.35(m,5H),4.23-4.21(m,1H),3.79-3.76(m,2H),3.76-3.69(m,4H),3.51-3.49(m,1H),3.09-3.06(m,2H),2.51(s,3H),2.28-2.22(m,3H),2.08-2.02(m,1H),1.54(s,3H),1.43(s,9H).
化合物112
1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),9.15(s,1H),8.40(d,J=42.3Hz,1H),8.25(d,J=8.2Hz,1H),8.04-7.98(m,2H),7.49-7.44(m,4H),7.33-7.26(m,2H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.83(t,J=14.4Hz,1H),5.76-5.72(m,1H),5.65(s,1H),4.59(t,J=8.0Hz,1H),4.51-4.49(m,1H),4.47-4.35(m,5H),4.23-4.21(m,1H),3.79-3.76(m,2H),3.76-3.69(m,8H),3.51-3.49(m,1H),3.09-3.06(m,2H),2.51(s,3H),2.28-2.22(m,3H),2.08-2.02(m,1H),1.54(s,3H),1.43(s,9H).
化合物113
1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),9.15(s,1H),8.40(d,J=42.3Hz,1H),8.25(d,J=8.2Hz,1H),8.04-7.98(m,2H),7.49-7.44(m,4H),7.33-7.26(m,2H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.83(t,J=14.4Hz,1H),5.76-5.72(m,1H),5.65(s,1H),4.59(t,J=8.0Hz,1H),4.51-4.49(m,1H),4.47-4.35(m,5H),4.23-4.21(m,1H),3.79-3.76(m,2H),3.76-3.69(m,12H),
3.51-3.49(m,1H),3.09-3.06(m,2H),2.51(s,3H),2.28-2.22(m,3H),2.08-2.02(m,1H),1.54(s,3H),1.43(s,9H).
化合物114
1H NMR(400MHz,DMSO-d6):δ11.11(s,1H),9.15(s,1H),8.40(d,J=42.3Hz,1H),8.25(d,J=8.2Hz,1H),8.04-7.98(m,2H),7.49-7.44(m,4H),7.33-7.26(m,2H),7.26(d,J=4.1Hz,1H),6.99(s,1H),6.92(s,1H),6.77(s,1H),5.83(t,J=14.4Hz,1H),5.76-5.72(m,1H),5.65(s,1H),4.59(t,J=8.0Hz,1H),4.51-4.49(m,1H),4.47-4.35(m,5H),4.23-4.21(m,1H),3.79-3.76(m,2H),3.76-3.69(m,16H),3.51-3.49(m,1H),3.09-3.06(m,2H),2.51(s,3H),2.28-2.22(m,3H),2.08-2.02(m,1H),1.54(s,3H),1.43(s,9H).
实施例115:化合物115的合成路线
称取5-溴-2-甲氧基吡啶-4-甲酸甲酯(3.00g,12.24mmol)置于反应瓶中,依次加入三丁基(1-乙氧基乙烯)锡(6.63g,18.35mmol,1.5eq.),Pd(dppf)Cl2(1.34g,1.83mmol,0.15eq.),三乙胺(3.72g,36.73mmol,3.0eq.)和1,4-二氧六环(30mL),置换氮气三次后,在90℃下反应8h,TLC监测反应完毕。将反应体系加入1M HCl(10mL),室温下搅拌0.5h后倒入水(100mL)中,用乙酸乙酯萃取(120mL×3),合并有机相,有机相经饱和氯化钠洗涤、无水硫酸钠干燥、过滤、减压浓缩得到粗品,粗产品经柱层析纯化,得到产品化合物115-P1-A1(2.14g)。
称取化合物115-P1-A1(2.10g,10.04mmol)置于反应瓶中,依次加入乙醇(20mL)、水合肼(2.75g,54.93mmol,4.0eq.,80%),在95℃下反应3h,TLC监测反应完全。将反应体系冷却至室温,用漏斗过滤,用少量乙醇洗涤滤饼,得到滤饼烘干得到产品化合物115-P1-A2(1.83g)。
称取化合物115-P1-A2(1.80g)置于反应瓶中,加入15mL浓盐酸,在85℃下反应6h,TLC监测反应完毕。将反应体系冷却至室温,过滤得到滤饼烘干得到产品化合物115-P1-A3(1.34g)。
称取化合物115-P1-A3(1.34g)置于反应瓶中,依次加入三氯氧磷(20mL),N,N-二异丙基苯胺(1.36g,9.11mmol,1.2eq.),置换氮气三次,在108℃下反应2h,反应完毕。将反应体系浓缩至干,加入二氯甲烷溶解,在冰浴中用饱和碳酸氢钠调节PH至8,后加入水(80mL),二氯甲烷萃取(100mL×3),合并有机相,有机相经饱和氯化钠水溶液洗涤(100mL×3)、无水硫酸钠干燥、过滤,减压浓缩得到粗产品,粗产品经柱层析纯化得到产品化合物115-P1-A4(325.9mg)。
称取化合物115-P1-A4(300.0mg)置于反应瓶中,依次加入(R)-3-(1-氨基乙基)-2-甲基苯甲腈(223.3mg)、氟化铯(318.2mg,2.11mmol,1.5eq.),DMSO(15mL),在油浴中130℃反应2h,反应完毕。将反应体系冷却至室温,加入水(50mL),乙酸乙酯萃取(50mL×3),合并有机相,有机相经饱和食盐水洗涤、无水硫酸钠干燥、过滤、浓缩得粗产物,粗产物经柱层析纯化得化合物115-P1-A5(210.0mg)。
称取化合物115-P1-A5(210.0mg)置于反应瓶中,加入过量的N-Boc-哌嗪在110℃下搅拌1h,TLC监测反应完全,粗产物经柱层析纯化得到化合物115-P1-A6。
称取化合物115-P1-A6(0.82mmol)置于反应瓶中,依次加入DCM(10mL)、三氟乙酸(0.5mL),室温下搅拌1h,TLC监测反应完全。将反应体系浓缩至干,加入乙酸乙酯使其溶解,再加入适量的水,用水洗涤乙酸乙酯相,合并水相并调节PH至8,然后经DCM萃取(50mL×3),合并有机相,有机相经无水硫酸钠干燥、过滤、减压浓缩即得化合物115-P1(202mg)。
将化合物106a(130mg,1.0eq.),HOBt(61mg,2.0eq.),EDCI(87mg,2.0eq.),DIEA(117mg,4.0eq.)加入反应瓶中,DMF(3mL)做溶剂,室温反应0.5h,再加入化合物115-P1(103mg,1.0eq.),加完室温反应2h,反应完毕将反应体系倒入30mL水中,EA萃取(10mL×3),合并有机相,有机相经无水硫酸钠干燥、过滤、浓缩得粗品,粗品经薄层层析纯化(DCM/MeOH=5:1)、制备纯化,得到目标产品化合物115;1H NMR(400MHz,DMSO-d6):δ9.36(s,1H),9.15(s,1H),8.51(s,1H),8.45-8.33(m,2H),7.74-7.72(m,1H),7.51(dd,J=7.6,1.2Hz,1H),7.49-7.44(m,4H),7.25(t,J=7.6Hz,1H),7.08(s,1H),5.65-5.61(m,1H),5.58(s,1H),4.59(t,J=8.0Hz,1H),4.51-4.49(m,2H),4.47-4.35(m,4H),3.82(s,2H),3.79-3.76(m,2H),3.36(t,J=5.6Hz,2H),3.09-3.01(m,2H),2.75(d,J=7.6Hz,6H),2.51(s,3H),2.40-2.37(m,2H),2.28-2.22(m,3H),2.08-2.02(m,1H),1.69-1.66(m,4H),1.65(d,J=7.2Hz,3H),1.43(s,9H);MS:m/z 928.5[M+1]+。
实施例116-123和实施例126-128:化合物116-123和126-128的合成路线
按照与实施例115基本相似的操作,合成化合物116-123和126-128。
化合物116
1H NMR(400MHz,DMSO-d6):δ9.36(s,1H),9.15(s,1H),8.51(s,1H),8.45-8.33(m,2H),7.74-7.72(m,1H),7.51(dd,J=7.6,1.2Hz,1H),7.49-7.44(m,4H),7.25(t,J=7.6Hz,1H),7.08(s,1H),5.65-5.61(m,1H),5.58(s,1H),4.59(t,J=8.0Hz,1H),4.51-4.49(m,2H),4.47-4.35(m,4H),3.82(s,2H),3.79-3.76(m,2H),3.36(t,J=5.6Hz,2H),3.09-3.01(m,2H),2.75(d,J=7.6Hz,6H),2.51(s,3H),2.40-2.37(m,2H),2.28-2.22(m,3H),2.08-2.02(m,1H),1.69-1.66(m,4H),1.65(d,J=7.2Hz,3H),1.43(s,9H),1.41-1.38(m,2H).
化合物117
1H NMR(400MHz,DMSO-d6):δ9.36(s,1H),9.15(s,1H),8.51(s,1H),8.45-8.33(m,2H),7.74-7.72(m,1H),7.51(dd,J=7.6,1.2Hz,1H),7.49-7.44(m,4H),7.25(t,J=7.6Hz,1H),7.08(s,1H),5.65-5.61(m,1H),5.58(s,1H),4.59(t,J=8.0Hz,1H),4.51-4.49(m,2H),4.47-4.35(m,4H),3.82(s,2H),
3.79-3.76(m,2H),3.36(t,J=5.6Hz,2H),3.09-3.01(m,2H),2.75(d,J=7.6Hz,6H),2.51(s,3H),2.40-2.37(m,2H),2.28-2.22(m,3H),2.08-2.02(m,1H),1.69-1.66(m,4H),1.65(d,J=7.2Hz,3H),1.43(s,9H),1.41-1.38(m,4H).
化合物118
1H NMR(400MHz,DMSO-d6):δ9.36(s,1H),9.15(s,1H),8.51(s,1H),8.45-8.33(m,2H),7.74-7.72(m,1H),7.51(dd,J=7.6,1.2Hz,1H),7.49-7.44(m,4H),7.25(t,J=7.6Hz,1H),7.08(s,1H),5.65-5.61(m,1H),5.58(s,1H),4.59(t,J=8.0Hz,1H),4.51-4.49(m,2H),4.47-4.35(m,4H),3.82(s,2H),3.79-3.76(m,2H),3.36(t,J=5.6Hz,2H),3.09-3.01(m,2H),2.75(d,J=7.6Hz,6H),2.51(s,3H),2.40-2.37(m,2H),2.28-2.22(m,3H),2.08-2.02(m,1H),1.69-1.66(m,4H),1.65(d,J=7.2Hz,3H),1.43(s,9H),1.41-1.36(m,6H).
化合物119
1H NMR(400MHz,DMSO-d6):δ9.36(s,1H),9.15(s,1H),8.51(s,1H),8.45-8.33(m,2H),7.74-7.72(m,1H),7.51(dd,J=7.6,1.2Hz,1H),7.49-7.44(m,4H),7.25(t,J=7.6Hz,1H),7.08(s,1H),5.65-5.61(m,1H),5.58(s,1H),4.59(t,J=8.0Hz,1H),4.51-4.49(m,2H),4.47-4.35(m,4H),3.82(s,2H),3.79-3.76(m,2H),3.36(t,J=5.6Hz,2H),3.09-3.01(m,2H),2.75(d,J=7.6Hz,6H),2.51(s,3H),2.40-2.37(m,2H),2.28-2.22(m,3H),2.08-2.02(m,1H),1.69-1.66(m,4H),1.65(d,J=7.2Hz,3H),1.43(s,9H),1.41-1.38(m,8H).
化合物120
1H NMR(400MHz,DMSO-d6):δ9.36(s,1H),9.15(s,1H),8.51(s,1H),8.45-8.33(m,2H),7.74-7.72(m,1H),7.51(dd,J=7.6,1.2Hz,1H),7.49-7.44(m,4H),7.25(t,J=7.6Hz,1H),7.08(s,1H),5.65-5.61(m,1H),5.58(s,1H),4.59(t,J=8.0Hz,1H),4.51-4.49(m,2H),4.47-4.35(m,6H),3.82(s,2H),3.79-3.76(m,2H),3.69(s,2H),3.36(t,J=5.6Hz,2H),3.09-3.01(m,2H),2.75(d,J=7.6Hz,6H),2.51(s,3H),2.28-2.22(m,1H),2.08-2.02(m,1H),1.65(d,J=7.2Hz,3H),1.43(s,9H).
化合物121
1H NMR(400MHz,DMSO-d6):δ9.36(s,1H),9.15(s,1H),8.51(s,1H),8.45-8.33(m,2H),7.74-7.72(m,1H),7.51(dd,J=7.6,1.2Hz,1H),7.49-7.44(m,4H),7.25(t,J=7.6Hz,1H),7.08(s,1H),5.65-5.61(m,1H),5.58(s,1H),4.59(t,J=8.0Hz,1H),4.51-4.49(m,2H),4.47-4.35(m,6H),3.82(s,2H),3.79-3.76(m,2H),3.69-3.65(m,6H),3.36(t,J=5.6Hz,2H),3.09-3.01(m,2H),2.75(d,J=7.6Hz,6H),2.51(s,3H),2.28-2.22(m,1H),2.08-2.02(m,1H),1.65(d,J=7.2Hz,3H),1.43(s,9H).
化合物122
1H NMR(400MHz,DMSO-d6):δ9.36(s,1H),9.15(s,1H),8.51(s,1H),8.45-8.33(m,2H),7.74-7.72(m,1H),7.51(dd,J=7.6,1.2Hz,1H),7.49-7.44(m,4H),7.25(t,J=7.6Hz,1H),7.08(s,1H),5.65-5.61(m,1H),5.58(s,1H),4.59(t,J=8.0Hz,1H),4.51-4.49(m,2H),4.47-4.35(m,6H),3.82(s,2H),3.79-3.76(m,2H),3.69-3.65(m,10H),3.36(t,J=5.6Hz,2H),3.09-3.01(m,2H),2.75(d,J=7.6Hz,6H),2.51(s,3H),2.28-2.22(m,1H),2.08-2.02(m,1H),1.65(d,J=7.2Hz,3H),1.43(s,9H).
化合物123
1H NMR(400MHz,DMSO-d6):δ9.36(s,1H),9.15(s,1H),8.51(s,1H),8.45-8.33(m,2H),7.74-7.72(m,1H),7.51(dd,J=7.6,1.2Hz,1H),7.49-7.44(m,4H),7.25(t,J=7.6Hz,1H),7.08(s,1H),5.65-5.61(m,1H),5.58(s,1H),4.59(t,J=8.0Hz,1H),4.51-4.49(m,2H),4.47-4.35(m,6H),3.82(s,2H),
3.79-3.76(m,2H),3.69-3.65(m,14H),3.36(t,J=5.6Hz,2H),3.09-3.01(m,2H),2.75(d,J=7.6Hz,6H),2.51(s,3H),2.28-2.22(m,1H),2.08-2.02(m,1H),1.65(d,J=7.2Hz,3H),1.43(s,9H).
化合物126
1H NMR(400MHz,DMSO-d6)δ11.10(s,1H),10.12(s,1H),9.36(s,1H),8.45-8.33(m,2H),7.74-7.72(m,1H),7.51(dd,J=7.6,1.2Hz,1H),7.47(s,1H),7.25(t,J=7.6Hz,1H),7.08-6.92(m,3H),5.65-5.61(m,1H),5.06-5.04(m,1H),4.48(s,4H),3.82(s,2H),3.60-3.58(m,8H),3.36(t,J=5.6Hz,2H),3.09-3.01(m,2H),2.75(d,J=7.6Hz,6H),2.66-2.36(m,2H),2.11-1.94(m,2H),1.65(d,J=7.2Hz,3H).
化合物127
1H NMR(400MHz,DMSO-d6)δ11.10(s,1H),10.12(s,1H),9.36(s,1H),8.45-8.33(m,2H),7.74-7.72(m,1H),7.51(dd,J=7.6,1.2Hz,1H),7.47(s,1H),7.25(t,J=7.6Hz,1H),7.08-6.92(m,3H),5.65-5.61(m,1H),5.06-5.04(m,1H),4.48(s,4H),3.82(s,2H),3.68-3.64(m,4H),3.60-3.58(m,8H),3.36(t,J=5.6Hz,2H),3.09-3.01(m,2H),2.75(d,J=7.6Hz,6H),2.66-2.36(m,2H),2.11-1.94(m,2H),1.65(d,J=7.2Hz,3H).
化合物128
1H NMR(400MHz,DMSO-d6)δ11.10(s,1H),10.12(s,1H),9.36(s,1H),8.45-8.33(m,2H),7.74-7.72(m,1H),7.51(dd,J=7.6,1.2Hz,1H),7.47(s,1H),7.25(t,J=7.6Hz,1H),7.08-6.92(m,3H),5.65-5.61(m,1H),5.06-5.04(m,1H),4.48(s,4H),3.82(s,2H),3.68-3.64(m,8H),3.60-3.58(m,8H),3.36(t,J=5.6Hz,2H),3.09-3.01(m,2H),2.75(d,J=7.6Hz,6H),2.66-2.36(m,2H),2.11-1.94(m,2H),1.65(d,J=7.2Hz,3H).
实验例1:化合物对H358细胞中SOS1蛋白的降解效果考察
1.实验目的
本实验通过Western Blot的方法,评估使用待测化合物处理H358细胞中SOS1蛋白水平的变化情况。
2.实验材料及耗材
2.1细胞系
H358细胞(ATCC CRL-5807)
2.2待测蛋白
SOS1(Sevenless同源子1)
β-Actin(β-肌动蛋白)
2.3试剂及耗材
3.实验步骤
3.1化合物的制备与处理
3.1.1待测化合物信息
3.1.2化合物储存
将待测化合物分别溶解于DMSO中,配制成浓度为10mM的储备液。新鲜配制的储备液在2-8℃条件下可储存至多1个月,长期存放则需置于-20℃冰箱中。
3.1.3储液的制备
1)将待测化合物的10mM储备液进行10倍梯度稀释,1个浓度梯度,以及无化合物的DMSO样品,起始储液浓度为10mM,1个待测试的储液浓度为1mM。
2)准备无化合物的DMSO储液。
3.2细胞培养及种板
1)H358细胞使用RPMI-1640+10%FBS+1%P/S培养基在37℃,5%CO2条件下培养,指数生长期进行实验。
2)收集细胞离心,培养液重悬细胞并计数。
3)将H358细胞接种到96孔细胞培养板中,每孔3×104个细胞,100μL培养基。
4)细胞培养板在37℃,5%CO2培养箱中培养过夜。
3.3化合物处理
1)每孔细胞中加入100nl制备好的化合物储液,以及无化合物的DMSO储液。待测化合物的工作终浓度为1μm。
2)细胞培养板在37℃,5%CO2培养箱中孵育24小时。
3.4试剂准备
1)细胞裂解工作液:
向20mL细胞裂解缓冲液中,加入一片蛋白酶抑制剂,以及一片磷酸酶抑制剂,轻轻混匀至完全溶解。
2)4×制样工作液:
向4×制样缓冲液中加入终浓度200mM DTT,配置成4×制样工作液。
3)电泳缓冲液:
用超纯水稀释20×电泳缓冲液至1×。
4)转膜缓冲液:
用超纯水稀释20×转膜缓冲液至1×,并加入20%甲醇。
5)TBST缓冲液:
用超纯水稀释10×电泳缓冲液至1×。
6)封闭液:
25g BSA用1×TBST稀释至500mL,4℃保存。
7)一抗工作液:
SOS1蛋白一抗工作液:在20mL封闭液中加入SOS1Antibody抗体20μl;
β-Actin一抗工作液:在20mL封闭液中加入beta-actin(13E5)Rabbit mAb抗体2μl。
8)二抗工作液:
SOS1蛋白二抗工作液:Anti-rabbit IgG,HRP-linked antibody在封闭液中进行1/5000稀释;
β-Actin二抗工作液:Anti-rabbit IgG,HRP-linked antibody在封闭液中进行1/10000稀释。
3.5蛋白提取
1)细胞培养板3000rpm,离心3min,小心吸掉大部分培养基,细胞板倒置,300rpm,离心30s;
2)每孔加入45μL lysis buffer,300转震荡30s,冰上静置30min,20min时吹吸30次,充分裂解细胞;
3)取45μL蛋白裂解液,加入15μL的4x制样工作液进行样品制备,70℃加热10min,进行蛋白变性。
3.6 Western Blot
1)在预制胶中,每孔上样8μl,恒压120V进行电泳,约60min。
2)使用PVDF膜进行转膜,恒流300mA,1小时。
3)转膜后,用封闭液室温封闭1小时。
4)一抗工作液4℃孵育过夜。
5)用1×TBST缓冲液洗膜,3×10min。二抗工作液室温孵育1小时。
6)用1×TBST缓冲液洗膜,3×10min,用显色液进行曝光显色。
4.数据分析
4.1 Western blot结果
化合物38处理不同时间后,H358细胞中SOS1和β-actin含量的检测结果如图1所示。
4.2半定量分析使用ImagJ软件,按照以下公式计算各个条带的灰度值(grey value),进行半定量分析:
其中:(SOS1)表示SOS1在某一时间点的含量,(actin)表示actin在某一时间点的含量,t表示加入化合物后检测的时间点,t0为加入化合物之前的时间点。
结果如图2所示。
5.结论
在本实验条件下,本发明的化合物针对SOS1表现出优异的诱导降解活性,具有良好的抗肿瘤活性,对于治疗哺乳动物(包括人类)的肿瘤性疾病具有良好的效果。尤其是,化合物38在1μm浓度下处理H358细胞6、15、24、48小时后,在6小时对于SOS1蛋白有明显的降解效果,在15、24、48小时对于SOS1蛋白有显著的降解效果。
实验例2:化合物对SOS1蛋白降解DC50测定
测试方法和试验例1类似,待测化合物终浓度选择10μm、3.33μm、1.11μm、0.37μm、0.123μm、0.041μm和0.013μm,并按照下法对应进行数据分析。
数据分析:半定量分析使用ImageJ软件,按照以下公式计算各个条带的灰度值(grey value),进行半定量分析:
其中:(SOS1)表示SOS1在某一时间点的含量,(actin)表示actin在某一时间点的含量,t表示加入化合物后检测的时间点(本测试时间点为24h),t0为加入化合物之前的时间点。
基于前面获得的分析结果,再利用XLFit 5.0按以下参数公式拟合计算DC50值和Dmax:
Y=Bottom+(Top-Bottom)/(1+10^((LogIC50-X)×HillSlope));
Y=Bottom+(Top-Bottom)/(1+10^((LogIC50-X)×HillSlope));
其中:X为化合物浓度log值,Y为复孔间SOS1蛋白降解率的平均值,Bottom为化合物最小抑制率,Top为化合物最大抑制率。
结果显示,本发明化合物对SOS1表现出优异的蛋白降解活性。
实验例3:化合物对NCI-H358和MKN1细胞SOS1下游蛋白ERK磷酸化的影响
1.实验材料、耗材及仪器
1.1材料
1.2耗材
1.3仪器
2.实验方法
待测化合物终浓度选择10μm、3.33μm、1.11μm、0.37μm、0.123μm、0.041μm、0.0137μm、0.0045μm、0.0015μm和0.00051μm。将梯度稀释好的化合物与过夜的细胞共孵育3小时后,将细胞固定渗透封闭,并于一抗中过夜孵育。之后使用红外荧光染料标记的二抗,利用Odyssey双色红外荧光成像系统检测荧光信号。
具体步骤如下:
第一天:将NCI-H358/MKN1细胞接种于384孔细胞培养板中,于37℃,5%二氧化碳细胞培养箱中过夜培养。
第二天:用Echo550将化合物加入板中,继续在37℃,5%二氧化碳细胞培养箱中培养3小时。最后细胞培养板经过多聚甲醛固定、甲醇渗透、封闭液封闭后,加入一抗混合液(rabbit anti pERK,mouse anti GAPDH),于4℃孵育过夜。
第三天:弃掉一抗,加入二抗混合液(goat anti rabbit 800CW,goat anti mouse 680RD),于室温避光孵育,最后用PBST清洗后,将细胞培养板倒扣离心1分钟,用Odyssey CLx读取荧光信号值。
3.数据分析
根据以下公式计算结果:
相对抑制率(%)=(化合物的荧光信号比值-阳性对照平均值)/(阴性对照平均值-阳性对照平均值)*100%;
其中:阴性对照为DMSO,阳性对照为10μM的化合物MRTX1133。
利用XLFit 5.0按参数公式拟合计算IC50值:
Y=Bottom+(Top-Bottom)/(1+10^((LogIC50-X)×HillSlope));
其中:X为化合物浓度log值,Y为复孔间p-ERK相对抑制率的平均值,Bottom为化合物最小抑制率,Top为化合物最大抑制率。
4.结论
结果显示,本发明化合物能够抑制SOS1下游蛋白ERK的磷酸化,具有优异的抗肿瘤活性。
实验例4:化合物在不同种属肝微粒体中代谢稳定性研究
1.实验材料
人肝微粒体,货号452117,购买于Corning;
小鼠肝微粒体,货号M1000,购买于Xenotech;
NADPH,货号BD11658,购买于毕得。
2.实验方法
微粒体(20mg/mL)保存于-80℃冰箱,使用之前于37℃水浴中融化,然后放置于冰上待用。
96孔板中加入微粒体(20mg/mL,终浓度0.5mg/mL)10μL、磷酸盐缓冲液(200mM,终浓度100mM)200μL、氯化镁(50mM,终浓度5mM)40μL和纯化水(106μL),该体系在37℃水浴中预孵育10分钟。向反应体系中加入NADPH溶液(10mM,终浓度1mM)40μL;同时用40μL超纯水代替NADPH溶液,作为阴性对照。
在反应中加入4μL的100mM的待测化合物和对照药(Verapamil)启动反应,药物的最终浓度为1μM。
在0、5、15、30和60min分别取出50μL反应样品,用4倍的含有内标(3%甲酸、100nM阿普唑仑、200nM拉贝洛尔、2μM酮洛芬、200nM咖啡因)的冷乙腈淬灭。样品在3220g转速下离心45min。离心完成后,取100μL上清液和100μL超纯水混匀,用于LC-MS/MS分析检测。
3.数据分析
所有数据计算均通过Microsoft Excel软件进行。通过提取离子图谱检测峰面积。通过对母药的
消失百分比与时间进行线性拟合,检测母药的体外半衰期(t1/2)。
体外半衰期(t1/2)通过斜率计算:
体外t1/2=0.693/k[K是速率常数(k=-斜率值)];
采用下列公式把体外t1/2转化为体外清除率(CLint)(μL/min/mg蛋白):
其中,孵育体积为400uL,蛋白量为0.2mg。
4.结论
结果显示,本发明化合物在人和小鼠肝微粒体为低到中等清除率,化合物稳定性较好。
实验例5:化合物对细胞色素P450酶CYP3A4、CYP2B6和CYP1A2的抑制作用
1.实验材料
人肝微粒体,货号452117,购买于Corning;
NADPH,货号BD11658,购买于毕得。
2.实验方法
加入1μL浓度为2mM的待测化合物或质控抑制剂(CYP3A4和CYP2B6抑制剂为酮康唑、CYP1A2抑制剂为呋拉茶碱),待测化合物或质控抑制剂的终浓度为10μM。DMSO作为溶媒对照,所有试验均为双平行。
按下表配制含磷酸盐缓冲盐、超纯水、MgCl2和人肝微粒体的混合溶液体系。
取下表底物储备液1μL加入到上述混合液中。
将反应体系在37℃水浴预热5min,然后加入20μL的10mM NADPH溶液启动反应,NADPH终浓度为1mM,并于37℃孵育,孵育时间如上表所示。
孵育结束后,在指定的时间点,用400μL冷甲醇(内标,500nM Labetalol,100nM Alprazolam和2μM Ketoprofen)终止反应。样品在3220g下离心60min沉淀蛋白。取100μL上清液用100μL超纯水稀释(根据LC-MS/MS的峰形和信号强度),用LC-MS/MS分析。
3.结论
结果显示,本发明化合物在10μM时对各CYP酶亚型没有强抑制,DDI风险小。
实验例6:化合物溶解度测试
1.缓冲液配制
pH6.8磷酸盐缓冲液配制:量取0.2mol/L磷酸二氢钾溶液(250mL)和0.2mol/L氢氧化钠溶液(118mL),加水稀释至1000mL,超声脱气,即得。
pH4.5醋酸盐缓冲液:称取醋酸钠(18g),加入水适量,缓缓加入冰醋酸(9.8mL),搅拌均匀,加水稀释至1000mL,超声脱气,即得。
2.实验方法
取样品至透明玻璃具塞管中(每个化合物测定2次),分别加入pH6.8磷酸盐缓冲液或pH4.5醋酸盐缓冲液适量(溶液温度控在25±2℃),观察样品溶解状态。取溶解后的样品溶液适量,过滤,进行HPLC分析,得到各个化合物的溶解度。
3.结论
结果显示,本发明化合物在pH4.5和pH6.8缓冲液中均有较好的溶解度。
实验例7:化合物在CD-1小鼠体内的血浆动力学研究
1.实验动物
CD-1小鼠,SPF级,雄性,购买于斯贝福(北京)生物技术有限公司。
2.实验方法
以标准方案测试化合物静脉注射给药后的啮齿类动物药代特征。
实验中,将候选化合物配成澄清溶液,给予小鼠单次静脉注射,静注溶媒为pH4.5醋酸盐缓冲液。每个化合物使用6只小鼠进行静脉注射给药,给药剂量为10mg/kg(药液浓度为1mg/mL,给药体积为10μL/g)。
灌胃给药后于0.0833h、0.25h、0.5h、1h、2h、4h、8h和24h采样,全血样品采集后立即放置于冰上,在采集后0.5h内,于4℃、2000g条件下离心5min,分离血浆,收集上层样品至样品管中,在0.5h内冻存至-10~-30℃冰箱,并于24h内转移至-60~-90℃冰箱。
采用LC-MS/MS方法检测各时间点血浆样品中各原形药物的浓度,使用WinNonlin软件计算达峰浓度(Cmax)、半衰期(t1/2)、药时曲线下面积(AUC0-t)、组织分布容积(Vd)、血浆清除率(CL)等PK参数。
结论:结果显示,本发明化合物具有血浆清除率较低,药物半衰期较长以及暴露量较好等特点,表明化合物具有良好的药代动力学性质。
尽管本发明通过之前的特定实施例说明,但不应将其解释为受此限制,而是本发明涵盖之前公开的一般方面,并且可在不背离本发明的精神和范围下进行多种修饰并具有多种实施方案。
Claims (31)
- 式(I’)结构的化合物或其药学上可接受的盐、水合物、溶剂化物、立体异构体、互变异构体、顺反异构体、同位素标记物或前药:
其中:表示单键或双键;A选自C6-10芳基、5至10元杂芳基和3至6元杂环基;W1为N、NR2、C或CR2;W2为N、NR4、C或CR4;W3为N、CR5或C(R5)2;W4为N、CR6或C(R6)2;W5为N或C;m为1或2;n为1、2或3;每一个R1独立地选自C1-6烷基、C2-6烯基、C2-6炔基、C1-6卤代烷基、C6-10芳基、5至10元杂芳基、C3-6环烷基、3至6元杂环基、羟基取代的C1-6烷基、羟基取代的C1-6卤代烷基、氨基、卤素、氰基和硝基;每一个R3独立地选自氢、C1-6烷基、C1-6卤代烷基、C3-6环烷基和卤素;若存在,R2选自氢、C1-6烷基、C1-6卤代烷基、C3-6环烷基、卤素、氰基、-NR2aR2b和-OR2a,其中R2a和R2b独立地选自氢、C1-6烷基、C1-6卤代烷基和C3-6环烷基;若存在,R4选自氢、C1-6烷基、C3-6环烷基、3至6元杂环基、C1-6烷氧基、氨基和卤素;或者,当W1为C,W2为NR4,W1与W2通过单键连接时,W1与R4连接,形成5至10元杂芳基;或者,当W1为NR2,W2为C,W1与W2通过单键连接时,W2与R2连接,形成5至10元杂芳基;或者,当W1为CR2,W2为CR4,W1与W2通过双键连接时,R2与R4连接,形成5至10元杂芳基;若存在,每一个R5和R6独立地选自氢、氧代基、羟基、C1-6烷氧基、硝基、卤素和氨基;或者,至少一个R5和至少一个R6与其所连接的碳原子一起形成至少一个C5-8环烷基或5至8元杂环基,所述C5-8环烷基和5至8元杂环基独立地任选被1、2、3、4、5或6个选自如下取代基的基团取代:氢、卤素、氧代基、-C(=O)R5a、-C(=O)NR5bR5c、-NR5bR5c、-OR5d、C1-6烷基、C3-14环烷基、3至14元杂环基、C6-10芳基和5至10元杂芳基,其中R5a、R5b、R5c和R5d独立地选自氢、C1-6烷基、C3-14环烷基、3至14元杂环基、C6-10芳基和5至10元杂芳基;R7选自氢、C1-6烷基、C2-6烯基和C3-6环烷基;L为-(Z)t-,其中t为1-20中的任一整数;每一个Z独立地选自单键、-O-、-S-、-NH-、-C(=O)-、-C(=S)-、-S(=O)-、-S(=O)2-、C1-6亚烷基、C2-3亚烯基、C2-3亚炔基、C3-10亚环烷基、3至10元亚杂环基、C6-10亚芳基和5至10元亚杂芳基,所述C1-6亚烷基、C2-3亚烯基、C2-3亚炔基、C3-10亚环烷基、3至10元亚杂环基、C6-10亚芳基和5至10元亚杂芳基独立地任选被1、2或3个R8取代;若存在,每一个R8独立地选自氢、卤素、羟基、氨基、氰基、氨基甲酰基、亚磷酸基、C1-6烷基、C3-6环烷基、3至6元杂环基、C1-6烷基-C(=O)-、C1-6烷基-C(=O)NH-、C1-6烷氧基、C1-6烷硫基和C1-6烷氨基,所述C1-6烷基、C3-6环烷基、3至6元杂环基、C1-6烷基-C(=O)-、C1-6烷基-C(=O)NH-、C1-6烷氧基、C1-6烷硫基和C1-6烷氨基独立地任选被1、2或3个R9取代;若存在,每一个R9独立地选自F、Cl、Br、I、OH、NH2、CH3、CH2F、CHF2和CF3;RE为如式(X1)、式(X2)或式(X3)所示的基团:
其中:Y1、Y2、Y3和Y4独立地为-C(=O)-或-CH2-,且Y1和Y2中的至少一个为-C(=O)-,Y3和Y4中的至少一个为-C(=O)-;q为0-3中的任一整数;r为0-4中的任一整数;若存在,每一个Ry独立地选自氢、卤素、羟基、氨基、氰基、C1-6烷基、C3-6环烷基、3至6元杂环基、C1-6烷氧基、C1-6烷硫基和C1-6烷氨基;优选地,W5与RE之间间隔至少6-25个共价键,优选至少8-22个共价键,更优选至少20-22个共价键。 - 根据权利要求1所述的化合物,或其药学上可接受的盐、水合物、溶剂化物、立体异构体、互变异构体、顺反异构体、同位素标记物或前药,其特征在于,所述化合物为式(I)化合物,
其中:表示单键或双键;A选自C6-10芳基、5至10元杂芳基和3至6元杂环基;W1为N或CR2;W2为N或CR4;W3为N、CR5或C(R5)2;W4为N、CR6或C(R6)2;W5为N或C;m为1或2;n为1、2或3;每一个R1独立地选自C1-6烷基、C2-6烯基、C2-6炔基、C1-6卤代烷基、C6-10芳基、5至10元杂芳基、C3-6环烷基、3至6元杂环基、羟基取代的C1-6烷基、羟基取代的C1-6卤代烷基、氨基、卤素、氰基和硝基;若存在,R2选自氢、C1-6烷基、C1-6卤代烷基、C3-6环烷基、卤素、氰基、-NR2aR2b和-OR2a,其中R2a和R2b独立地选自氢、C1-6烷基、C1-6卤代烷基和C3-6环烷基;每一个R3独立地选自氢、C1-6烷基、C1-6卤代烷基、C3-6环烷基和卤素;若存在,R4选自氢、C1-6烷基、C3-6环烷基、3至6元杂环基、C1-6烷氧基、氨基和卤素;若存在,每一个R5和R6独立地选自氢、氧代基、羟基、C1-6烷氧基、硝基、卤素和氨基;或者,至少一个R5和至少一个R6与其所连接的碳原子一起形成至少一个C5-8环烷基或5至8元杂环基,所述C5-8环烷基和5至8元杂环基独立地任选被1、2、3、4、5或6个选自如下取代基的基团取代:氢、卤素、氧代基、-C(=O)R5a、-C(=O)NR5bR5c、-NR5bR5c、-OR5d、C1-6烷基、C3-14环烷基、3至14元杂环基、C6-10芳基和5至10元杂芳基,其中R5a、R5b、R5c和R5d独立地选自氢、C1-6烷基、C3-14环烷基、3至14元杂环基、C6-10芳基和5至10元杂芳基;R7选自氢、C1-6烷基、C2-6烯基和C3-6环烷基;L为-(Z)t-,其中t为1-20中的任一整数;每一个Z独立地选自单键、-O-、-S-、-NH-、-C(=O)-、-C(=S)-、-S(=O)-、-S(=O)2-、C1-6亚烷基、C2-3亚烯基、C2-3亚炔基、C3-10亚环烷基、3至10元亚杂环基、C6-10亚芳基和5至10元亚杂芳基,所述C1-6亚烷基、C2-3亚烯基、C2-3亚炔基、C3-10亚环烷基、3至10元亚杂环基、C6-10亚芳基和5至10元亚杂芳基独立地任选被1、2或3个R8取代;若存在,每一个R8独立地选自氢、卤素、羟基、氨基、氰基、氨基甲酰基、亚磷酸基、C1-6烷基、C3-6环烷基、3至6元杂环基、C1-6烷基-C(=O)-、C1-6烷基-C(=O)NH-、C1-6烷氧基、C1-6烷硫基和C1-6烷氨基,所述C1-6烷基、C3-6环烷基、3至6元杂环基、C1-6烷基-C(=O)-、C1-6烷基-C(=O)NH-、C1-6烷氧基、C1-6烷硫基和C1-6烷氨基独立地任选被1、2或3个R9取代;若存在,每一个R9独立地选自F、Cl、Br、I、OH、NH2、CH3、CH2F、CHF2和CF3;RE为如式(X1)、式(X2)或式(X3)所示的基团:
其中:Y1、Y2、Y3和Y4独立地为-C(=O)-或-CH2-,且Y1和Y2中的至少一个为-C(=O)-,Y3和Y4中的至少一个为-C(=O)-;q为0-3中的任一整数;r为0-4中的任一整数;若存在,每一个Ry独立地选自氢、卤素、羟基、氨基、氰基、C1-6烷基、C3-6环烷基、3至6元杂环基、C1-6烷氧基、C1-6烷硫基和C1-6烷氨基;优选地,W5与RE之间间隔至少8-22个共价键,优选至少20-22个共价键。 - 根据权利要求1所述的化合物,或其药学上可接受的盐、水合物、溶剂化物、立体异构体、互变异构体、顺反异构体、同位素标记物或前药,其特征在于,所述化合物为式(IA)化合物至式(IF)化合物中的任意一种:
其中:A、n、R1-R7、L和RE如权利要求1中所定义;或者,所述化合物为式(I-1)化合物至式(I-10)化合物中的任意一种:
其中:D为N或CR5;A、n、R1、R3、R5、R6、R7、L和RE如权利要求1中所定义;优选地,-L-片段的主链包含至少8-22个共价键,优选包含至少20-22个共价键。 - 根据权利要求3所述的化合物,或其药学上可接受的盐、水合物、溶剂化物、立体异构体、互变异构体、顺反异构体、同位素标记物或前药,其特征在于,当式(IA)中的R5和R6与其所连接的碳原子一起形成环系时,式(IA)化合物为如式(IA’)所示的化合物:
其中:G为C5-8环烷基或5至8元杂环基,优选C5-6环烷基,更优选C5环烷基;A、n、R1-R3、R7、L和RE如权利要求3中所定义。 - 根据权利要求3所述的化合物,或其药学上可接受的盐、水合物、溶剂化物、立体异构体、互变异构体、顺反异构体、同位素标记物或前药,其特征在于,当式(IB)中的R6为羟基时,式(IB)化合物为如式(IB’)所示的化合物:
其中:A、n、R1-R3、R7、L和RE如权利要求3中所定义。 - 根据权利要求3所述的化合物,或其药学上可接受的盐、水合物、溶剂化物、立体异构体、互变异构体、顺反异构体、同位素标记物或前药,其特征在于,当式(IC)中的R5为羟基时,式(IC)化合物为如式(IC’)所示的化合物:
其中:A、n、R1、R3、R4、R7、L和RE如权利要求3中所定义。 - 根据权利要求1-6中任一项所述的化合物,或其药学上可接受的盐、水合物、溶剂化物、立体异构体、互变异构体、顺反异构体、同位素标记物或前药,其特征在于,A选自C6-10芳基和5至10元杂芳基,优选C6-10芳基,更优选苯基。
- 根据权利要求1-7中任一项所述的化合物,或其药学上可接受的盐、水合物、溶剂化物、立体异构体、互变异构体、顺反异构体、同位素标记物或前药,其特征在于,n为1或2,优选2。
- 根据权利要求1-8中任一项所述的化合物,或其药学上可接受的盐、水合物、溶剂化物、立体异构体、互变异构体、顺反异构体、同位素标记物或前药,其特征在于,每一个R1独立地选自C1-6烷基、C1-6卤代烷基、氨基、卤素和氰基,优选甲基、乙基、丙基、异丙基、丁基、异丁基、-CH2F、-CHF2、-CF3、-CH2CH2F、-CH2CHF2、-CH2CF3、-CH2CH2CH2F、-CH2CH2CHF2、-CH2CH2CF3、氨基、氟、氯、溴和氰基,更优选甲基、-CH2F、-CHF2、-CF3、氨基、氟、氯、溴和氰基。
- 根据权利要求1-5和7-9中任一项所述的化合物,或其药学上可接受的盐、水合物、溶剂化物、立体异构体、互变异构体、顺反异构体、同位素标记物或前药,其特征在于,R2选自氢、C1-6烷基和C1-6卤代烷基,优选氢、甲基、氟甲基、二氟甲基和三氟甲基,优选甲基。
- 根据权利要求1-10中任一项所述的化合物,或其药学上可接受的盐、水合物、溶剂化物、立体异构体、互变异构体、顺反异构体、同位素标记物或前药,其特征在于,每一个R3独立地选自氢、C1-6烷基和C1-6卤代烷基,优选氢、甲基、氟甲基、二氟甲基和三氟甲基,更优选氢。
- 根据权利要求1、2、3和6中任一项所述的化合物,或其药学上可接受的盐、水合物、溶剂化物、立体异构体、互变异构体、顺反异构体、同位素标记物或前药,其特征在于,R4选自氢、C1-6烷基和C1-6烷氧基,优选氢、甲基、乙基、甲氧基和乙氧基,更优选甲基。
- 根据权利要求1-3和7-12中任一项所述的化合物,或其药学上可接受的盐、水合物、溶剂化物、立体异构体、互变异构体、顺反异构体、同位素标记物或前药,其特征在于,每一个R5和R6独立地选自氢、羟基和C1-6烷氧基,优选氢、羟基、甲氧基和乙氧基,优选氢、羟基和甲氧基。
- 根据权利要求1-13中任一项所述的化合物,或其药学上可接受的盐、水合物、溶剂化物、立体异构体、互变异构体、顺反异构体、同位素标记物或前药,其特征在于,R7选自氢、C1-6烷基和C3-6环烷基,优选氢、甲基、乙基、丙基、异丙基、环丙基、环丁基、环戊基和环己基,更优选甲基。
- 根据权利要求1-14中任一项所述的化合物,或其药学上可接受的盐、水合物、溶剂化物、立体异构体、互变异构体、顺反异构体、同位素标记物或前药,其特征在于,L为-(Z)t-,其中t为4-18中的任一整数,优选4-13中的任一整数或5-18中的任一整数;每一个Z独立地选自单键、-O-、-NH-、-C(=O)-、C1-6亚烷基、C2-3亚烯基、C3-10亚环烷基和3至10元亚杂环基,优选单键、-O-、-NH-、-C(=O)-、-CH2-、-CH=CH-、C3-6亚环烷基和3至6元亚杂环基。
- 根据权利要求15所述的化合物,或其药学上可接受的盐、水合物、溶剂化物、立体异构体、互变异构体、顺反异构体、同位素标记物或前药,其特征在于,L为如式(L1)至式(L40)所示的基团之一,优选如式(L1)至式(L27)所示的基团之一,或者优选如式(L8)、式(L22)、式(L28)、式(L29)和式(L31)所示的基团之一,且基团左端连接稠合双环基团,右端连接RE:
其中:p1、p6和p7独立地为1-6中的任一整数;p2、p9和p11独立地为1-4中的任一整数;p3、p5、p10、p12和p13独立地为1-4中的任一整数,优选1-2中的任一整数;p4和p8独立地为1-8中的任一整数;p14为0-2中的任一整数。 - 根据权利要求15或16所述的化合物,或其药学上可接受的盐、水合物、溶剂化物、立体异构体、互变异构体、顺反异构体、同位素标记物或前药,其特征在于,L为如式(L22)所示的基团,且基团左端连接稠合双环基团,右端连接RE:
其中:p2为1-4中的任一整数,优选1-2中的任一整数,更优选1;p3为1-2中的任一整数,优选1;p10为1-2中的任一整数,优选2。 - 根据权利要求15或16所述的化合物,或其药学上可接受的盐、水合物、溶剂化物、立体异构体、互变异构体、顺反异构体、同位素标记物或前药,其特征在于,L为如式(L28)所示的基团,且基团左端连接稠合双环基团,右端连接RE:
其中:p9为1-4中的任一整数,优选1-2中的任一整数,更优选1;p10为1-2中的任一整数,优选1;p14为0-2中的任一整数,优选1-2中的任一整数。 - 根据权利要求15或16所述的化合物,或其药学上可接受的盐、水合物、溶剂化物、立体异构体、互变异构体、顺反异构体、同位素标记物或前药,其特征在于,L为如式(L8)所示的基团,且基团左端连接稠合双环基团,右端连接RE:
其中:p9为1-4中的任一整数,优选2-4中的任一整数,更优选4;p10为1-2中的任一整数,优选2。 - 根据权利要求15或16所述的化合物,或其药学上可接受的盐、水合物、溶剂化物、立体异构体、互变异构体、顺反异构体、同位素标记物或前药,其特征在于,L为如式(L29)或式(L31)所示的基团,且基团左端连接稠合双环基团,右端连接RE:
其中:p9为1-4中的任一整数,优选1-2中的任一整数,更优选1;p10为1-2中的任一整数,优选2;p14为0-2中的任一整数,优选1。 - 根据权利要求1-20中任一项所述的化合物,或其药学上可接受的盐、水合物、溶剂化物、立体异构体、互变异构体、顺反异构体、同位素标记物或前药,其特征在于,RE为如式(X1-1)至式(X1-6)所示的基团之一:
- 根据权利要求1-20中任一项所述的化合物,或其药学上可接受的盐、水合物、溶剂化物、立体异构体、互变异构体、顺反异构体、同位素标记物或前药,其特征在于,RE为如式(X2-1)所示的基团:
- 根据权利要求1-20中任一项所述的化合物,或其药学上可接受的盐、水合物、溶剂化物、立体异构体、互变异构体、顺反异构体、同位素标记物或前药,其特征在于,RE为如式(X3-1)或式(X3-2)所示的基团:
- 下列化合物,或其药学上可接受的盐、水合物、溶剂化物、立体异构体、互变异构体、顺反异构体、同位素标记物或前药,
- 一种药物组合物,其包含根据权利要求1-24中任一项所述的化合物,或其药学上可接受的盐、水合物、溶剂化物、立体异构体、互变异构体、顺反异构体、同位素标记物或前药;优选地,所述药物组合物还包含至少一种药学上可接受的载体。
- 一种药物制剂,其由根据权利要求1-24中任一项所述的化合物,或其药学上可接受的盐、水 合物、溶剂化物、立体异构体、互变异构体、顺反异构体、同位素标记物或前药,或者根据权利要求25所述的药物组合物制成。
- 根据权利要求1-24中任一项所述的化合物,或其药学上可接受的盐、水合物、溶剂化物、立体异构体、互变异构体、顺反异构体、同位素标记物或前药,或者根据权利要求25所述的药物组合物,或者根据权利要求26所述的药物制剂在制备用于预防和/或治疗至少部分由SOS1蛋白介导的疾病的药物中的用途。
- 根据权利要求1-24中任一项所述的化合物,或其药学上可接受的盐、水合物、溶剂化物、立体异构体、互变异构体、顺反异构体、同位素标记物或前药,或者根据权利要求25所述的药物组合物,或者根据权利要求26所述的药物制剂在制备用于预防和/或治疗癌症的药物中的用途;优选地,所述癌症选自胰腺癌、肺癌、结直肠癌、胆管癌、多发性骨髓瘤、黑素瘤、子宫癌、子宫内膜癌、甲状腺癌、急性髓性白血病、膀胱癌、尿路上皮癌、胃癌、宫颈癌、头颈部鳞状细胞癌、弥漫性大B细胞淋巴瘤、食道癌、慢性淋巴细胞白血病、肝细胞癌、乳腺癌、卵巢癌、前列腺癌、胶质母细胞瘤、肾癌和肉瘤。
- 根据权利要求1-24中任一项所述的化合物,或其药学上可接受的盐、水合物、溶剂化物、立体异构体、互变异构体、顺反异构体、同位素标记物或前药,或者根据权利要求25所述的药物组合物,或者根据权利要求26所述的药物制剂,其用于预防和/或治疗至少部分由SOS1蛋白介导的疾病,优选癌症;优选地,所述癌症选自胰腺癌、肺癌、结直肠癌、胆管癌、多发性骨髓瘤、黑素瘤、子宫癌、子宫内膜癌、甲状腺癌、急性髓性白血病、膀胱癌、尿路上皮癌、胃癌、宫颈癌、头颈部鳞状细胞癌、弥漫性大B细胞淋巴瘤、食道癌、慢性淋巴细胞白血病、肝细胞癌、乳腺癌、卵巢癌、前列腺癌、胶质母细胞瘤、肾癌和肉瘤。
- 一种用于预防和/或治疗至少部分由SOS1蛋白介导的疾病,优选癌症的方法,其包括将预防和/或治疗有效量的根据权利要求1-24中任一项所述的化合物,或其药学上可接受的盐、水合物、溶剂化物、立体异构体、互变异构体、顺反异构体、同位素标记物或前药,或者根据权利要求25所述的药物组合物,或者根据权利要求26所述的药物制剂施用于对其有需求的个体;优选地,所述癌症选自胰腺癌、肺癌、结直肠癌、胆管癌、多发性骨髓瘤、黑素瘤、子宫癌、子宫内膜癌、甲状腺癌、急性髓性白血病、膀胱癌、尿路上皮癌、胃癌、宫颈癌、头颈部鳞状细胞癌、弥漫性大B细胞淋巴瘤、食道癌、慢性淋巴细胞白血病、肝细胞癌、乳腺癌、卵巢癌、前列腺癌、胶质母细胞瘤、肾癌和肉瘤。
- 一种药物联合形式,其包含根据权利要求1-24中任一项所述的化合物,或其药学上可接受的盐、水合物、溶剂化物、立体异构体、互变异构体、顺反异构体、同位素标记物或前药,或者根据权利要求25所述的药物组合物,或者根据权利要求26所述的药物制剂,以及至少一种额外的癌症治疗剂。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210725527.5 | 2022-06-23 | ||
CN202210725527 | 2022-06-23 | ||
CN202210868337.9 | 2022-07-22 | ||
CN202210868337 | 2022-07-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023246656A1 true WO2023246656A1 (zh) | 2023-12-28 |
Family
ID=87987301
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2023/100787 WO2023246656A1 (zh) | 2022-06-23 | 2023-06-16 | Sos1蛋白降解靶向嵌合体及其组合物、制剂和用途 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN116768861A (zh) |
WO (1) | WO2023246656A1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023246656A1 (zh) * | 2022-06-23 | 2023-12-28 | 北京福元医药股份有限公司 | Sos1蛋白降解靶向嵌合体及其组合物、制剂和用途 |
WO2024083255A1 (zh) * | 2022-10-21 | 2024-04-25 | 上海领泰生物医药科技有限公司 | 苄基或噻吩亚甲基取代的氨基喹唑啉衍生物及其作为sos1降解剂的用途 |
WO2024083257A1 (zh) * | 2022-10-21 | 2024-04-25 | 上海领泰生物医药科技有限公司 | Sos1蛋白降解剂及其应用 |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022061348A1 (en) * | 2020-09-16 | 2022-03-24 | Biotheryx, Inc. | Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications |
WO2022156792A1 (en) * | 2021-01-25 | 2022-07-28 | Guangdong Newopp Biopharmaceuticals Co., Ltd. | Heterocyclic compounds as sos1 inhibitors |
WO2022187236A1 (en) * | 2021-03-02 | 2022-09-09 | Viva Star Biosciences (Suzhou) Co., Ltd. | Novel substituted tricyclic aza-heterocycles as sos1 inhibitors |
CN115043817A (zh) * | 2021-03-09 | 2022-09-13 | 苏州泽璟生物制药股份有限公司 | Sos1蛋白水解调节剂及其制备方法和应用 |
CN115215869A (zh) * | 2021-04-21 | 2022-10-21 | 苏州泽璟生物制药股份有限公司 | 取代三环类抑制剂及其制备方法和应用 |
CN115232108A (zh) * | 2021-04-23 | 2022-10-25 | 上海领泰生物医药科技有限公司 | Sos1降解剂及其制备方法和应用 |
WO2022271679A1 (en) * | 2021-06-21 | 2022-12-29 | Mirati Therapeutics, Inc. | Sos1 inhibitors |
CN115677701A (zh) * | 2021-07-22 | 2023-02-03 | 昆药集团股份有限公司 | 一种苯并杂环化合物及其制备方法和应用 |
CN116768858A (zh) * | 2022-03-15 | 2023-09-19 | 杭州中美华东制药有限公司 | 具有kras-sos1抑制或降解活性的嵌合化合物及其用途 |
CN116768861A (zh) * | 2022-06-23 | 2023-09-19 | 北京福元医药股份有限公司 | Sos1蛋白降解靶向嵌合体及其组合物、制剂和用途 |
-
2023
- 2023-06-16 WO PCT/CN2023/100787 patent/WO2023246656A1/zh unknown
- 2023-06-16 CN CN202310717008.9A patent/CN116768861A/zh active Pending
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022061348A1 (en) * | 2020-09-16 | 2022-03-24 | Biotheryx, Inc. | Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications |
WO2022156792A1 (en) * | 2021-01-25 | 2022-07-28 | Guangdong Newopp Biopharmaceuticals Co., Ltd. | Heterocyclic compounds as sos1 inhibitors |
WO2022187236A1 (en) * | 2021-03-02 | 2022-09-09 | Viva Star Biosciences (Suzhou) Co., Ltd. | Novel substituted tricyclic aza-heterocycles as sos1 inhibitors |
CN115043817A (zh) * | 2021-03-09 | 2022-09-13 | 苏州泽璟生物制药股份有限公司 | Sos1蛋白水解调节剂及其制备方法和应用 |
WO2022188819A1 (zh) * | 2021-03-09 | 2022-09-15 | 苏州泽璟生物制药股份有限公司 | Sos1蛋白水解调节剂及其制备方法和应用 |
CN115215869A (zh) * | 2021-04-21 | 2022-10-21 | 苏州泽璟生物制药股份有限公司 | 取代三环类抑制剂及其制备方法和应用 |
CN115232108A (zh) * | 2021-04-23 | 2022-10-25 | 上海领泰生物医药科技有限公司 | Sos1降解剂及其制备方法和应用 |
WO2022271679A1 (en) * | 2021-06-21 | 2022-12-29 | Mirati Therapeutics, Inc. | Sos1 inhibitors |
CN115677701A (zh) * | 2021-07-22 | 2023-02-03 | 昆药集团股份有限公司 | 一种苯并杂环化合物及其制备方法和应用 |
CN116768858A (zh) * | 2022-03-15 | 2023-09-19 | 杭州中美华东制药有限公司 | 具有kras-sos1抑制或降解活性的嵌合化合物及其用途 |
CN116768861A (zh) * | 2022-06-23 | 2023-09-19 | 北京福元医药股份有限公司 | Sos1蛋白降解靶向嵌合体及其组合物、制剂和用途 |
Also Published As
Publication number | Publication date |
---|---|
CN116768861A (zh) | 2023-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108884079B (zh) | 作为雌激素受体调节剂的6,7-二氢-5h-苯并[7]轮烯衍生物 | |
CN109311889B (zh) | 激活素受体样激酶抑制剂 | |
WO2023246656A1 (zh) | Sos1蛋白降解靶向嵌合体及其组合物、制剂和用途 | |
CN107001328B (zh) | 作为突变型异柠檬酸脱氢酶抑制剂的吡啶-2(1h)-酮喹啉酮衍生物 | |
CN105408335B (zh) | 吡唑并吡咯烷衍生物及其在治疗疾病中的用途 | |
JP2024020220A (ja) | 免疫調節剤としての複素環式化合物 | |
EP3473626B1 (en) | Pyrrolopyrimidine crystal for preparing jak inhibitor | |
TW201706257A (zh) | 化合物 | |
WO2022001767A1 (zh) | 一种杂环化合物及其应用 | |
CN114423753A (zh) | 作为cd38抑制剂的杂双环酰胺 | |
TW201348213A (zh) | 喹唑啉二酮衍生物 | |
KR20220018475A (ko) | Ep300 또는 cbp 조절 및 이의 표시를 위한 응축 아진 | |
CN115698020A (zh) | 大环rip2-激酶抑制剂 | |
TW201625587A (zh) | 新穎化合物 | |
WO2023066377A1 (zh) | 一种含氮化合物、其制备方法及应用 | |
WO2023280237A1 (zh) | 一种磷酸酶降解剂的合成和应用 | |
TWI822666B (zh) | Janus激酶抑制劑之結晶型 | |
CN111315750B (zh) | 作为mTORC1/2双激酶抑制剂的吡啶并嘧啶类化合物 | |
CN112313216A (zh) | 作为axl/mer rtk和csf1r的抑制剂的喹啉衍生物 | |
CN115536660A (zh) | 苄氨基取代的杂多环化合物及其组合物、制剂和用途 | |
WO2022122037A1 (zh) | 一种二氢异喹啉酮衍生物及其应用 | |
CN109206360B (zh) | 咔唑酰胺类衍生物或其盐及其制备方法和用途 | |
WO2021185348A1 (zh) | 取代的丙烯酰胺衍生物及其组合物及用途 | |
EP3589615B1 (en) | Pyridyl derivatives as bromodomain inhibitors | |
WO2020233645A1 (zh) | 大环类衍生物、及其制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23826305 Country of ref document: EP Kind code of ref document: A1 |